Compositions and methods for the treatment of TAU-related disorders

Abstract

The disclosure provides compositions and methods for the preparation, manufacture and use of an adeno-associated virus (AAV) particle for the vectorized delivery of an antibody molecule that binds to tau.

Description

Attorney Docket No.: V2071-3035PCT COMPOSITIONS AND METHODS FOR THE TREATMENT OF TAU-RELATED DISORDERS RELATED APPLICATIONS

[0001] This application claims priority to U.S. Provisional Application No.63 / 606,378 filed on December 5, 2023; the entire contents of which are hereby incorporated by reference in their entirety. SEQUENCE LISTING

[0002] The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing file, entitled V2071-3035PCT_SL.xml, was created on October 15, 2024, and is 3,338,240 bytes in size. The information in electronic format of the Sequence Listing is incorporated herein by reference in its entirety. FIELD OF THE DISCLOSURE

[0003] Described herein are compositions and methods relating to AAV particles for delivery of an anti-tau antibody molecule for use in the treatment of tau-related disorders (e.g., tauopathies). BACKGROUND

[0004] Tauopathies are a group of neurodegenerative diseases characterized by the dysfunction and / or aggregation of the microtubule associated protein tau. Tau is normally a very soluble protein known to associate with microtubules based on the extent of its phosphorylation. Tau is considered a critical component of intracellular trafficking processes, particularly in neuronal cells, given their unique and extended structure. Hyperphosphorylation of tau depresses its binding to microtubules and microtubule assembly activity. Further, hyperphosphorylation of tau renders it prone to misfolding and aggregation. In tauopathies, the tau becomes hyperphosphorylated, misfolds and aggregates as neurofibrillary tangles (NFT) of paired helical filaments (PHF), twisted ribbons or straight filaments. These NFT are largely considered indicative of impending neuronal cell death and thought to contribute to widespread neuronal cell loss, leading to a variety of behavioral and cognitive deficits.

[0005] Several approaches have been proposed for therapeutically interfering with progression of tau pathology and preventing the subsequent molecular and cellular consequences. Given that NFT are composed of hyperphosphorylated, misfolded and aggregated forms of tau, interference at each of these stages provides targets that can be pursued. Introducing agents that limit phosphorylation, block misfolding or prevent aggregation are promising strategies. It has also been suggested that introduction of anti-tau antibodies can prevent the trans-neuronal spread of tau pathology.

[0006] There remains a need for anti-tau antibodies for use in tauopathy treatment, diagnostics, and other applications. The present disclosure addresses this need with related compounds and methods described herein. 1 321651967.1Attorney Docket No.: V2071-3035PCT SUMMARY

[0007] The present disclosure addresses the need in the art for improved methods for delivery of antibodies and antibody-based therapeutics targeting tau by providing novel AAV particles comprising an adeno-associated (AAV) capsid variant comprising viral genomes encoding an anti-tau antibody molecule and / or an antibody-based composition and methods of using the same for the treatment, prevention, diagnosis, and research of diseases, disorders and / or conditions associated with tau pathology.

[0008] Accordingly, in one aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4681), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein (i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, K, E, S, P, R, N, H, or a conservative substitution thereof; and / or (ii) [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, T, M, S, N, L, F, or a conservative substitution thereof. In some embodiments, position X4of [N1] is Q. In some embodiments, position X4of [N1] is K. In some embodiments, position X5of [N3] is I. In some embodiments, [N1] replaces positions 582-585 (e.g., T582, N583, H584, Q585), numbered according to SEQ ID NO: 138. In some embodiments, [N1] corresponds to positions 582-585 (e.g., T582, N583, T584, Q585) of SEQ ID NO: 981. In some embodiments, [N1] is present at positions 582-585, numbered according to SEQ ID NO: 981. In some embodiments, X1of [N1] is present at position 582, X2of [N1] is present at position 583, X3of [N1] is present at position 584, and X4of [N1] is present at position 585, numbered according to SEQ ID NO: 981. In some embodiments, [N2] replaces positions 586-589 (e.g., S586, A587, Q588, A589), numbered according to SEQ ID NO: 138. In some embodiments [N2] corresponds to positions 586-589 (e.g., D586, W587, H588, and R589) of SEQ ID NO: 981. In some embodiments, [N2] is present at positions 586- 589, numbered according to SEQ ID NO: 981. In some embodiments [N3] replaces positions 590-592 (e.g., Q590, A591, Q592), numbered according to SEQ ID NO: 138. In some embodiments, [N3] corresponds to positions 590-592 (e.g., I590, A591, Q592) of SEQ ID NO: 981. In some embodiments, [N3] is present at positions 590-592, numbered according to SEQ ID NO: 981. In some embodiments, X5of [N3] is present at position 590, X6of [N3] is present at position 591, and X7of [N3] is present at position 592, numbered according to SEQ ID NO: 981. In some embodiments, [N1]-[N2] is present at positions 582-589, numbered according to SEQ ID NO: 981. In some embodiments, [N2]-[N3] is present at positions 586-592, numbered according to SEQ ID NO: 981. In some embodiments, [N1]-[N2]-[N3] is present at positions 582-592, numbered according to SEQ ID NO: 981.

[0009] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein 2 321651967.1Attorney Docket No.: V2071-3035PCT the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4683), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein (i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, P, or a conservative substitution thereof; and / or (ii) [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, or a conservative substitution thereof. In some embodiments, position X4of [N1] is Q. In some embodiments, position X5of [N3] is I. In some embodiments, [N1] replaces positions 582-585 (e.g., T582, N583, H584, Q585), numbered according to SEQ ID NO: 138. In some embodiments, [N1] corresponds to positions 582-585 (e.g., T582, N583, T584, Q585) of SEQ ID NO: 981. In some embodiments, [N1] is present at positions 582-585, numbered according to SEQ ID NO: 981. In some embodiments, X1of [N1] is present at position 582, X2of [N1] is present at position 583, X3of [N1] is present at position 584, and X4of [N1] is present at position 585, numbered according to SEQ ID NO: 981. In some embodiments, [N2] replaces positions 586-589 (e.g., S586, A587, Q588, A589), numbered according to SEQ ID NO: 138. In some embodiments [N2] corresponds to positions 586-589 (e.g., D586, W587, H588, and R589) of SEQ ID NO: 981. In some embodiments, [N2] is present at positions 586- 589, numbered according to SEQ ID NO: 981. In some embodiments [N3] replaces positions 590-592 (e.g., Q590, A591, Q592), numbered according to SEQ ID NO: 138. In some embodiments, [N3] corresponds to positions 590-592 (e.g., I590, A591, Q592) of SEQ ID NO: 981. In some embodiments, [N3] is present at positions 590-592, numbered according to SEQ ID NO: 981. In some embodiments, X5of [N3] is present at position 590, X6of [N3] is present at position 591, and X7of [N3] is present at position 592, numbered according to SEQ ID NO: 981. In some embodiments, [N1]-[N2] is present at positions 582-589, numbered according to SEQ ID NO: 981. In some embodiments, [N2]-[N3] is present at positions 586-592, numbered according to SEQ ID NO: 981. In some embodiments, [N1]-[N2]-[N3] is present at positions 582-592, numbered according to SEQ ID NO: 981.

[0010] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14, consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; (c) an amino acid sequence comprising at least one, two, or three, but no more than four different amino acids, relative to any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31. In some embodiments, the amino acid sequence is present in loop VIII. In some embodiments, 3 321651967.1Attorney Docket No.: V2071-3035PCT the amino acid sequence replaces positions 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and / or 596 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, Q592, T593, G594, W595, and / or V596), numbered according to SEQ ID NO: 138.

[0011] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. In some embodiments, the amino acid sequence is present in loop VIII. In some embodiments, the amino acid sequence replaces positions 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and / or 596 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, Q592, T593, G594, W595, and / or V596), numbered according to SEQ ID NO: 138. In some embodiments, the amino acid sequence replaces positions 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and / or 596 (e.g., A581, T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, Q592, T593, G594, W595, and / or V596), numbered according to SEQ ID NO: 138.

[0012] In yet another aspect, present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of TQDWHRI (SEQ ID NO: 941), wherein: (i) the at least 3 consecutive amino acids comprise TQD; (ii) the at least 4 consecutive amino acids comprise TQDW (SEQ ID NO: 4684); (iii) the at least 5 consecutive amino acids comprise TQDWH (SEQ ID NO: 4685); or (iv) the at least 6 consecutive amino acids comprise TQDWHR (SEQ ID NO: 4686); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-736 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence 4 321651967.1Attorney Docket No.: V2071-3035PCT of positions 203-736 of SEQ ID NO: 138 or positions 203-736 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 70% (e.g., at least 75, 80, 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c).

[0013] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of TQDWHRI (SEQ ID NO: 941), wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138- 736 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-736 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 70% (e.g., at least 75, 80, 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c).

[0014] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and / or Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and / or Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981.

[0015] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. 5 321651967.1Attorney Docket No.: V2071-3035PCT

[0016] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of the substitutions H584T, S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the substitutions H584T, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138.

[0017] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981.

[0018] In another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the substitutions H584T, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138.

[0019] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981.

[0020] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981. 6 321651967.1Attorney Docket No.: V2071-3035PCT

[0021] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises an amino acid sequence comprising 30, 20, or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981.

[0022] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981.

[0023] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 95% identical thereto.

[0024] In another aspect, the present disclosure provides an AAV capsid variant comprising the amino acid H at position 597, numbered according to SEQ ID NO: 138 or 981, and one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, I at position 590, and H at position 597, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 943.

[0025] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, I at position 590, and H at position 597, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 943.

[0026] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the substitution Q597H, numbered according to SEQ ID NO: 138; and one, two, three, four, five or all of the substitutions H584T, S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the substitutions H584T, S586D, 7 321651967.1Attorney Docket No.: V2071-3035PCT A587W, Q588H, A589R, Q590I, and Q597H, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 943.

[0027] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the substitutions H584T, S586D, A587W, Q588H, A589R, Q590I, and Q597H, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 943.

[0028] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the amino acid sequence of TNTQDWHRIAQTGWVH (SEQ ID NO: 943). In some embodiments, the amino acid sequence of SEQ ID NO: 943 is present at positions 582 to 597, numbered according to SEQ ID NO: 138 or 981.

[0029] In another aspect, the present disclosure provides an AAV capsid variant comprising the amino acid T at position 583 and Q at position 584, numbered according to SEQ ID NO: 138 or 981; and one, two, three, four, or all of the amino acid D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid T at position 583, Q at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 984.

[0030] In yet another aspect, the present disclosure an AAV capsid variant comprising the amino acid T at position 583, Q at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 984.

[0031] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the substitutions N583T and H584Q, numbered according to SEQ ID NO: 138; and one, two, three, four, or all of the substitutions S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the substitutions N583T, H584Q, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 984.

[0032] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the substitutions N583T, H584Q, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. In some embodiments, the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 984. 8 321651967.1Attorney Docket No.: V2071-3035PCT

[0033] In yet another aspect, the present disclosure provides an AAV capsid variant comprising the amino acid sequence of TTQQDWHRIAQTGWV (SEQ ID NO: 984). In some embodiments, the amino acid sequence of SEQ ID NO: 984 is present at positions 582 to 596, numbered according to SEQ ID NO: 138 or 981.

[0034] In yet another aspect, the present disclosure provides an AAV particle comprising an AAV capsid variant described herein and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau).

[0035] In some embodiments, the anti-tau antibody molecule binds to the N-terminal region, mid- domain region, C-terminal region, microtubule binding domain, or the proline-rich domain of a tau protein (e.g., a human tau protein comprising the amino acid sequence of SEQ ID NO: 9200). In some embodiments, the anti-tau antibody molecule binds to (a) all or a portion of (e.g., one or more residues within) amino acid residues (1) 9-18, (2) 15-25, (3) 25-30, and / or (4) 15-30, numbered according to SEQ ID NO: 9200; (b) all or a portion of (e.g., one or more residues within) amino acid residues (1) 125-131, (2) 204-222, (3) 234-246, (4) 234-259, and / or (5) 235-246, numbered according to SEQ ID NO: 9200; (c) an epitope which includes one or more of pT181, pS199, pS202, pT205, pT212, pS214, pT217, pT231, pS234, pS235, pS258, pS259, pS396, pS404, pS422, and / or pT217, numbered according to SEQ ID NO: 9200; (d) all or a portion of (one or more residues within) amino acid residues (1) 387-408 and / or (2) 409- 436, numbered according to SEQ ID NO: 9200; (e) all or a portion of (e.g., one or more residues within) amino acid residues (1) 32-49, (2) 55-76, (3) 57-72, (4) 159-194, (5) 175-191, (6) 185-200, (7) 219-247, (8) 223-238, (9) 381-426, (10) 383-400, (11) 409-436, and / or (12) 413-430, numbered according to SEQ ID NO: 9200; (f) a conformational epitope which includes all or a portion of (e.g., one or more residues within) amino acid residues (1) 55-76, (2) 159-194, (3) 219-247, and / or (4) 381-426, numbered according to SEQ ID NO: 9200.

[0036] In some embodiments, the anti-tau antibody molecule comprises: (i) a heavy chain variable region comprising one, two, or three heavy chain complementary determining region (HCDR) sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C); and / or (ii) a light chain variable region comprising one, two, or three light chain complementary determining region (LCDR) sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C).

[0037] In some embodiments, the anti-tau antibody molecule comprises: (i) a heavy chain variable region (VH) comprising the amino acid sequence of the VH of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence 9 321651967.1Attorney Docket No.: V2071-3035PCT identity to the VH sequence of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VH of any of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C); and / or (ii) a light chain variable region (VL) comprising the amino acid sequence of the VL of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VL of any of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C).

[0038] In some embodiments, the anti-tau antibody molecule comprises (a) the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences, (b) the VH and / or VL sequences, or (c) the heavy chain and / or light chain sequences of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, or V0052 (as described, e.g., in WO2020223276 and WO2021 / 211753), or Ab1, Ab2, Ab3, Ab4, or Ab5. In some embodiments, the anti-tau antibody molecule has at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in a CDR relative to the HCDR1-3 and LCDR1-3 sequences of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, or V0052. In some embodiments, the anti-tau antibody molecule comprises a VH sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5, and / or a VL sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5. In some embodiments, the anti-tau antibody molecule comprises a VH sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VH sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5, and / or a VL sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VL sequence of any one of IPN002, AT8, PT3, UCB, PT76, PHF1, C10.2, V0004, V0009, V0022, V0023, V0024, V0052, Ab1, Ab2, Ab3, Ab4, or Ab5. 10 321651967.1Attorney Docket No.: V2071-3035PCT

[0039] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively. In some embodiments, the antibody is a humanized antibody.

[0040] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or all of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562; and / or (ii) the VL comprises and amino acid sequence comprising one, two, or all of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO: 1573. 11 321651967.1Attorney Docket No.: V2071-3035PCT

[0041] In yet another aspect, the present disclosure provides antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or all of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562; and / or (ii) the VL comprises and amino acid sequence comprising one, two, or all of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573.

[0042] In yet another aspect, the present disclosure provides antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ 12 321651967.1Attorney Docket No.: V2071-3035PCT ID NOs: 67-71; and / or (ii) the VL comprises an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76.

[0043] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; and (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573.

[0044] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3) and / or a light chain variable region (VL) comprising a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, 13 321651967.1Attorney Docket No.: V2071-3035PCT LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69; and / or (ii) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73.

[0045] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain variable region (VH) comprising the amino acid sequence of SEQ ID NO: 69, and a light chain variable region (VL) comprising the amino acid sequence of SEQ ID NO: 73.

[0046] In yet another aspect, the present disclosure provides an antibody molecule that binds to human tau, which comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 172, and a light chain (LC) comprising the amino acid sequence of SEQ ID NO: 176.

[0047] In some embodiments, the anti-tau antibody molecules have a heavy chain constant region and / or light chain constant region listed in Table 17, or a sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the heavy chain and / or light chain constant region sequences in Table 17, or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the heavy chain and / or light chain constant region sequences in Table 17.

[0048] In some embodiments, the anti-tau antibody molecule competes for binding to tau with an antibody described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C). In some embodiments, the anti-tau antibody molecule binds to the same epitope, substantially the same epitope as, an epitope that overlaps with, or an epitope that substantially overlaps with an antibody described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C).

[0049] In some embodiments, the anti-tau antibody molecule comprises one or more of (a) an Fc region or functional variant thereof, e.g., an Fc region with altered effector function (e.g., reduced affinity for Fc receptor, reduced ADCC, reduced CDC), (b) a signal sequence, (c) a linker (e.g., a linker listed in Table 19).

[0050] In some embodiments, the anti-tau antibody molecule is a multispecific antibody molecule comprising at least two antigen-binding domains (e.g., a bispecific antibody molecule).

[0051] In some embodiments, the AAV particle comprises a viral genome comprising one or more of 14 321651967.1Attorney Docket No.: V2071-3035PCT the following: a promoter operably linked to the nucleic acid sequence encoding the antibody molecule, a poly A sequence, an inverted terminal repeat (ITR) sequence (positioned 5’ and / or 3’ relative to the encoded antibody molecule), an enhancer, a Kozak sequence (e.g., GCCGCCACCATG (SEQ ID NO: 9021) or GAGGAGCCACC (SEQ ID NO: 9022)), an intron region, and / or an exon region described herein. In some embodiments, the viral genome comprises a nucleotide sequence encoding a miR binding site described herein.

[0052] In some embodiments, the viral genome is single stranded or self-complementary. In some embodiments, the viral genome further comprises a nucleotide sequence encoding a Rep protein described herein.

[0053] Also provided herein are cells (e.g., a host cell) comprising an AAV particle described herein. In some embodiments, the cell is a mammalian cell (e.g., a cell of a brain region, such as a neuron, astrocyte, or glial cell) or an insect cell.

[0054] In yet another aspect, provided herein is a method of making an AAV particle described herein, comprising (a) providing a host cell comprising a viral genome; and (b) incubating the host cell under conditions suitable to enclose the viral genome in an AAV capsid variant, e.g., an AAV capsid variant described herein, thereby making the AAV particle.

[0055] In yet another aspect, provided herein is a pharmaceutical composition comprising an AAV particle described herein, and a carrier (e.g., a pharmaceutically acceptable excipient).

[0056] In yet another aspect, provided herein is a method of delivering a payload to a cell or tissue (e.g., CNS cell or CNS tissue) comprising administering an effective amount of a pharmaceutical composition described herein or an AAV particle described herein. In some embodiments, the cell or tissue is within a subject.

[0057] In yet another aspect, provided herein is a method of treating a subject having or diagnosed with having a neurological disorder (e.g., a neurodegenerative disorder), tau-related disease, or tauopathy, comprising administering to the subject an effective amount of the pharmaceutical composition described herein, or an AAV particle comprising an AAV capsid variant described herein described herein. In some embodiments, the AAV particles, compositions, and methods may, for example, be used for treating a tau-related disorder (e.g., disease associated with expression of tau, neurological (e.g., neurodegenerative) disorders, and / or tauopathies), such as Alzheimer’s disease (AD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), chronic traumatic encephalopathy (CTE), progressive Supranuclear Palsy (PSP), Down’s syndrome, Pick’s disease, corticobasal degeneration (CBD), corticobasal syndrome, amyotrophic lateral sclerosis (ALS), prion diseases, Creutzfeldt-Jakob disease (CJD), multiple system 15 321651967.1Attorney Docket No.: V2071-3035PCT atrophy, tangle-only dementia, and progressive subcortical gliosis.

[0058] In some embodiments, the AAV particle is administered to the subject intravenously, via intra- cisterna magna injection (ICM), intracerebrally, intrathecally, intracerebroventricularly, via intraparenchymal administration, or intramuscularly, or via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration.

[0059] In some embodiments, administration of the AAV particle or pharmaceutical composition described herein results in a decreased presence, level, and / or activity of a tau mRNA, tau protein, or combination thereof. In other embodiments, administration of the AAV particle or pharmaceutical composition described herein results in a increased presence, level, and / or activity of a tau mRNA, tau protein, or combination thereof.

[0060] Those skilled in the art will recognize or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following enumerated embodiments. Enumerated Embodiments 1. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4681), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein: (i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, K, E, S, P, R, N, H, or a conservative substitution thereof; and / or (ii) [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, T, M, S, N, L, F, or a conservative substitution thereof. 2. The AAV particle of embodiment 1, wherein the AAV capsid variant comprises the amino acid Q at position 585, numbered according to SEQ ID NO: 138 or 981. 3. The AAV particle of embodiment 1, wherein the AAV capsid variant comprises an amino acid other than Q at position 585, numbered according to SEQ ID NO: 138 or 981. 4. The AAV particle of embodiment 1 or 3, wherein the AAV capsid variant comprises the amino acid K at position 585, numbered according to SEQ ID NO: 138 or 981. 16 321651967.1Attorney Docket No.: V2071-3035PCT 5. The AAV particle of any one of embodiments 1-4, wherein the AAV capsid variant comprises one, two, three, or all of an amino acid other than T at position 582 (e.g., S, R, A, I, C, N, K, L, or Q), an amino acid other than N at position 583 (e.g., T, G, V, S, Y, K, I, H, D, or F), an amino acid other than H at position 584 (e.g., T, N, K, D, I, S, P, A, Y, E, V, L, M, R, Q, or C), and / or an amino acid other than Q at position 585 (e.g., K, E, S, P, R, N, H), numbered according to SEQ ID NO: 138. 6. The AAV particle of any one of embodiments 1-5, wherein [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, K, E, S, P, R, N, or H. 7. The AAV particle of any one of embodiments 1-6, wherein position X4is Q or K. 8. The AAV particle of any one of embodiments 1, 2, or 5-7, wherein position X4is Q. 9. The AAV particle of any one of embodiments 1 or 3-7, wherein position X4is K. 10. The AAV particle of any one of embodiments 1-9, wherein the AAV capsid variant comprises an amino acid other than H at position 584 (e.g., T), numbered according to SEQ ID NO: 138. 11. The AAV particle of any one of embodiments 1-10, wherein the AAV capsid variant comprises the amino acid T at position 584, numbered according to SEQ ID NO: 138 or 981. 12. The AAV particle of any one of embodiments 1-11, wherein: (i) position X1is T, S, R, A, I, C, N, K, L, or Q; (ii) position X2is N, T, G, V, S, Y, K, I, H, D, or F; and / or (iii) position X3is T, N, K, D, I, S, P, A, Y, E, V, L, M, R, H, Q, or C. 13. The AAV particle of any one of embodiments 1-12, wherein [N1] comprises TN, NT, NK, SN, TT, RN, TG, TV, ST, TS, TY, AN, TK, TI, IN, TH, TD, CN, NN, KN, LN, SG, TF, RT, SY, SS, QN, ND, NP, GK, TA, VK, NY, TE, SK, NI, YN, GT, TL, TM, YT, TR, NS, IT, NA, KT, GN, HT, DT, NE, NH, YI, HN, NQ, FS, NM, NL, SM, NC, VT, KQ, TQ, DQ, IQ, SQ, PS, KE, AQ, YQ, TP, EQ, VQ, LQ, MQ, KS, IE, RQ, IK, AK, PK, NR, HQ, QQ, or CQ. 14. The AAV particle of any one of embodiments 1-13, wherein [N1] comprises TNT, TNK, TNN, SNN, SNK, SNT, TTN, TND, TTI, RNT, TTK, TTS, TTD, TNP, TTT, TGK, TTA, TVK, TNY, STK, TTE, 17 321651967.1Attorney Docket No.: V2071-3035PCT TSK, TNI, TYN, STI, TTV, TGT, TTL, TTM, ANN, SNI, TKN, TYT, TTR, TNS, TST, TIT, INT, TNA, TKT, STN, ANT, RNN, TGN, TSN, THT, TDT, TNE, CNT, INN, NNN, KNN, LNN, TIN, TNH, STT, SNS, STS, TYI, SGT, THN, TNQ, RNI, TFS, RNS, TNM, RTT, KNT, TNL, TSM, SYT, TNC, SST, TVT, QNT, NTK, NNQ, NKQ, NNE, NTQ, NDQ, TIQ, TKQ, TSQ, TDQ, NPS, NKE, TTQ, GKQ, TAQ, VKQ, NYQ, NTP, TEQ, SKQ, NIQ, YNQ, TVQ, GTQ, NTR, TLQ, TMQ, KNQ, YTQ, NKS, NTE, NIE, TRQ, NSQ, YTK, NIK, NNK, NSK, ITK, NAK, KTK, GNQ, SNQ, HTK, DTK, NEQ, NPK, YTE, NNR, INQ, NHQ, YIQ, HNQ, ITQ, STQ, NSN, NQQ, NNP, ITE, NTN, FSQ, NNH, NMQ, NTS, NLQ, SMQ, NCQ, or VTQ 15. The AAV particle of any one of embodiments 1-14, wherein [N1] is or comprises TNTQ (SEQ ID NO: 4688), TNTK (SEQ ID NO: 4689), TNNQ (SEQ ID NO: 4690), SNNQ (SEQ ID NO: 4691), TNKQ (SEQ ID NO: 4692), TNNE (SEQ ID NO: 4693), SNKQ (SEQ ID NO: 4694), SNTQ (SEQ ID NO: 4695), TTNQ (SEQ ID NO: 4696), TNDQ (SEQ ID NO: 4697), TTIQ (SEQ ID NO: 4698), RNTQ (SEQ ID NO: 4699), TTKQ (SEQ ID NO: 4700), TTSQ (SEQ ID NO: 4701), TTDQ (SEQ ID NO: 4702), TNPS (SEQ ID NO: 4703), TNKE (SEQ ID NO: 4704), TTTQ (SEQ ID NO: 4705), TGKQ (SEQ ID NO: 4706), TTAQ (SEQ ID NO: 4707), TVKQ (SEQ ID NO: 4708), TNYQ (SEQ ID NO: 4709), TNTP (SEQ ID NO: 4710), STKQ (SEQ ID NO: 4711), TTEQ (SEQ ID NO: 4712), TSKQ (SEQ ID NO: 4713), TNIQ (SEQ ID NO: 4714), TYNQ (SEQ ID NO: 4715), STIQ (SEQ ID NO: 4716), TTVQ (SEQ ID NO: 4717), TGTQ (SEQ ID NO: 4718), TNTR (SEQ ID NO: 4719), TTLQ (SEQ ID NO: 4720), TTMQ (SEQ ID NO: 4721), ANNQ (SEQ ID NO: 4722), SNIQ (SEQ ID NO: 4723), TKNQ (SEQ ID NO: 4724), TYTQ (SEQ ID NO: 4725), TNKS (SEQ ID NO: 4726), SNTE (SEQ ID NO: 4727), TNTE (SEQ ID NO: 4728), TNIE (SEQ ID NO: 4729), TTRQ (SEQ ID NO: 4730), TNSQ (SEQ ID NO: 4731), TYTK (SEQ ID NO: 4732), TTTK (SEQ ID NO: 4733), TNIK (SEQ ID NO: 4734), SNTK (SEQ ID NO: 4735), TNNK (SEQ ID NO: 4736), TNSK (SEQ ID NO: 4737), TSTK (SEQ ID NO: 4738), TITK (SEQ ID NO: 4739), INTK (SEQ ID NO: 4740), TNAK (SEQ ID NO: 4741), TKTK (SEQ ID NO: 4742), STNQ (SEQ ID NO: 4743), ANTK (SEQ ID NO: 4744), RNNQ (SEQ ID NO: 4745), TGNQ (SEQ ID NO: 4746), TSNQ (SEQ ID NO: 4747), THTK (SEQ ID NO: 4748), TDTK (SEQ ID NO: 4749), TNEQ (SEQ ID NO: 4750), CNTQ (SEQ ID NO: 4751), TNPK (SEQ ID NO: 4752), INNQ (SEQ ID NO: 4753), TYTE (SEQ ID NO: 4754), NNNQ (SEQ ID NO: 4755), KNNQ (SEQ ID NO: 4756), TNNR (SEQ ID NO: 4757), LNNQ (SEQ ID NO: 4758), TINQ (SEQ ID NO: 4759), TNHQ (SEQ ID NO: 4760), STTQ (SEQ ID NO: 4761), SNSQ (SEQ ID NO: 4762), STSQ (SEQ ID NO: 4763), TYIQ (SEQ ID NO: 4764), SGTQ (SEQ ID NO: 4765), THNQ (SEQ ID NO: 4766), TITQ (SEQ ID NO: 4767), TSTQ (SEQ ID NO: 4768), TNSN (SEQ ID NO: 4769), TNQQ (SEQ ID NO: 4770), RNIQ (SEQ ID NO: 4771), TNNP (SEQ ID NO: 4772), TITE (SEQ ID NO: 4773), TNTN (SEQ ID NO: 4774), TFSQ 18 321651967.1Attorney Docket No.: V2071-3035PCT (SEQ ID NO: 4775), RNSQ (SEQ ID NO: 4776), INTQ (SEQ ID NO: 4777), RNTE (SEQ ID NO: 4778), TNNH (SEQ ID NO: 4779), TNMQ (SEQ ID NO: 4780), RTTQ (SEQ ID NO: 4781), SNIE (SEQ ID NO: 4782), TNTS (SEQ ID NO: 4783), KNTQ (SEQ ID NO: 4784), TNLQ (SEQ ID NO: 4785), TSMQ (SEQ ID NO: 4786), SYTQ (SEQ ID NO: 4787), TNCQ (SEQ ID NO: 4788), SSTQ (SEQ ID NO: 4789), TVTQ (SEQ ID NO: 4790), or QNTQ (SEQ ID NO: 4791). 16. The AAV particle of any one of embodiments 1-15, wherein [N1] is or comprises TNTQ (SEQ ID NO: 4688). 17. The AAV particle of any one of embodiments 1-15, wherein [N1] is or comprises TNTK (SEQ ID NO: 4689). 18. The AAV particle of any one of embodiments 1-17, wherein [N1]-[N2] comprises: (i) TQDWHR (SEQ ID NO: 4686), TKDWHR (SEQ ID NO: 4792), NQDWHR (SEQ ID NO: 4793), KQDWHR (SEQ ID NO: 4794), NEDWHR (SEQ ID NO: 4795), DQDWHR (SEQ ID NO: 4796), IQDWHR (SEQ ID NO: 4797), SQDWHR (SEQ ID NO: 4798), PSDWHR (SEQ ID NO: 4799), KEDWHR (SEQ ID NO: 4800), AQDWHR (SEQ ID NO: 4801), YQDWHR (SEQ ID NO: 4802), TPDWHR (SEQ ID NO: 4803), EQDWHR (SEQ ID NO: 4804), VQDWHR (SEQ ID NO: 4805), TRDWHR (SEQ ID NO: 4806), LQDWHR (SEQ ID NO: 4807), MQDWHR (SEQ ID NO: 4808), KSDWHR (SEQ ID NO: 4809), TEDWHR (SEQ ID NO: 4810), IEDWHR (SEQ ID NO: 4811), RQDWHR (SEQ ID NO: 4812), IKDWHR (SEQ ID NO: 4813), NKDWHR (SEQ ID NO: 4814), SKDWHR (SEQ ID NO: 4815), AKDWHR (SEQ ID NO: 4816), PKDWHR (SEQ ID NO: 4817), NRDWHR (SEQ ID NO: 4818), HQDWHR (SEQ ID NO: 4819), SNDWHR (SEQ ID NO: 4820), QQDWHR (SEQ ID NO: 4821), NPDWHR (SEQ ID NO: 4822), TNDWHR (SEQ ID NO: 4823), NHDWHR (SEQ ID NO: 4824), TSDWHR (SEQ ID NO: 4825), or CQDWHR (SEQ ID NO: 4826); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 19. The AAV particle of any one of embodiments 1-18, wherein [N1]-[N2] comprises: 19 321651967.1Attorney Docket No.: V2071-3035PCT (i) NTQDWHR (SEQ ID NO: 4827), NTKDWHR (SEQ ID NO: 4828), NNQDWHR (SEQ ID NO: 4829), NKQDWHR (SEQ ID NO: 4830), NNEDWHR (SEQ ID NO: 4831), TNQDWHR (SEQ ID NO: 4832), NDQDWHR (SEQ ID NO: 4833), TIQDWHR (SEQ ID NO: 4834), TKQDWHR (SEQ ID NO: 4835), TSQDWHR (SEQ ID NO: 4836), TDQDWHR (SEQ ID NO: 4837), NPSDWHR (SEQ ID NO: 4838), NKEDWHR (SEQ ID NO: 4839), TTQDWHR (SEQ ID NO: 4840), GKQDWHR (SEQ ID NO: 4841), TAQDWHR (SEQ ID NO: 4842), VKQDWHR (SEQ ID NO: 4843), NYQDWHR (SEQ ID NO: 4844), NTPDWHR (SEQ ID NO: 4845), TEQDWHR (SEQ ID NO: 4846), SKQDWHR (SEQ ID NO: 4847), NIQDWHR (SEQ ID NO: 4848), YNQDWHR (SEQ ID NO: 4849), TVQDWHR (SEQ ID NO: 4850), GTQDWHR (SEQ ID NO: 4851), NTRDWHR (SEQ ID NO: 4852), TLQDWHR (SEQ ID NO: 4853), TMQDWHR (SEQ ID NO: 4854), KNQDWHR (SEQ ID NO: 4855), YTQDWHR (SEQ ID NO: 4856), NKSDWHR (SEQ ID NO: 4857), NTEDWHR (SEQ ID NO: 4858), NIEDWHR (SEQ ID NO: 4859), TRQDWHR (SEQ ID NO: 4860), NSQDWHR (SEQ ID NO: 4861), YTKDWHR (SEQ ID NO: 4862), TTKDWHR (SEQ ID NO: 4863), NIKDWHR (SEQ ID NO: 4864), NNKDWHR (SEQ ID NO: 4865), NSKDWHR (SEQ ID NO: 4866), STKDWHR (SEQ ID NO: 4867), ITKDWHR (SEQ ID NO: 4868), NAKDWHR (SEQ ID NO: 4869), KTKDWHR (SEQ ID NO: 4870), GNQDWHR (SEQ ID NO: 4871), SNQDWHR (SEQ ID NO: 4872), HTKDWHR (SEQ ID NO: 4873), DTKDWHR (SEQ ID NO: 4874), NEQDWHR (SEQ ID NO: 4875), NPKDWHR (SEQ ID NO: 4876), YTEDWHR (SEQ ID NO: 4877), NNRDWHR (SEQ ID NO: 4878), INQDWHR (SEQ ID NO: 4879), NHQDWHR (SEQ ID NO: 4880), YIQDWHR (SEQ ID NO: 4881), HNQDWHR (SEQ ID NO: 4882), ITQDWHR (SEQ ID NO: 4883), STQDWHR (SEQ ID NO: 4884), NSNDWHR (SEQ ID NO: 4885), NQQDWHR (SEQ ID NO: 4886), NNPDWHR (SEQ ID NO: 4887), ITEDWHR (SEQ ID NO: 4888), NTNDWHR (SEQ ID NO: 4889), FSQDWHR (SEQ ID NO: 4890), NNHDWHR (SEQ ID NO: 4891), NMQDWHR (SEQ ID NO: 4892), NTSDWHR (SEQ ID NO: 4893), NLQDWHR (SEQ ID NO: 4894), SMQDWHR (SEQ ID NO: 4895), NCQDWHR (SEQ ID NO: 4896), VTQDWHR (SEQ ID NO: 4897); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5 or 6 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 20. The AAV particle of any one of embodiments 1-19, wherein [N1]-[N2] is or comprises: 20 321651967.1Attorney Docket No.: V2071-3035PCT (i) TNTQDWHR (SEQ ID NO: 4898), TNTKDWHR (SEQ ID NO: 4899), TNNQDWHR (SEQ ID NO: 4900), SNNQDWHR (SEQ ID NO: 4901), TNKQDWHR (SEQ ID NO: 4902), TNNEDWHR (SEQ ID NO: 4903), SNKQDWHR (SEQ ID NO: 4904), SNTQDWHR (SEQ ID NO: 4905), TTNQDWHR (SEQ ID NO: 4906), TNDQDWHR (SEQ ID NO: 4907), TTIQDWHR (SEQ ID NO: 4908), RNTQDWHR (SEQ ID NO: 4909), TTKQDWHR (SEQ ID NO: 4910), TTSQDWHR (SEQ ID NO: 4911), TTDQDWHR (SEQ ID NO: 4912), TNPSDWHR (SEQ ID NO: 4913), TNKEDWHR (SEQ ID NO: 4914), TTTQDWHR (SEQ ID NO: 4915), TGKQDWHR (SEQ ID NO: 4916), TTAQDWHR (SEQ ID NO: 4917), TVKQDWHR (SEQ ID NO: 4918), TNYQDWHR (SEQ ID NO: 4919), TNTPDWHR (SEQ ID NO: 4920), STKQDWHR (SEQ ID NO: 4921), TTEQDWHR (SEQ ID NO: 4922), TSKQDWHR (SEQ ID NO: 4923), TNIQDWHR (SEQ ID NO: 4924), TYNQDWHR (SEQ ID NO: 4925), STIQDWHR (SEQ ID NO: 4926), TTVQDWHR (SEQ ID NO: 4927), TGTQDWHR (SEQ ID NO: 4928), TNTRDWHR (SEQ ID NO: 4929), TTLQDWHR (SEQ ID NO: 4930), TTMQDWHR (SEQ ID NO: 4931), ANNQDWHR (SEQ ID NO: 4932), SNIQDWHR (SEQ ID NO: 4933), TKNQDWHR (SEQ ID NO: 4934), TYTQDWHR (SEQ ID NO: 4935), TNKSDWHR (SEQ ID NO: 4936), SNTEDWHR (SEQ ID NO: 4937), TNTEDWHR (SEQ ID NO: 4938), TNIEDWHR (SEQ ID NO: 4939), TTRQDWHR (SEQ ID NO: 4940), TNSQDWHR (SEQ ID NO: 4941), TYTKDWHR (SEQ ID NO: 4942), TTTKDWHR (SEQ ID NO: 4943), TNIKDWHR (SEQ ID NO: 4944), SNTKDWHR (SEQ ID NO: 4945), TNNKDWHR (SEQ ID NO: 4946), TNSKDWHR (SEQ ID NO: 4947), TSTKDWHR (SEQ ID NO: 4948), TITKDWHR (SEQ ID NO: 4949), INTKDWHR (SEQ ID NO: 4950), TNAKDWHR (SEQ ID NO: 4951), TKTKDWHR (SEQ ID NO: 4952), STNQDWHR (SEQ ID NO: 4953), ANTKDWHR (SEQ ID NO: 4954), RNNQDWHR (SEQ ID NO: 4955), TGNQDWHR (SEQ ID NO: 4956), TSNQDWHR (SEQ ID NO: 4957), THTKDWHR (SEQ ID NO: 4958), TDTKDWHR (SEQ ID NO: 4959), TNEQDWHR (SEQ ID NO: 4960), CNTQDWHR (SEQ ID NO: 4961), TNPKDWHR (SEQ ID NO: 4962), INNQDWHR (SEQ ID NO: 4963), TYTEDWHR (SEQ ID NO: 4964), NNNQDWHR (SEQ ID NO: 4965), KNNQDWHR (SEQ ID NO: 4966), TNNRDWHR (SEQ ID NO: 4967), LNNQDWHR (SEQ ID NO: 4968), TINQDWHR (SEQ ID NO: 4969), TNHQDWHR (SEQ ID NO: 4970), STTQDWHR (SEQ ID NO: 4971), SNSQDWHR (SEQ ID NO: 4972), STSQDWHR (SEQ ID NO: 4973), TYIQDWHR (SEQ ID NO: 4974), SGTQDWHR (SEQ ID NO: 4975), THNQDWHR (SEQ ID NO: 4976), TITQDWHR (SEQ ID NO: 4977), TSTQDWHR (SEQ ID NO: 4978), TNSNDWHR (SEQ ID NO: 4979), TNQQDWHR (SEQ ID NO: 4980), RNIQDWHR (SEQ ID NO: 4981), TNNPDWHR (SEQ ID NO: 4982), TITEDWHR (SEQ ID NO: 4983), TNTNDWHR (SEQ ID NO: 4984), TFSQDWHR (SEQ ID NO: 4985), RNSQDWHR (SEQ ID NO: 4986), INTQDWHR (SEQ ID NO: 4987), RNTEDWHR (SEQ ID NO: 4988), TNNHDWHR (SEQ ID NO: 4989), TNMQDWHR (SEQ ID NO: 4990), RTTQDWHR (SEQ ID NO: 4991), SNIEDWHR (SEQ ID NO: 21 321651967.1Attorney Docket No.: V2071-3035PCT 4992), TNTSDWHR (SEQ ID NO: 4993), KNTQDWHR (SEQ ID NO: 4994), TNLQDWHR (SEQ ID NO: 4995), TSMQDWHR (SEQ ID NO: 4996), SYTQDWHR (SEQ ID NO: 4997), TNCQDWHR (SEQ ID NO: 4998), SSTQDWHR (SEQ ID NO: 4999), TVTQDWHR (SEQ ID NO: 5000), or QNTQDWHR (SEQ ID NO: 5001); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 56, or 7 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 21. The AAV particle of any one of embodiments 1-20, wherein [N1]-[N2] is or comprises TNTQDWHR (SEQ ID NO: 4898). 22. The AAV particle of any one of embodiments 1-20, wherein [N1]-[N2] is or comprises TNTKDWHR (SEQ ID NO: 4899). 23. The AAV particle of any one of embodiments 1-22, wherein the AAV capsid variant comprises one, two, or all of an amino acid other than Q at position 590 (e.g., I, V, T, M, S, N, L, or F), A at position 591 (e.g., Y, P, N, S, T, G, E, V, W, F, Q), and / or Q at position 592 (e.g., G, N, K, H, R, E, L, P, or M), numbered according to SEQ ID NO: 138. 24. The AAV particle of any one of embodiments 1-23, wherein the AAV capsid variant comprises an amino acid other than Q at position 590 (e.g., I, V, T, M, S, N, L, or F), numbered according to SEQ ID NO: 138. 25. The AAV particle of any one of embodiments 1-24, wherein the AAV capsid variant comprises the amino acid I at position 590, numbered according to SEQ ID NO: 138. 26. The AAV particle of any one of embodiments 1-24, wherein the AAV capsid variant comprises the amino acid V at position 590, numbered according to SEQ ID NO: 138. 22 321651967.1Attorney Docket No.: V2071-3035PCT 27. The AAV particle of any one of embodiments 1-26, wherein the AAV capsid variant comprises the amino acid A at position 591 and / or the amino acid Q at position 592, numbered according to SEQ ID NO: 138 or 981. 28. The AAV particle of any one of embodiments 1-27, wherein [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, T, M, S, N, L, or F. 29. The AAV particle of any one of embodiments 1-28, wherein position X5is I or V. 30. The AAV particle of any one of embodiments 1-25 or 27-29, wherein position X5is I. 31. The AAV particle of any one of embodiments 1-30, wherein: (i) position X6is A, Y, P, N, S, T, G, E, V, W, F, or Q; and / or (ii) position X7is Q, G, N, K, H, R, E, L, P, or M. 32. The AAV particle of any one of embodiments 1-31, wherein [N3] comprises IA, IY, VP, IN, VN, VY, VA, IS, IT, TA, MA, SA, IG, IE, IV, NA, LA, IP, FA, VS, VT, IW, IF, IQ, VQ, AQ, AG, YQ, PQ, AN, NQ, SG, SQ, TQ, GQ, EQ, AK, AH, AR, AE, AL, AP, TM, SM, WQ, FQ, QQ, FM, AM, or SN. 33. The AAV particle of any one of embodiments 1-32, wherein [N3] is or comprises IAQ, IAG, IYQ, VPQ, IAN, INQ, VNQ, VYQ, VAN, ISG, ISQ, VAQ, ITQ, TAQ, MAQ, SAQ, IGQ, IEQ, IVQ, NAQ, LAQ, IAK, IAH, IPQ, IAR, IAE, IAL, IAP, FAQ, VSQ, VTM, ISM, IWQ, IFQ, IQQ, VQQ, IFM, IAM, or ISN. 34. The AAV particle of any one of embodiments 1-33, wherein [N3] is or comprises IAQ. 35. The AAV particle of any one of embodiments 1-34, wherein [N2]-[N3] comprises: (i) DWHRIA (SEQ ID NO: 5002), DWHRIY (SEQ ID NO: 5003), DWHRVP (SEQ ID NO: 5004), DWHRIN (SEQ ID NO: 5005), DWHRVN (SEQ ID NO: 5006), DWHRVY (SEQ ID NO: 5007), DWHRVA (SEQ ID NO: 5008), DWHRIS (SEQ ID NO: 5009), DWHRIT (SEQ ID NO: 5010), DWHRTA (SEQ ID NO: 5011), DWHRMA (SEQ ID NO: 5012), DWHRSA (SEQ ID NO: 5013), DWHRIG (SEQ ID NO: 5014), DWHRIE (SEQ ID NO: 5015), DWHRIV (SEQ ID NO: 5016), DWHRNA (SEQ ID NO: 5017), DWHRLA (SEQ ID NO: 5018), DWHRIP (SEQ ID NO: 5019), DWHRFA (SEQ ID NO: 5020), DWHRVS (SEQ ID NO: 5021), DWHRVT (SEQ ID NO: 5022), 23 321651967.1Attorney Docket No.: V2071-3035PCT DWHRIW (SEQ ID NO: 5023), DWHRIF (SEQ ID NO: 5024), DWHRIQ (SEQ ID NO: 5025), or DWHRVQ (SEQ ID NO: 5026); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 36. The AAV particle of any one of embodiments 1-35, wherein [N2]-[N3] is or comprises: (i) DWHRIAQ (SEQ ID NO: 5027), DWHRIAG (SEQ ID NO: 5028), DWHRIYQ (SEQ ID NO: 5029), DWHRVPQ (SEQ ID NO: 5030), DWHRIAN (SEQ ID NO: 5031), DWHRINQ (SEQ ID NO: 5032), DWHRVNQ (SEQ ID NO: 5033), DWHRVYQ (SEQ ID NO: 5034), DWHRVAN (SEQ ID NO: 5035), DWHRISG (SEQ ID NO: 5036), DWHRISQ (SEQ ID NO: 5037), DWHRVAQ (SEQ ID NO: 5038), DWHRITQ (SEQ ID NO: 5039), DWHRTAQ (SEQ ID NO: 5040), DWHRMAQ (SEQ ID NO: 5041), DWHRSAQ (SEQ ID NO: 5042), DWHRIGQ (SEQ ID NO: 5043), DWHRIEQ (SEQ ID NO: 5044), DWHRIVQ (SEQ ID NO: 5045), DWHRNAQ (SEQ ID NO: 5046), DWHRLAQ (SEQ ID NO: 5047), DWHRIAK (SEQ ID NO: 5048), DWHRIAH (SEQ ID NO: 5049), DWHRIPQ (SEQ ID NO: 5050), DWHRIAR (SEQ ID NO: 5051), DWHRIAE (SEQ ID NO: 5052), DWHRIAL (SEQ ID NO: 5053), DWHRIAP (SEQ ID NO: 5054), DWHRFAQ (SEQ ID NO: 5055), DWHRVSQ (SEQ ID NO: 5056), DWHRVTM (SEQ ID NO: 5057), DWHRISM (SEQ ID NO: 5058), DWHRIWQ (SEQ ID NO: 5059), DWHRIFQ (SEQ ID NO: 5060), DWHRIQQ (SEQ ID NO: 5061), DWHRVQQ (SEQ ID NO: 5062), DWHRIFM (SEQ ID NO: 5063), DWHRIAM (SEQ ID NO: 5064), or DWHRISN (SEQ ID NO: 5065); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, or 6 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 24 321651967.1Attorney Docket No.: V2071-3035PCT 37. The AAV particle of any one of embodiments 1-36, wherein [N2]-[N3] is or comprises DWHRIAQ (SEQ ID NO: 5027). 38. The AAV particle of any one of embodiments 1-37, wherein [N1]-[N2]-[N3] is or comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 343-538; (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 39. The AAV particle of any one of embodiments 1-38, wherein [N1]-[N2]-[N3] is or comprises TNTQDWHRIAQ (SEQ ID NO: 343). 40. The AAV particle of any one of embodiments 1-38, wherein [N1]-[N2]-[N3] is or comprises TNTKDWHRIAQ (SEQ ID NO: 344). 41. The AAV particle of any one of embodiments 1-40, wherein the AAV capsid variant comprises one, two, three, or all of an amino acid other than T at position 593 (e.g., S, N, P, A, or I), a G at position 594 (e.g., N, D, R, V, A, S, or Q), a W at position 595 (e.g., S, C, R, L, or G), and / or a V at position 596 (e.g., A, S, I, C, G, D, F, L, or T), numbered according to SEQ ID NO: 138 or 981. 42. The AAV particle of any one of embodiments 1-40, wherein the AAV capsid variant comprises the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid V at position 596, numbered according to SEQ ID NO: 138 or 981. 43. The AAV particle of any one of embodiments 1-42, wherein the AAV capsid variant further comprises [N4], wherein [N4] comprises positions X8, X9, X10, and X11, wherein: (i) position X8is T, S, N, P, A, or I; (ii) position X9is G, N, D, R, V, A, S, or Q; (iii) position X10is W, S, C, R, L, or G; and / or (iv) position X11is V, A, S, I, C, G, D, F, L, or T. 25 321651967.1Attorney Docket No.: V2071-3035PCT 44. The AAV particle of embodiment 43, wherein [N4] comprises TG, TN, SN, NN, SG, PG, TD, AG, IG, NG, TR, TV, TA, TS, SV, TQ, WV, WA, WS, WI, WC, WG, CV, RV, LV, GV, WD, WF, WL, WT, GW, NW, GS, DW, GC, GR, GL, GG, RW, VW, AW, SW, or QW. 45. The AAV particle of embodiment 43 or 44, wherein [N4] comprises TGW, TNW, SNW, NNW, SGW, PGW, TGS, TDW, TGC, TGR, TGL, TGG, AGW, IGW, NGW, TRW, TVW, TAW, TSW, SVW, TQW, GWV, GWA, NWS, NWV, NWI, GWS, GWI, GWC, GWG, GSV, DWV, GCV, GRV, GLV, GGV, GWD, GWF, RWV, VWV, GWL, AWV, SWV, GWT, or QWV. 46. The AAV particle of any one of embodiments 43-45, wherein [N4] is or comprises TGWV (SEQ ID NO: 5066), TGWA (SEQ ID NO: 5067), TNWS (SEQ ID NO: 5068), SNWV (SEQ ID NO: 5069), TNWV (SEQ ID NO: 5070), TNWI (SEQ ID NO: 5071), NNWV (SEQ ID NO: 5072), TGWS (SEQ ID NO: 5073), TGWI (SEQ ID NO: 5074), TGWC (SEQ ID NO: 5075), TGWG (SEQ ID NO: 5076), SGWV (SEQ ID NO: 5077), PGWV (SEQ ID NO: 5078), TGSV (SEQ ID NO: 5079), TDWV (SEQ ID NO: 5080), TGCV (SEQ ID NO: 5081), TGRV (SEQ ID NO: 5082), TGLV (SEQ ID NO: 5083), TGGV (SEQ ID NO: 5084), AGWV (SEQ ID NO: 5085), IGWV (SEQ ID NO: 5086), TGWD (SEQ ID NO: 5087), NGWV (SEQ ID NO: 5088), TGWF (SEQ ID NO: 5089), TRWV (SEQ ID NO: 5090), TVWV (SEQ ID NO: 5091), TGWL (SEQ ID NO: 5092), TAWV (SEQ ID NO: 5093), TSWV (SEQ ID NO: 5094), TGWT (SEQ ID NO: 5095), SVWV (SEQ ID NO: 5096), TQWV (SEQ ID NO: 5097), or PGWG (SEQ ID NO: 5098). 47. The AAV particle of any one of embodiments 43-46, wherein [N4] is or comprises TGWV (SEQ ID NO: 5066). 48. The AAV particle of any one of embodiments 43-47, wherein [N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 201-245, 247-250, 253-255, 257-265, 268-274, 276-286, 288, 290-297, 299-303, 305-309, 311, 313-319, 323-328, 330-337, 339-342, 539-542, 544, 546, 547, 549-557, 559-589, 592, 593, 595, 596, 598, 599, 601-608, 610-614, 616-622, 625, 628, 630, 631, 633, 636, 638, 639-646, 649, 651-657, 667, 669, 670, 672, 673, 679-683, 685-690, 692, 693, 695, 697, 699-701, 703-705, 708-710, 712-717, 719-723, 728-731, 733-738, 740, or 742; (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof; 26 321651967.1Attorney Docket No.: V2071-3035PCT (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 49. The AAV particle of any one of embodiments 43-48, wherein [N1]-[N2]-[N3]-[N4] is or comprises TNTQDWHRIAQTGWV (SEQ ID NO: 201). 50. The AAV particle of any one of embodiments 43-48, wherein [N1]-[N2]-[N3]-[N4] is or comprises TNTKDWHRIAQTGWV (SEQ ID NO: 202). 51. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4683), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein: (i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, P, or a conservative substitution thereof; and / or (ii) [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, or a conservative substitution thereof. 52. The AAV particle of embodiment 51, wherein the AAV capsid variant comprises the amino acid Q at position 585, numbered according to SEQ ID NO: 138 or 981. 53. The AAV particle of embodiment 51 or 52, wherein the AAV capsid variant comprises one, two, three, or all of an amino acid other than T at position 582 (e.g., S), an amino acid other than N at position 583 (e.g., T, G, S, I, or V), an amino acid other than H at position 584 (e.g., N, I, S, A, V, or L), and / or an amino acid other than Q at position 585 (e.g., P), numbered according to SEQ ID NO: 138. 54. The AAV particle of any one of embodiments 51-53, wherein [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q or P. 55. The AAV particle of any one of embodiments 51, 52, or 54, wherein position X4is Q. 27 321651967.1Attorney Docket No.: V2071-3035PCT 56. The AAV particle of any one of embodiments 51-55, wherein the AAV capsid variant comprises an amino acid other than H at position 584 (e.g., T), numbered according to SEQ ID NO: 138. 57. The AAV particle of any one of embodiments 51-56, wherein the AAV capsid variant comprises the amino acid T at position 584, numbered according to SEQ ID NO: 138 or 981. 58. The AAV particle of any one of embodiments 51-57, wherein: (i) position X1is T or S; (ii) position X2is N, T, G, S, I, or V; and / or (iii) position X3is T, N, I, S, A, V, or L. 59. The AAV particle of any one of embodiments 51-58, wherein [N1] comprises TN, TT, TG, ST, TS, TI, TV, TQ, NQ, IQ, SQ, AQ, VQ, TP, LQ, NT, TA, NI, GT, IT, NN, TL, NS, or VT. 60. The AAV particle of any one of embodiments 51-59, wherein [N1] comprises TNT, TTN, TTI, TTS, TTT, TTA, TNI, TTV, TGT, STT, TST, TIT, TNN, TTL, TNS, TVT, NTQ, TNQ, TIQ, TSQ, TTQ, TAQ, NIQ, TVQ, GTQ, STQ, ITQ, NTP, NNQ, TLQ, NSQ, or VTQ. 61. The AAV particle of any one of embodiments 51-60, wherein [N1] is or comprises TNTQ (SEQ ID NO: 4688), TTNQ (SEQ ID NO: 4696), TTIQ (SEQ ID NO: 4698), TTSQ (SEQ ID NO: 4701), TTTQ (SEQ ID NO: 4705), TTAQ (SEQ ID NO: 4707), TNIQ (SEQ ID NO: 4714), TTVQ (SEQ ID NO: 4717), TGTQ (SEQ ID NO: 4718), STTQ (SEQ ID NO: 4761), TSTQ (SEQ ID NO: 4768), TITQ (SEQ ID NO: 4767), TNTP (SEQ ID NO: 4710), TNNQ (SEQ ID NO: 4690), TTLQ (SEQ ID NO: 4720), TNSQ (SEQ ID NO: 4731), or TVTQ (SEQ ID NO: 4790). 62. The AAV particle of any one of embodiments 51-61, wherein [N1] is or comprises TNTQ (SEQ ID NO: 4688). 63. The AAV particle of any one of embodiments 51-62, wherein [N1]-[N2] comprises: (i) TQDWHR (SEQ ID NO: 4686), NQDWHR (SEQ ID NO: 4793), IQDWHR (SEQ ID NO: 4797), SQDWHR (SEQ ID NO: 4798), AQDWHR (SEQ ID NO: 4801), VQDWHR (SEQ ID NO: 4805), TPDWHR (SEQ ID NO: 4803), or LQDWHR (SEQ ID NO: 4807); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; 28 321651967.1Attorney Docket No.: V2071-3035PCT (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 64. The AAV particle of any one of embodiments 51-63, wherein [N1]-[N2] comprises: (i) NTQDWHR (SEQ ID NO: 4827), TNQDWHR (SEQ ID NO: 4832), TIQDWHR (SEQ ID NO: 4834), TSQDWHR (SEQ ID NO: 4836), TTQDWHR (SEQ ID NO: 4840), TAQDWHR (SEQ ID NO: 4842), NIQDWHR (SEQ ID NO: 4848), TVQDWHR (SEQ ID NO: 4850), GTQDWHR (SEQ ID NO: 4851), STQDWHR (SEQ ID NO: 4884), ITQDWHR (SEQ ID NO: 4883), NTPDWHR (SEQ ID NO: 4845), NNQDWHR (SEQ ID NO: 4829), TLQDWHR (SEQ ID NO: 4853), NSQDWHR (SEQ ID NO: 4861), VTQDWHR (SEQ ID NO: 4897); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5 or 6 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 65. The AAV particle of any one of embodiments 51-64, wherein [N1]-[N2] is or comprises: (i) TNTQDWHR (SEQ ID NO: 4898), TTNQDWHR (SEQ ID NO: 4906), TTIQDWHR (SEQ ID NO: 4908), TTSQDWHR (SEQ ID NO: 4911), TTTQDWHR (SEQ ID NO: 4915), TTAQDWHR (SEQ ID NO: 4917), TNIQDWHR (SEQ ID NO: 4924), TTVQDWHR (SEQ ID NO: 4927), TGTQDWHR (SEQ ID NO: 4928), STTQDWHR (SEQ ID NO: 4971), TSTQDWHR (SEQ ID NO: 4978), TITQDWHR (SEQ ID NO: 4977), TNTPDWHR (SEQ ID NO: 4920), TNNQDWHR (SEQ ID NO: 4900), TTLQDWHR (SEQ ID NO: 4930), TNSQDWHR (SEQ ID NO: 4941), TVTQDWHR (SEQ ID NO: 5000); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 56, or 7 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or 29 321651967.1Attorney Docket No.: V2071-3035PCT (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 66. The AAV particle of any one of embodiments 51-65, wherein [N1]-[N2] is or comprises TNTQDWHR (SEQ ID NO: 4898). 67. The AAV particle of any one of embodiments 51-66, wherein the AAV capsid variant comprises one, two, or all of an amino acid other than Q at position 590 (e.g., I or V), A at position 591 (e.g., P, S, Y, or N), and / or Q at position 592 (e.g., G or N), numbered according to SEQ ID NO: 138. 68. The AAV particle of any one of embodiments 51-67, wherein the AAV capsid variant comprises an amino acid other than Q at position 590 (e.g., I or V), numbered according to SEQ ID NO: 138. 69. The AAV particle of any one of embodiments 51-68, wherein the AAV capsid variant comprises the amino acid I at position 590, numbered according to SEQ ID NO: 138. 70. The AAV particle of any one of embodiments 51-68, wherein the AAV capsid variant comprises the amino acid V at position 590, numbered according to SEQ ID NO: 138. 71. The AAV particle of any one of embodiments 51-70, wherein the AAV capsid variant comprises the amino acid A at position 591 and / or the amino acid Q at position 592, numbered according to SEQ ID NO: 138 or 981. 72. The AAV particle of any one of embodiments 51-71, [N3] comprises positions X5, X6, and X7, wherein position X5is I or V. 73. The AAV particle of any one of embodiments 51-72, wherein position X5is I. 74. The AAV particle of any one of embodiments 51-73, wherein: (i) position X6is A, P, S, Y, or N; and / or (ii) position X7is Q, G, or N. 75. The AAV particle of any one of embodiments 51-74, wherein [N3] comprises IA, VP, VA, VS, IY, IN, IS, AQ, AG, PQ, SQ, AN, YQ, or NQ. 30 321651967.1Attorney Docket No.: V2071-3035PCT 76. The AAV particle of any one of embodiments 51-75, wherein [N3] is or comprises IAQ, IAG, VPQ, VAQ, VSQ, IAN, IYQ, INQ, or ISQ. 77. The AAV particle of any one of embodiments 51-76, wherein [N3] is or comprises IAQ. 78. The AAV particle of any one of embodiments 51-77, wherein [N2]-[N3] comprises: (i) DWHRIA (SEQ ID NO: 5002), DWHRVP (SEQ ID NO: 5004), DWHRVA (SEQ ID NO: 5008), DWHRVS (SEQ ID NO: 5021), DWHRIY (SEQ ID NO: 5003), DWHRIN (SEQ ID NO: 5005), or DWHRIS (SEQ ID NO: 5009); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, or 5 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 79. The AAV particle of any one of embodiments 51-78, wherein [N2]-[N3] is or comprises: (i) DWHRIAQ (SEQ ID NO: 5027), DWHRIAG (SEQ ID NO: 5028), DWHRVPQ (SEQ ID NO: 5030), DWHRVAQ (SEQ ID NO: 5038), DWHRVSQ (SEQ ID NO: 5056), DWHRIAN (SEQ ID NO: 5031), DWHRIYQ (SEQ ID NO: 5029), DWHRINQ (SEQ ID NO: 5032), or DWHRISQ (SEQ ID NO: 5037); (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, or 6 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 80. The AAV particle of any one of embodiments 51-79, wherein [N2]-[N3] is or comprises DWHRIAQ (SEQ ID NO: 5027). 81. The AAV particle of any one of embodiments 51-80, wherein [N1]-[N2]-[N3] is or comprises: 31 321651967.1Attorney Docket No.: V2071-3035PCT (i) the amino acid sequence of any one of SEQ ID NOs: 343, 350, 352, 355, 359, 361, 364, 367, 370, 371, 373, 374, 376, 377, 378, 381, 395, 420, 454, 457, 460, 464, 481, 482, 488, 493, 494, 516, 525, 536; (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 82. The AAV particle of any one of embodiments 51-81, wherein [N1]-[N2]-[N3] is or comprises TNTQDWHRIAQ (SEQ ID NO: 343). 83. The AAV particle of any one of embodiments 51-82, wherein the AAV capsid variant comprises the amino acid W at position 595, numbered according to SEQ ID NO: 138 or 981. 84. The AAV particle of any one of embodiments 51-83, wherein the AAV capsid variant comprises one, two or all of an amino acid other than T (e.g., S or N) at position 593, a G (e.g., N) a position 594, and / or V (e.g., A, I or S) at position 596, numbered according to SEQ ID NO: 138 or 981. 85. The AAV particle of any one of embodiments 51-84 wherein the AAV capsid variant comprises: (i) the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid V at position 596, numbered according to SEQ ID NO: 138 or 981; (ii) the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid A at position 596, numbered according to SEQ ID NO: 138 or 981; (iii) the amino acid S at position 593, the amino acid N at position 594, the amino acid W at position 595, and the amino acid V at position 596, numbered according to SEQ ID NO: 138 or 981; (iv) the amino acid N at position 593, the amino acid N at position 594, the amino acid W at position 595, and the amino acid V at position 596, numbered according to SEQ ID NO: 138 or 981; (v) the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid I at position 596, numbered according to SEQ ID NO: 138 or 981; or (vi) the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid S at position 596, numbered according to SEQ ID NO: 138 or 981. 32 321651967.1Attorney Docket No.: V2071-3035PCT 86. The AAV particle of any one of embodiments 51-85 which comprises the amino acid T at position 593, the amino acid G at position 594, the amino acid W at position 595, and the amino acid V at position 596, numbered according to SEQ ID NO: 138 or 981. 87. The AAV particle of any one of embodiments 51-86, wherein the AAV capsid variant further comprises [N4], wherein [N4] comprises positions X8, X9, X10, and X11, wherein position X10is W. 88. The AAV particle of embodiment 87, wherein: (i) position X8is T, S, or N; (ii) position X9is G or N; and / or (iv) position X11is V, A, I, or S. 89. The AAV particle of embodiment 87 or 88, wherein [N4] comprises TG, SN, NN, WV, WA, WI, WS, GW, or NW. 90. The AAV particle of any one of embodiments 87-89, wherein [N4] comprises TGW, SNW, NNW, GWV, GWA, NWV, GWI, or GWS. 91. The AAV particle of any one of embodiments 87-90, wherein [N4] is or comprises TGWV (SEQ ID NO: 5066), TGWA (SEQ ID NO: 5067), SNWV (SEQ ID NO: 5069), NNWV (SEQ ID NO: 5072), TGWI (SEQ ID NO: 5074), or TGWS (SEQ ID NO: 5073). 92. The AAV particle of any one of embodiments 87-91, wherein [N4] is or comprises TGWV (SEQ ID NO: 5066). 93. The AAV particle of any one of embodiments 87-92, wherein [N1]-[N2]-[N3]-[N4] is or comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (ii) an amino acid sequence comprising any portion of an amino acid sequence in (i), e.g., any 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 amino acids, e.g., consecutive amino acids, thereof; (iii) an amino acid sequence comprising one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), insertions, or deletions, relative to any of the amino acid sequences in (i); or 33 321651967.1Attorney Docket No.: V2071-3035PCT (iv) an amino acid sequence comprising one, two, or three but no more than four different amino acids, relative to any one of the amino acid sequences in (i). 94. The AAV particle of any one of embodiments 87-93, wherein [N1]-[N2]-[N3]-[N4] is or comprises TNTQDWHRIAQTGWV (SEQ ID NO: 201). 95. The AAV particle of any one of embodiments 1-94, wherein [N1]-[N2]-[N3] is present in loop VIII, optionally wherein loop VIII comprises positions 580-599, numbered according to SEQ ID NO: 138 or 981. 96. The AAV particle of any one of embodiments 43-50 or 87-95, wherein [N4] is present in loop VIII, optionally wherein loop VIII comprises positions 580-599, numbered according to SEQ ID NO: 138 or 981. 97. The AAV particle of any one of embodiments 1-96, wherein [N1] replaces positions 582-585 (e.g., T582, N583, H584, Q585), numbered according to SEQ ID NO: 138. 98. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, or 85-97, wherein [N1] corresponds to positions 582-585 (e.g., T582, N583, T584, Q585) of SEQ ID NO: 981. 99. The AAV particle of any one of embodiments 1-98, wherein [N1] is present at positions 582-585, numbered according to SEQ ID NO: 138 or 981. 100. The AAV particle of any one of embodiments 1-99, wherein [N1] corresponds to positions 582-585 (e.g., T582, N583, T584, Q585) of SEQ ID NO: 981. 101. The AAV particle of any one of embodiments 1-100, wherein [N2] replaces positions 586-589 (e.g., S586, A587, Q588, A589), numbered according to the amino acid sequence of SEQ ID NO: 138. 102. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101, wherein [N2] corresponds to positions 586-589 (e.g., D586, W587, H588, R589) of SEQ ID NO: 981. 34 321651967.1Attorney Docket No.: V2071-3035PCT 103. The AAV particle of any one of embodiments 1-102, wherein [N2] is present at positions 586-589, numbered according to SEQ ID NO: 138 or 981. 104. The AAV particle of any one of embodiments 1-103, wherein [N1]-[N2] replaces to positions 582- 589 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589), numbered according to SEQ ID NO: 138. 105. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-104, wherein [N1]-[N2] corresponds to positions 582-589 (e.g., T582, N583, T584, Q585, D586, W587, H588, R589) of SEQ ID NO: 981. 106. The AAV particle of any one of embodiments 1-105, wherein [N1]-[N2] is present at positions 582- 589, numbered according to SEQ ID NO: 138 or 981. 107. The AAV particle of any one of embodiments 1-106, wherein [N3] replaces positions 590-592 (e.g., Q590, A591, and Q592), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 108. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-107, wherein [N3] corresponds to positions 590-592 (e.g., I590, A591, and Q592) of SEQ ID NO: 981. 109. The AAV particle of any one of embodiments 1-108, wherein [N3] is present at positions 590-592, numbered according to SEQ ID NO: 138 or 981. 110. The AAV particle of any one of embodiments 1-109, wherein [N2]-[N3] replaces positions 586-592 (e.g., S586, A587, Q588, A589, Q590, A591, and Q592), numbered according to SEQ ID NO: 138. 111. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-110, wherein [N2]-[N3] corresponds to positions 586-592 (e.g., D586, W587, H588, R589, I590, A591, and Q592) of SEQ ID NO: 981. 112. The AAV particle of any one of embodiments 1-111, wherein [N2]-[N3] is present at positions 586- 592, numbered according to SEQ ID NO: 138 or 981. 35 321651967.1Attorney Docket No.: V2071-3035PCT 113. The AAV particle of any one of embodiments 1-112, wherein [N1]-[N2]-[N3] replaces positions 582-592 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, Q592), numbered according to SEQ ID NO: 138. 114. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-113, wherein [N1]-[N2]-[N3] corresponds to positions 582-592 (e.g., T582, N583, T584, Q585, D586, W587, H588, R589, I590, A591, Q592) of SEQ ID NO: 981. 115. The AAV particle of any one of embodiments 1-114, wherein [N1]-[N2]-[N3] is present at positions 582-592, numbered according to SEQ ID NO: 138 or 981. 116. The AAV particle of any one of embodiments 43-50 or 87-115, wherein [N4] replaces positions 593- 596 (e.g., T593, G594, W595, and V596), numbered according to SEQ ID NO: 138. 117. The AAV particle of any one of embodiments 43-49 or 87-115, wherein [N4] corresponds to positions 593-596 (e.g., T593, G594, W595, and V596) of SEQ ID NO: 138 or 981. 118. The AAV particle of any one of embodiments 43-50 or 87-117, wherein [N4] is present at positions 593-596, numbered according to SEQ ID NO: 138 or 981. 119. The AAV particle of any one of embodiments 43-50 or 87-118, wherein [N2]-[N3]-[N4] replaces positions 586-596 (e.g., S586, A587, Q588, A589, Q590, A591, Q592, T593, G594, W595, and V596), relative to a reference sequence numbered according to the amino acid sequence of SEQ ID NO: 138. 120. The AAV particle of any one of embodiments 43-49 or 87-119, wherein [N2]-[N3]-[N4] corresponds to positions 586-596 (e.g., D586, W587, H588, R589, I590, A591, Q592, T593, G594, W595, and V596) of SEQ ID NO: 981. 121. The AAV particle of any one of embodiments 43-50 or 87-120, wherein [N2]-[N3]-[N4] is present at positions 586-596, numbered according to SEQ ID NO: 138 or 981. 122. The AAV particle of any one of embodiments 43-50 or 87-121, wherein [N1]-[N2]-[N3]-[N4] replaces positions 582-596 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, 36 321651967.1Attorney Docket No.: V2071-3035PCT Q592, T593, G594, W595, and V596), numbered according to the amino acid sequence of SEQ ID NO: 138. 123. The AAV particle of any one of embodiments 43-49 or 87-122, wherein [N1]-[N2]-[N3]-[N4] corresponds to positions 582-596 (e.g., T582, N583, T584, Q585, D586, W587, H588, R589, I590, A591, Q592, T593, G594, W595, and V596) of SEQ ID NO: 981. 124. The AAV particle of any one of embodiments 43-50 or 87-123, wherein [N1]-[N2]-[N3]-[N4] is present at positions 582-596, numbered according to the amino acid sequence of SEQ ID NO: 138 or 981. 125. The AAV particle of any one of embodiments 1-124, wherein [N2] is present immediately subsequent to [N1]. 126. The AAV particle of any one of embodiments 1-125, wherein [N3] is present immediately subsequent to [N2]. 127. The AAV particle of any one of embodiments 43-50 or 87-126, wherein [N4] is present immediately subsequent to [N3]. 128. The AAV particle of any one of embodiments 1-127, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]. 129. The AAV particle of any one of embodiments 43-50 or 87-128, wherein the AAV capsid variant comprises from N-terminus to C-terminus, [N1]-[N2]-[N3]-[N4]. 130. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; or 37 321651967.1Attorney Docket No.: V2071-3035PCT (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of the sequences provided in Tables 1, 2A, 2B, 9A, 14A, 15A, 16A, or 26-31. 131. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises: (a) the amino acid sequence of any of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (b) an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; (c) an amino acid sequence comprising at least one, two, or three but no more than four different amino acids, relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336; or (d) an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. 132. The AAV particle of embodiment 130 or 131, wherein the AAV capsid variant does not comprise at least 3, 4, 5, 6, 7, 8, or 9 consecutive amino acids from TNHQSAQAQ (SEQ ID NO: 5100), optionally wherein the TNHQSAQAQ (SEQ ID NO: 5100) corresponds to positions 582-592 of SEQ ID NO: 138. 133. The AAV particle of any one of embodiments 130-132, wherein the AAV capsid variant does not comprise: TNH, TNHQ (SEQ ID NO: 4760), TNHQS (SEQ ID NO: 5101), TNHQSA (SEQ ID NO: 5102), TNHQSAQ (SEQ ID NO: 5103), TNHQSAQA (SEQ ID NO: 5104), TNHQSAQAQ (SEQ ID NO: 5100), NHQ, NHQS (SEQ ID NO: 5105), NHQSA (SEQ ID NO: 5106), NHQSAQ (SEQ ID NO: 5107), NHQSAQA (SEQ ID NO: 5108), NHQSAQAQ (SEQ ID NO: 5109), HQS, HQSA (SEQ ID NO: 5110), HQSAQ (SEQ ID NO: 5111), HQSAQA (SEQ ID NO: 5112), HQSAQAQ (SEQ ID NO: 5113), 38 321651967.1Attorney Docket No.: V2071-3035PCT QSA, QSAQ (SEQ ID NO: 5114), QSAQA (SEQ ID NO: 5115), QSAQAQ (SEQ ID NO: 5116), SAQA (SEQ ID NO: 5117), or SAQAQ (SEQ ID NO: 5118). 134. The AAV particle of any one of embodiments 130-124, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 consecutive amino acids from any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262- 265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. 135. The AAV particle of any one of embodiments 130-134, wherein the 3 consecutive amino acids comprise TQD. 136. The AAV particle of any one of embodiments 130-135, wherein the at least 4 consecutive amino acids comprise TQDW (SEQ ID NO: 4684). 137. The AAV particle of any one of embodiments 130-136, wherein the at least 5 consecutive amino acids comprise TQDWH (SEQ ID NO: 4685). 138. The AAV particle of any one of embodiments 130-137, wherein the at least 6 consecutive amino acids comprise TQDWHR (SEQ ID NO: 4686). 139. The AAV particle of embodiment 130-138, wherein the at least 7 consecutive amino acids comprise TQDWHRI (SEQ ID NO: 941). 140. The AAV particle of any one of embodiments 130-134, wherein the at least 3 consecutive amino acids comprise TNT. 141. The AAV particle of any one of embodiments 130-134 or 140, wherein the at least 4 consecutive amino acids comprise TNTQ (SEQ ID NO: 4688). 142. The AAV particle of any one of embodiments 130-134, 140, or 141, wherein the at least 5 consecutive amino acids comprise TNTQD (SEQ ID NO: 5119). 143. The AAV particle of any one of embodiments 130-134 or 140-142, wherein the at least 6 consecutive amino acids comprise TNTQDW (SEQ ID NO: 5120). 39 321651967.1Attorney Docket No.: V2071-3035PCT 144. The AAV particle of embodiment 130-134 or 140-143, wherein the at least 7 consecutive amino acids comprise TNTQDWH (SEQ ID NO: 5121). 145. The AAV particle of any one of embodiments 130-134 or 140-144, wherein the at least 8 consecutive amino acids comprise TNTQDWHR (SEQ ID NO: 4898). 146. The AAV particle of any one of embodiments 130-134 or 140-145, wherein the at least 9 consecutive amino acids comprise TNTQDWHRI (SEQ ID NO: 746). 147. The AAV particle of any one of embodiments 130-146, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. 148. The AAV particle of any one of embodiments 130-147, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of TQDWHRI (SEQ ID NO: 941). 149. The AAV particle of any one of embodiments 130-147, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of TNTQDWHRI (SEQ ID NO: 746). 150. The AAV particle of any one of embodiments 130-149, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of ATNTQDWHRIAQT (SEQ ID NO: 744). 151. The AAV particle of any one of embodiments 130-150, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. 40 321651967.1Attorney Docket No.: V2071-3035PCT 152. The AAV particle of any one of embodiments 130-149 or 151, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to the amino acid sequence of TQDWHRI (SEQ ID NO: 941). 153. The AAV particle of any one of embodiments 130-149, 151, or 152, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to relative to the amino acid sequence of TNTQDWHRI (SEQ ID NO: 746). 154. The AAV particle of any one of embodiments 130-153, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two, or three but no more than four different amino acids relative to relative to the amino acid sequence of ATNTQDWHRIAQT (SEQ ID NO: 744). 155. The AAV particle of any one of embodiments 1-154, wherein the AAV capsid variant comprises the amino acid sequence of any of SEQ ID NOs: 201, 205-209, 211-214, 216, 219, 220, 230, 232, 237, 238, 255, 262-265, 274, 283, 286, 290, 291, 293, 301, 306, 307, 308, 309, 314, or 336. 156. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-155, wherein the AAV capsid variant comprises the amino acid sequence of TQDWHRI (SEQ ID NO: 941), optionally wherein the amino acid sequence replaces positions 584-590, numbered according to SEQ ID NO: 138. 157. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-156, which comprises the amino acid sequence of TQDWHRI (SEQ ID NO: 941), optionally wherein the amino acid sequence corresponds to positions 584-590 of SEQ ID NO: 981. 158. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-149, 151-153, or 155-157, comprising an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions, but no more than ten modifications, e.g., substitutions, relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942. 41 321651967.1Attorney Docket No.: V2071-3035PCT 159. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-158, comprising an amino acid sequence encoded by: the nucleotide sequence of SEQ ID NO: 747; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions, but no more than ten modifications, e.g., substitutions, relative to the nucleotide sequence of SEQ ID NO: 747; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 747. 160. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-149, 151-153, or 155-158, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 942; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions, but no more than ten modifications, e.g., substitutions, relative to the nucleotide sequence of SEQ ID NO: 942; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 942. 161. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-160, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 747; a nucleotide sequence comprising at least one, two, three, four, five, six, or seven modifications, e.g., substitutions, but no more than ten modifications, e.g., substitutions, relative to the nucleotide sequence of SEQ ID NO: 747; or a nucleotide sequence comprising at least one, two, three, four, five, six, or seven, but no more than ten different nucleotides relative to the nucleotide sequence of SEQ ID NO: 747. 162. The AAV particle of any one of embodiments 130-161, wherein the amino acid sequence is present in loop VIII, optionally wherein loop VIII comprises positions 580-599, numbered according to SEQ ID NO: 138 or 981. 163. The AAV particle of any one of embodiments 130-153, wherein the amino acid sequence replaces positions 584, 585, 586, 587, 588, 589, and / or 590 (e.g., H584, Q585, S586, A587, Q588, A589, and / or Q590), numbered according to the amino acid sequence of SEQ ID NO: 138. 42 321651967.1Attorney Docket No.: V2071-3035PCT 164. The AAV particle of any one of embodiments 130-163, wherein the amino acid sequence is present at positions 584, 585, 586, 587, 588, 589, and / or 590, numbered according to the amino acid sequence of SEQ ID NO: 138 or 981. 165. The AAV particle of any one of embodiments 130-164, wherein the amino acid sequence corresponds to positions 584-590 (e.g., T584, Q585, D586, W587, H588, R589, and / or I590), numbered according to the amino acid sequence of SEQ ID NO: 981. 166. The AAV particle of any one of embodiments 121-165, wherein the amino acid sequence replaces positions 582, 583, 584, 585, 586, 587, 588, 589, and / or 590 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, and / or Q590), numbered according to the amino acid sequence of SEQ ID NO: 138. 167. The AAV particle of any one of embodiments 121-166, wherein the amino acid sequence is present at positions 582, 583, 584, 585, 586, 587, 588, 589, and / or 590, numbered according to the amino acid sequence of SEQ ID NO: 138 or 981. 168. The AAV particle of any one of embodiments 121-167, wherein the amino acid sequence replaces positions 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and / or 596 (e.g., T582, N583, H584, Q585, S586, A587, Q588, A589, Q590, A591, Q592, T593, G594, W595, and / or V5965), numbered according to the amino acid sequence of SEQ ID NO: 138. 169. The AAV particle of any one of embodiments 121-168, wherein the amino acid sequence is present at positions 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and / or 596, numbered according to the amino acid sequence of SEQ ID NO: 138 or 981. 170. The AAV particle of any one of embodiments 1-169, wherein the AAV capsid variant comprises one, two, three, four, five or all of an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and / or Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138. 171. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at 43 321651967.1Attorney Docket No.: V2071-3035PCT position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and / or Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138. 172. The AAV particle of any one of embodiments 1-171, wherein the AAV capsid variant comprises one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. 173. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. 174. The AAV particle of any one of embodiments 1-173, wherein the AAV capsid variant comprises one, two, three, four, five or all of the substitutions H584T, S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. 175. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises one, two, three, four, five or all of the substitutions H584T, S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. 176. The AAV particle of any one of embodiments 1-175, wherein the AAV capsid variant comprises an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138. 177. The AAV particle of any one of embodiments 1-176, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. 178. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-98, or 100-164, which corresponds to positions 584, 586, 587, 588, 589, and 590 of SEQ ID NO: 981. 44 321651967.1Attorney Docket No.: V2071-3035PCT 179. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-178, which corresponds to positions 582, 583, 584, 586, 587, 588, 589, and 590 of SEQ ID NO: 981. 180. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, or 101-179, which corresponds to positions 582, 583, 584, 586, 587, 588, 589, 590, 591, 592, 593, 594, 595, and 596 of SEQ ID NO: 981. 181. The AAV particle of any one of embodiments 1-181, wherein the AAV capsid variant comprises the substitutions H584T, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. 182. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. 183. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the substitutions H584T, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. 184. The AAV particle of any one of embodiments 1-183, wherein the AAV capsid variant further comprises an amino acid other than A position 581, numbered according to SEQ ID NO: 138 or 981. 185. The AAV particle of any one of embodiments 1-184, wherein the AAV capsid variant further comprises a T at position 581 or a V at position 581, numbered according to SEQ ID NO: 138 or 981. 186. The AAV particle of any one of embodiments 1-185, wherein the AAV capsid variant comprises the substitutions A581T or A581V, numbered according to SEQ ID NO: 138 or 981. 187. The AAV particle of any one of embodiments 1, 3-7, 9-15, 17-20, 22-38, 40-48, 50, 130-134, 147, 151, 155, 162, 163, 166-177, or 181-186, wherein the AAV capsid variant comprises an amino acid other than Q at position 585, numbered according to SEQ ID NO: 138. 45 321651967.1Attorney Docket No.: V2071-3035PCT 188. The AAV particle of any one of embodiments 1, 3-7, 9-15, 17-20, 22-38, 40-48, 50, 130-134, 147, 151, 155, 162, 163, 166-177, 181-187, wherein the AAV capsid variant comprises the amino acid K at position 585, numbered according to SEQ ID NO: 138. 189. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant further comprises: (i) a modification, e.g., an insertion, substitution (e.g., conservative substitution), and / or deletion, in loop I, II, IV, and / or VI; and / or (ii) a substitution at position K449, e.g., a K449R substitution, numbered according to SEQ ID NO: 138. 190. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 138. 191. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three, but no more than 30, 20 or 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 138. 192. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 138, or an amino acid sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 193. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 138. 194. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 137, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 195. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the AAV capsid variant comprises the nucleotide sequence of SEQ ID NO: 137, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 46 321651967.1Attorney Docket No.: V2071-3035PCT 196. The AAV particle of any one of the preceding embodiments, wherein the AAV capsid variant comprises a VP1 protein, a VP2 protein, a VP3 protein, or a combination thereof. 197. The AAV particle of any one of embodiments 1-196, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 138-736, e.g., a VP2, of SEQ ID NO: 981, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 198. The AAV particle of any one of embodiments 1-197, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 203-736, e.g., a VP3, of SEQ ID NO: 981, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 199. The AAV particle of any one of embodiments 1-198, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 138-736, e.g., a VP2, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 200. The AAV particle of any one of embodiments 1-199, wherein the AAV capsid variant comprises the amino acid sequence corresponding to positions 203-736, e.g., a VP3, of SEQ ID NO: 138, or a sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 201. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, 101-186, or 189-200, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of TQDWHRI (SEQ ID NO: 941), wherein: (i) the at least 3 consecutive amino acids comprise TQD; (ii) the at least 4 consecutive amino acids comprise TQDW (SEQ ID NO: 4684); (iii) the at least 5 consecutive amino acids comprise TQDWH (SEQ ID NO: 4685); (iv) the at least 6 consecutive amino acids comprise TQDWHR (SEQ ID NO: 4686); or (v) the at least 7 consecutive amino acids comprise TQDWHRI (SEQ ID NO: 941); wherein the AAV capsid variant comprises: (a) a VP1 protein comprising the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981; (b) a VP2 protein comprising the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or positions 138-736 of SEQ ID NO: 981; (c) a VP3 protein comprising the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or positions 203-736 of SEQ ID NO: 981; or (d) an amino acid sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any of the amino acid sequences in (a)-(c). 47 321651967.1Attorney Docket No.: V2071-3035PCT 202. The AAV particle of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, 101-186, or 189-201, wherein the AAV capsid variant comprises an amino acid sequence comprising at least 3, 4, 5, 6, 3, 4, 5, 6, or 7 consecutive amino acids from the amino acid sequence of TQDWHRI (SEQ ID NO: 941), wherein: (i) the at least 3 consecutive amino acids comprise TQD; (ii) the at least 4 consecutive amino acids comprise TQDW (SEQ ID NO: 4684); (iii) the at least 5 consecutive amino acids comprise TQDWH (SEQ ID NO: 4685); (iv) the at least 6 consecutive amino acids comprise TQDWHR (SEQ ID NO: 4686); or (v) the at least 7 consecutive amino acids comprise TQDWHRI (SEQ ID NO: 941); wherein the AAV capsid variant comprises an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 981. 203. The AAV particle of any one of embodiments 11-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, 101-186, or 189-202, wherein the AAV capsid variant comprises one or two, but no more than three substitutions relative to the amino acid sequence of TQDWHRI (SEQ ID NO: 941), wherein the AAV capsid variant comprises an amino acid sequence at least 90% (e.g., at least 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 138 or SEQ ID NO: 981. 204. The AAV particle of any one of embodiments 1-203, wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NO: 981, or an amino acid sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 205. The AAV particle of any one of embodiments 1-204, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three modifications, e.g., substitutions (e.g., conservative substitutions), but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions), relative to the amino acid sequence of SEQ ID NO: 981. 206. The AAV particle of any one of embodiments, 1-205, wherein the AAV capsid variant comprises an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids, relative to the amino acid sequence of SEQ ID NO: 981. 207. The AAV particle of any one of embodiments 1-206, wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 48 321651967.1Attorney Docket No.: V2071-3035PCT 208. The AAV particle of any one of the preceding embodiments 1-207, wherein the nucleotide sequence encoding the capsid variant comprises the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence with at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) sequence identity thereto. 209. The AAV particle of any one of the preceding embodiments, wherein the nucleotide sequence encoding the capsid variant is codon optimized. 210. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of any one of embodiments 1-3, 5-8, 10-16, 18-21, 23-39, 42-49, 51-69, 71-83, 85-99, 101-186, or 189, and further comprising an amino acid sequence at least 95% identical to SEQ ID NO: 981. 211. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981. 212. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 983, or a nucleotide sequence at least 95% identical thereto. 213. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. 214. The AAV particle of embodiment 213, wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981. 215. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 981. 49 321651967.1Attorney Docket No.: V2071-3035PCT 216. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. 217. The AAV particle any one of embodiments 213-216, wherein the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981. 218. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 981. 219. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau), wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981, or an amino acid sequence at least 80% (e.g., at least 85, 90, 95, 96, 97, 98, or 99%) thereto, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 981. 220. The AAV particle of any one of embodiments 213-219, wherein the AAV capsid variant comprises the amino acid sequence of SEQ ID NO: 981. 221. The AAV particle of any one of the preceding embodiments, which comprises an amino acid other than Q at position 597, numbered according to SEQ ID NO: 138 or 981. 222. The AAV particle of any one of the preceding embodiments, which comprises the amino acid H at position 597, numbered according to SEQ ID NO: 138 or 981. 223.The AAV particle of any one of embodiments 1-176 or 189-200, 204-209, 221, or 222, wherein the AAV capsid variant comprises: 50 321651967.1Attorney Docket No.: V2071-3035PCT (i) an amino acid other than N at position 583 (e.g., T), an amino acid H at position 584 (e.g., T or Q), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), and Q at position 590 (e.g., I), numbered according to SEQ ID NO: 138; (ii) an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), Q at position 590 (e.g., I or V), and A at position 591 (e.g., P or W), numbered according to SEQ ID NO: 138; or (iii) an amino acid other than H at position 584 (e.g., T), S at position 586 (e.g., D), A at position 587 (e.g., W), Q at position 588 (e.g., H), A at position 589 (e.g., R), Q at position 590 (e.g., I), and Q at position 597 (e.g., H), numbered according to SEQ ID NO: 138. 224. The AAV particle of any one of embodiments 1-176 or 189-200, 204-209, or 220-223, wherein the AAV capsid variant comprises: (i) the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, V at position 590, and P at position 591, numbered according to SEQ ID NO: 138 or 981; (ii) the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, I at position 590, and H at position 597, numbered according to SEQ ID NO: 138 or 981; (iii) the amino acid T at position 583, T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981; (iv) the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and V at position 590, numbered according to SEQ ID NO: 138 or 981; (v) the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, I at position 590, and W at position 591, numbered according to SEQ ID NO: 138 or 981; or (vi) the amino acid T at position 583, Q at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. 225. The AAV particle of any one of embodiments 1-176 or 189-200, 204-209, or 220-224, wherein the AAV capsid variant comprises: (i) the substitutions H584T, S586D, A587W, Q588H, A589R, Q590V, and A591P, numbered according to SEQ ID NO: 138; (ii) the substitutions H584T, S586D, A587W, Q588H, A589R, Q590I, and Q597H, numbered according to SEQ ID NO: 138; (iii) the substitutions N583T, H584T, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138; 51 321651967.1Attorney Docket No.: V2071-3035PCT (iv) the substitutions H584T, S586D, A587W, Q588H, A589R, and Q590V, numbered according to SEQ ID NO: 138; (v) the substitutions H584T, S586D, A587W, Q588H, A589R, Q590I, and A591W, numbered according to SEQ ID NO: 138; or (vi) the substitutions N583T, H584Q, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. 226. The AAV particle of any one of embodiments 1-176 or 189-200, 204-209, or 220-225, wherein the AAV capsid variant comprises the amino acid sequence of any one of SEQ ID NOs: 208, 216, 232, 241, 943, or 984; optionally wherein: (i) the amino acid sequence of SEQ ID NO: 943 is present at positions 582-597, numbered according to SEQ ID NO: 138 or 981; or (ii) the amino acid sequences of any one of SEQ ID NOs: 208, 216, 232, 241, or 984 are present at positions 582-596, numbered according to SEQ ID NO: 138 or 981. 227. An AAV capsid variant comprising the amino acid H at position 597, numbered according to SEQ ID NO: 138 or 981, and one, two, three, four, five or all of the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. 228. An AAV capsid variant comprising the substitution Q597H, numbered according to SEQ ID NO: 138; and one, two, three, four, five or all of the substitutions H584T, S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. 229. The AAV capsid variant of embodiment 227 or 228, comprising the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, I at position 590, and H at position 597, numbered according to SEQ ID NO: 138 or 981. 230. The AAV capsid variant of any one of embodiments 227-229, comprising the substitutions H584T, S586D, A587W, Q588H, A589R, Q590I, and Q597H, numbered according to SEQ ID NO: 138. 231. The AAV capsid variant of any one of embodiments 227-230, which comprises the amino acid sequence of SEQ ID NO: 943, optionally wherein the amino acid sequence of SEQ ID NO: 943 is present at positions 582-597, numbered according to SEQ ID NO: 138 or 981. 52 321651967.1Attorney Docket No.: V2071-3035PCT 232. An AAV capsid variant comprising the amino acid T at position 583 and Q at position 584, numbered according to SEQ ID NO: 138 or 981; and one, two, three, four, or all of the amino acid D at position 586, W at position 587, H at position 588, R at position 589, and / or I at position 590, numbered according to SEQ ID NO: 138 or 981. 233. An AAV capsid variant comprising the substitutions N583T and H584Q, numbered according to SEQ ID NO: 138; and one, two, three, or four or all of the substitutions S586D, A587W, Q588H, A589R, and / or Q590I, numbered according to SEQ ID NO: 138. 234. The AAV capsid variant of embodiment 232 or 233, which comprises the amino acid T at position 583, Q at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO: 138 or 981. 235. The AAV capsid variant of any one of embodiments 232-234, comprising the substitutions N583T, H584Q, S586D, A587W, Q588H, A589R, and Q590I, numbered according to SEQ ID NO: 138. 236. The AAV capsid variant of any one of embodiments 232-235, which comprises the amino acid sequence of SEQ ID NO: 984, optionally wherein the amino acid sequence of SEQ ID NO: 984 is present at positions 582-596, numbered according to SEQ ID NO: 138 or 981. 237. The AAV capsid variant of any one of embodiments 227-236, which further comprises the amino acid sequence of positions 203-736 of SEQ ID NO: 138 or 981, or an amino acid sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to positions 203-736 of SEQ ID NO: 138 or 981. 238. The AAV capsid variant of any one of embodiments 227-237, which further comprises the amino acid sequence of positions 138-736 of SEQ ID NO: 138 or 981, or an amino acid sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to positions 138-736 of SEQ ID NO: 138 or 981. 239. The AAV capsid variant of any one of embodiments 227-238, which further comprises the amino acid sequence SEQ ID NO: 138 or 981, or an amino acid sequence at least 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 138 or 981. 53 321651967.1Attorney Docket No.: V2071-3035PCT 240. An AAV particle comprising the AAV capsid variant of any one of embodiments 227-239, and a nucleic acid encoding an antibody molecule which binds to tau (e.g., human tau). 241. The AAV particle of any one of embodiments 1-226 or 240, which has increased tropism for a CNS cell or tissue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138. 242. The AAV particle of any one of embodiments 1-226, 240, or 241, which transduces a brain region, e.g., sensory cortex, motor cortex, putamen, thalamus, caudate, hippocampus, cerebellum, optionally wherein the level of transduction is at least 39, 50, 100, 120, 132, 146, 150, 161, 174, 175, 200, 225, 250, 275, 283, 300, 350, 400, 450, 500, 525, 528, or 550-fold greater as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR or ddPCR assay, e.g., as described in Example 2. 243. The AAV particle of any one of embodiments 1-226 or 240-242, wherein the AAV capsid variant is enriched at least about 10, 14, 20, 24, 50, 100, 150, 200, 250, 300, 350, 400, 425, 450, or 460-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 3. 244. The AAV particle of any one of embodiments 1-226 or 240-243, wherein the AAV capsid variant is enriched at least about 200, 300, 400, 425, 450, or 460-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1. 245. The AAV particle of any one of embodiments 1-226 or 240-244, wherein the AAV capsid variant is enriched in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., mouse), e.g., as compared to a reference sequence of SEQ ID NO: 138. 246. The AAV particle of any one of embodiments 1-226 or 240-245, wherein the AAV capsid variant is enriched at least about 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 190, 200, 205, or 210-fold, in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., mouse), compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 4. 54 321651967.1Attorney Docket No.: V2071-3035PCT 247. The AAV particle of embodiment 245 or 246, wherein the at least two to three species are Macaca fascicularis, Chlorocebus sabaeus, Callithrix jacchus, and / or mouse (e.g., outbred mice). 248. The AAV particle of any one of embodiments 1-226 or 240-247, wherein the AAV capsid variant is enriched at least about 2, 3, 4, 5, 10, 15, 17, 20, 50, 75, 100, 103, 107, 125, 150, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1200-fold, in the brain compared to a reference sequence of SEQ ID NO: 981, e.g., when measured by an assay as described in Example 3. 249. The AAV particle of any one of embodiments 1-226 or 240-248, which delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 39, 50, 100, 120, 132, 146, 150, 161, 174, 175, 200, 225, 250, 275, 283, 300, 350, 400, 450, 500, 525, 528, or 550-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR, a ddPCR, or a qPCR assay (e.g., as described in Example 2). 250. The AAV particle of any one of embodiments 1-226 or 240-249, which delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 2, 5, 7, 10, 15, 19, 20, 22, or 25-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2). 251. The AAV particle of embodiment 249 or 250, wherein the brain region is a sensory cortex, motor cortex, putamen, thalamus, caudate, hippocampus, and / or cerebellum. 252. The AAV particle of any one of embodiments 1-226 or 240-251, wherein the AAV capsid variant is enriched at least about 5, 10, 50, 100, 115, 120, 150, 175, 200, 207, 225, 250, or 275-fold, in the spinal cord compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 2. 253. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to the N-terminal region or an epitope within the N-terminal region of a tau protein (e.g., human tau). 254. The AAV particle of embodiment 253, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 9-18, (b) 15-25, (c) 25-30, and / or (d) 15-30 of a tau protein, numbered according to SEQ ID NO: 9200. 55 321651967.1Attorney Docket No.: V2071-3035PCT 255. The AAV particle of any one of embodiments 1-226 or 240-254, wherein the antibody molecule binds to the mid-domain region or an epitope within the mid-domain region of a tau protein (e.g., human tau). 256. The AAV particle of embodiment 255, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 125-131, (b) 204-222, (c) 234-246, (d) 234- 259, and / or (e) 235-246, numbered according to SEQ ID NO: 9200. 257. The AAV particle of embodiment 256, wherein the antibody molecule binds to an epitope which includes one or more of pS422, pT181, pS199, pS202, pT205, pT212, pS214, pT217, pT231, pS234, pS235, pS258, pS259, pS396, pS404, and pS409, numbered according to SEQ ID NO: 9200. 258. The AAV particle of embodiment 257, wherein the antibody molecule binds to an epitope which includes (a) pS202 and pT205, (b) pT212 and pS214, (c) pT212 and pT217, (c) pT217 and pT231, (d) pT231 and pT234 (or pT235), (e) pS234 and pS259 (or pS258), and (f) pS396 and pS404, numbered according to SEQ ID NO: 9200. 259. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to the C-terminal region or an epitope within the C-terminal region of a tau protein (e.g., human tau). 260. The AAV particle of embodiment 259, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 387-408 and / or (b) 409-436, numbered according to SEQ ID NO: 9200. 261. The AAV particle of embodiment 260, wherein the antibody molecule binds to an epitope which includes pS409, numbered according to SEQ ID NO: 9200. 262. The AAV particle of embodiment 259, wherein the antibody molecule binds to an epitope which includes pS422, numbered according to SEQ ID NO: 9200. 263. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to the microtubule-binding domain or an epitope within the microtubule-binding domain of a tau protein (e.g., human tau). 56 321651967.1Attorney Docket No.: V2071-3035PCT 264. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to the proline rich domain or an epitope within the proline rich domain of a tau protein (e.g., human tau). 265. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to a region that overlaps with the N-terminal domain and the mid-domain of a tau protein (e.g., human tau). 266. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to a region that overlaps with the mid-domain and the microtubule-binding domain of a tau protein (e.g., human tau). 267. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to a region that overlaps with the mid-domain and the C-terminal domain of a tau protein (e.g., human tau). 268. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 32-49, (b) 55-76, (c) 57-72, (d) 159-194, (e) 175-191, (f) 185-200, (g) 219-247, (h) 223-238, (i) 381-426, (j) 383-400, (k) 409- 436, and / or (l) 413-430, numbered according to SEQ ID NO: 9200. 269. The AAV particle of embodiment 268, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 55-76, (b) 159-194, (c) 219-247, and / or (d) 381-426, numbered according to SEQ ID NO: 9200. 270. The AAV particle of embodiment 268, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues (a) 57-72, (b) 175-191, (c) 223-238, and / or (d) 383-400, numbered according to SEQ ID NO: 9200. 271. The AAV particle of embodiment 268 and 270, wherein the antibody molecule binds to all or a portion of (e.g., one or more residues within) amino acid residues 223-238, numbered according to SEQ ID NO: 9200. 57 321651967.1Attorney Docket No.: V2071-3035PCT 272. The AAV particle of embodiment 271, wherein the antibody molecule binds a conformational epitope which includes all or a portion of (e.g., one or more residues within) amino acid residues (a) 55- 76, (b) 159-194, (c) 219-247, and / or (d) 381-426, numbered according to SEQ ID NO: 9200. 273. The AAV particle of any one of embodiments 1-226 or 240-272, wherein the antibody molecule comprises: (i) a heavy chain variable region comprising the HCDR1, HCDR2, and HCDR3 sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C); and / or (ii) a light chain variable region comprising the LCDR1, LCDR2, and LCDR3 sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C). 274. The AAV particle of any one of embodiments 1-226 or 240-273, wherein the antibody molecule comprises a heavy chain variable region comprising HCDR1, HCDR2, and HCDR3, and a light chain variable region comprising LCDR1, LCDR2, and LCDR3, of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C); optionally wherein at least one, two, three, four, five or all of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 comprises at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in a CDR relative to the CDR sequences of any one of the anti-tau antibody molecules described herein (e.g., an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C). 275. The AAV particle of any one of embodiments 1-226 or 240-274, wherein the antibody molecule comprises: (i) a heavy chain variable region (VH) comprising the amino acid sequence of the VH of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VH of any of the anti-tau antibody molecules described herein (e.g., the VH sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C); and / or (ii) a light chain variable region (VL) comprising the amino acid sequence of the VL of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed 58 321651967.1Attorney Docket No.: V2071-3035PCT in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C), or an amino acid sequence having at least one, two or three modifications, but not more than 30, 20 or 10 modifications, to the amino acid sequence of the VL of any of the anti-tau antibody molecules described herein (e.g., the VL sequence of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C). 276. The AAV particle of any one of embodiments 1-226 or 240-275, wherein the antibody molecule comprises the VH region and the VL region of any one of the anti-tau antibody molecule described herein (e.g., the VH and VL region sequences of an antibody molecule listed in Tables 7-16, 13A, 13B, and 13C). 277. The AAV particle of any one of embodiments 1-226 or 240-276, wherein the antibody molecule comprises the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences of Ab1, Ab2, Ab3, Ab4, Ab5, V0022, V0004, V0009, V0023, V0024, V0052, IPN002, AT8, PT3, UCB, PT76, PHF1, or C10.2. 278. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein, the antibody molecule is a humanized antibody. 59 321651967.1Attorney Docket No.: V2071-3035PCT 279. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or all of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562; and / or (ii) the VL comprises and amino acid sequence comprising one, two, or all of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO: 1573. 280. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: 60 321651967.1Attorney Docket No.: V2071-3035PCT (i) the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or all of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562; and / or (ii) the VL comprises and amino acid sequence comprising one, two, or all of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573. 281. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and optionally wherein: (i) the VH comprises an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; and / or (ii) the VL comprises an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 282. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-281, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively. 283. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-282, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively. 61 321651967.1Attorney Docket No.: V2071-3035PCT 284. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-283, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively. 285. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-284, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively. 286. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-285, wherein the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, nine, or all of: an amino acid other than Q at position 5, P at position 7, T at position 9, L at position 11, V at position 12, N at position 19, L at position 20, K at position 67, A at position 68, and / or S at position 76, numbered according to SEQ ID NO: 1562. 287. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-286, wherein the VH comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: an amino acid other than Q at position 5; an amino acid other than Q at position 6; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than S at position 91; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or all of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at 62 321651967.1Attorney Docket No.: V2071-3035PCT position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than E at position 89; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than P at position 14; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than E at position 39; an amino acid other than R at position 40; an amino acid other than H at position 43; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than T at position 71; an amino acid other than V at position 72; an amino acid other than H at position 73; an amino acid other than K at position 74; an amino acid other than S at position 76; an amino acid other than S at position 84; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all of: an amino acid other than Q at position 1; an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than S at position 85; an amino acid other than E at position 89, an amino acid other than S at position 113; and / or an amino acid other than T at position 115, numbered according to SEQ ID NO: 1562; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than H at position 43; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than T at position 87; and / or an amino acid other than S at position 91, numbered according to SEQ ID NO: 1562. 63 321651967.1Attorney Docket No.: V2071-3035PCT 288. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-287, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than P at position 14; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 38; an amino acid other than E at position 39; an amino acid other than R at position 40; an amino acid other than H at position 43; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than T at position 71; an amino acid other than V at position 72; an amino acid other than H at position 73; an amino acid other than K at position 74; an amino acid other than S at position 76; an amino acid other than S at position 84; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562. 289. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-287, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: an amino acid other than Q at position 5; an amino acid other than Q at position 6; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid other than Q at position 82; an amino acid other than T at position 87; an amino acid other than S at position 91; and / or an amino acid other than S at position 113, numbered according to SEQ ID NO: 1562. 290. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-287, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all of: an amino acid other than Q at position 1; an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than V at position 79; an amino acid other than F at position 80; an amino acid other than I at position 81; an amino acid 64 321651967.1Attorney Docket No.: V2071-3035PCT other than Q at position 82; an amino acid other than S at position 85; an amino acid other than E at position 89, an amino acid other than S at position 113; and / or an amino acid other than T at position 115, numbered according to SEQ ID NO: 1562. 291. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-287, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: an amino acid other than Q at position 5; an amino acid other than P at position 7; an amino acid other than T at position 9; an amino acid other than L at position 11; an amino acid other than V at position 12; an amino acid other than S at position 16; an amino acid other than N at position 19; an amino acid other than L at position 20; an amino acid other than H at position 43; an amino acid other than I at position 48; an amino acid other than K at position 67; an amino acid other than A at position 68; an amino acid other than L at position 70; an amino acid other than S at position 76; an amino acid other than T at position 77; an amino acid other than T at position 87; and / or an amino acid other than S at position 91, numbered according to SEQ ID NO: 1562. 292. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-291, wherein the VH comprises an amino acid sequence comprising one, two, three, four, five, six, seven, eight, or all of: a V at position 5, an S at position 7, an A at position 9, a V at position 11, a K at position 12, a K at position 19, a V at position 20, an R at position 67, and / or a V at position 68, numbered according to SEQ ID NO: 1562. 293. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-292, wherein the VH comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; R at position 38; R at position 67; V at position 68; M at position 70; I at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; D at position 89; and / or L at position 113, numbered according to SEQ ID NO: 1562; 65 321651967.1Attorney Docket No.: V2071-3035PCT (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562. 294. The AAV particle of any one of embodiments 1-226 or 240-252, 278, 288, 292, or 293, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562. 295. The AAV particle of any one of embodiments 1-226 or 240-252, 278-287, 289, 292, or 293, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562. 296. The AAV particle of any one of embodiments 1-226 or 240-252, 278-287, 290, 292, or 293, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at 66 321651967.1Attorney Docket No.: V2071-3035PCT position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562. 297. The AAV particle of any one of embodiments 1-226 or 240-252, 278-287, or 291-293, wherein the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562. 298. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-297, wherein the VL comprises and amino acid sequence comprising one, two, or all of: an amino acid other than D at position 17, Q at position 18, and / or G at position 68, numbered according to SEQ ID NO: 1573. 299. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-298, wherein the VL comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: an amino acid other than V at position 2; an amino acid other than T at position 7; an amino acid other than P at position 12; an amino acid other than S at position 14; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; an amino acid other than G at position 105; and / or an amino acid other than L at position 109, numbered according to SEQ ID NO: 1573; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of: an amino acid other than V at position 2; an amino acid other than L at position 11; an amino acid other than T at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than S at position 48; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than S at 67 321651967.1Attorney Docket No.: V2071-3035PCT position 72; an amino acid other than S at position 81; an amino acid other than L at position 88; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of: an amino acid other than V at position 2; an amino acid other than V at position 3; an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than L at position 51; an amino acid other than G at position 68; and / or an amino acid other than L at position 88, numbered according to SEQ ID NO: 1573; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: an amino acid other than D at position 1; an amino acid other than V at position 2; an amino acid other than M at position 4; an amino acid other than T at position 7; an amino acid other than L at position 9; an amino acid other than S at position 10; an amino acid other than P at position 12; an amino acid other than V at position 13; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than S at position 20; an amino acid other than I at position 21; an amino acid other than S at position 48; an amino acid other than V at position 63; an amino acid other than G at position 68; an amino acid other than S at position 72; an amino acid other than K at position 79; an amino acid other than R at position 82; an amino acid other than V at position 83; an amino acid other than A at position 85; and / or an amino acid other than G at position 89, numbered according to SEQ ID NO: 1573. 300. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-299, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: an amino acid other than V at position 2; an amino acid other than T at position 7; an amino acid other than P at position 12; an amino acid other than S at position 14; an amino acid other than L at position 15; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than L at position 88; an amino acid other than F at position 92; an amino acid other than G at position 105; and / or an amino acid other than L at position 109, numbered according to SEQ ID NO: 1573. 301. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-299, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: an amino acid other than T at position 7; an amino acid other than S at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other 68 321651967.1Attorney Docket No.: V2071-3035PCT than L at position 88; an amino acid other than F at position 92; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573. 302. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-299, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of: an amino acid other than V at position 2; an amino acid other than L at position 11; an amino acid other than T at position 14; an amino acid other than D at position 17; an amino acid other than Q at position 18; an amino acid other than L at position 42; an amino acid other than K at position 44; an amino acid other than S at position 48; an amino acid other than K at position 50; an amino acid other than G at position 68; an amino acid other than S at position 72; an amino acid other than S at position 81; an amino acid other than L at position 88; and / or an amino acid other than G at position 105, numbered according to SEQ ID NO: 1573. 303. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-302, wherein the VL comprises and amino acid sequence comprising one, two, or all of: Q or E at position 17, P or R at position 18, and / or S at position 68, numbered according to SEQ ID NO: 1573 304. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-303, wherein the VL comprises: (a) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573; (b) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573; (c) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of: I at position 2; S at position 11; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; P at position 48; R at position 50; S at position 68; A at position 72; N at position 81; V at position 88; and / or Q at position 105, numbered according to SEQ ID NO: 1573; (d) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or all of: I at position 2; E at position 3; S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; R at position 51; S at position 68; and / or V at position 88, numbered according to SEQ ID NO: 1573; or (e) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: E at position 1; I at position 2; L at position 4; S at position 7; A at position 9; T at position 10; S at position 12; L at 69 321651967.1Attorney Docket No.: V2071-3035PCT position 13; P at position 15; E at position 17; R at position 18; T at position 20; L at position 21; A at position 48; I at position 63; S at position 68; P at position 72; T at position 79; S at position 82; L at position 83; P at position 85; and / or A at position 89, numbered according to SEQ ID NO: 1573. 305. The AAV particle of any one of embodiments 1-226 or 240-252, 278-300, 303, or 304, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 306. The AAV particle of any one of embodiments 1-226 or 240-252, 278-299, 301, 303, or 304, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 307. The AAV particle of any one of embodiments 1-226 or 240-252, 278-299, or 301-304, wherein the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of: I at position 2; S at position 11; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; P at position 48; R at position 50; S at position 68; A at position 72; N at position 81; V at position 88; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 308. The AAV particle of any one of embodiments 1-226 or 240-252 or 278-307, wherein: (i) the VH comprises one, two, three, or four framework regions, e.g., one, two, three, or all of a FRH1, FRH2, FRH3, and / or FRH4; optionally wherein the VH comprises from N-terminus to C- terminus, FRH1-CDRH1-FRH2-CDRH2-FRH3-CDRH3-FRH4; and / or (ii) the VL comprises one, two, three, or four framework regions, e.g., one, two, three, or all of a FRL1, FRL2, FRL3, and / or FRL4; optionally wherein the VL comprises from N terminus to C-terminus, FRL1-CDRL1-FRL2-CDRL2-FRL3-CDRL3-FRL4. 309. The AAV particle of embodiment 308, wherein: (a) (i) the FRH1 corresponds to positions 1-25 of a heavy chain variable region, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH2 corresponds to positions 36-49, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH3 corresponds to positions 67-96, 70 321651967.1Attorney Docket No.: V2071-3035PCT numbered according to any one of SEQ ID NOs: 1562 or 67-71; and / or the FRH4 corresponds to positions 108-118, numbered according to any one of SEQ ID NOs: 1562 or 67-71; or (ii) the FRH1 corresponds to positions 1-30 of a heavy chain variable region, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH2 corresponds to positions 36-49, numbered according to any one of SEQ ID NOs: 1562 or 67-71; the FRH3 corresponds to positions 67-98, numbered according to any one of SEQ ID NOs: 1562 or 67-71; and / or the FRH4 corresponds to positions 108-118, numbered according to any one of SEQ ID NOs: 1562 or 67-71; and / or (b) the FRL1 corresponds to positions 1-23 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or 1573; the FRL2 corresponds to positions 40-54 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or 1573; the FRL3 corresponds to positions 62-93 of a light chain variable region, numbered according to any one of SEQ ID NOs: 72-76 or 1573; and / or the FRL4 corresponds to positions 103-112, numbered according to any one of SEQ ID NOs: 72-76 or 1573. 310. The AAV particle of any one of embodiments 278-309, wherein (a) the VH comprises one, two, three, or all of: (i) a FRH1 comprising amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 1-25 or 1-30 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); (ii) a FRH2 comprising amino acids 36-49 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 36-49 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 36-49 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); (iii) a FRH3 comprising amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionally any one of 71 321651967.1Attorney Docket No.: V2071-3035PCT SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 67-96 or 67-98 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); and / or (iv) a FRH4 comprising amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); or an amino acid sequence comprising one, two, three, but no more than four different amino acids relative to amino acids 108-118 of any one of SEQ ID NOs: 67-71 (optionally any one of SEQ ID NOs: 67 or 69-71); and / or (b) the VL comprises one, two, three or all of: (i) a FRL1 comprising amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 1-23 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); (ii) a FRL2 comprising amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 40-54 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); (iii) a FRL3 comprising amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 62-93 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); and / or (iv) a FRL4 comprising amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); an amino acid sequence comprising one, two, three 72 321651967.1Attorney Docket No.: V2071-3035PCT but no more than four modifications (e.g., substitutions, e.g., conservative substitutions) relative to amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74); or an amino acid sequence comprising one, two, three but no more than four different amino acids relative to amino acids 103-112 of any one of SEQ ID NOs: 72-76 (optionally any one of SEQ ID NOs: 72-74). 311. The AAV particle of any one of embodiments 278-310, wherein the: (i) the VH does not comprise one, two, three, or all of a FRH1 comprising amino acids 1-25 or 1- 30 of SEQ ID NO: 1562; a FRH2 comprising amino acids 36-49 of SEQ ID NO: 1562; an FRH3 comprising amino acids 67-96 or 67-98 of SEQ ID NO: 1562; and / or a FRH4 comprising amino acids 108-118 of SEQ ID NO: 1562; and / or (ii) the VL does not comprise one, two, three, or all of a FRL1 comprising amino acids 1-23 of SEQ ID NO: 1573; a FRL2 comprising amino acids 40-54 of SEQ ID NO: 1573; an FRL3 comprising amino acids 62-93 of SEQ ID NO: 1573; and / or a FRL4 comprising amino acids 103-112 of SEQ ID NO: 1573. 312. The AAV particle of any one of embodiments 278-311, wherein the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71. 313. The AAV particle of any one of embodiments 278-312, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67-71. 314. The AAV particle of any one of embodiments 278-313, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67-71. 315. The AAV particle of any one of embodiments 278-444, 448-450, or 454-470, wherein VH comprises the amino acid sequence of SEQ ID NO: 69; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69. 73 321651967.1Attorney Docket No.: V2071-3035PCT 316. The AAV particle of any one of embodiments 278-444, 448-450, or 454-471, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 69. 317. The AAV particle of any one of embodiments 278-288, 292-294, or 298-316, wherein the VH comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of SEQ ID NO: 69. 318. The AAV particle of any one of embodiments 278-287, 289, 292, 293, 295, or 298-314, wherein the VH comprises: (i) the amino acid sequence of SEQ ID NO: 67; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 67; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 67; or (iii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of SEQ ID NO: 67. 319. The AAV particle of any one of embodiments 278-287, 290, 292, 293, 296, or 298-314, wherein the VH comprises: (i) the amino acid sequence of SEQ ID NO: 70; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 70; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 70; or (iii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of SEQ ID NO: 70. 320. The AAV particle of any one of embodiments 278-287, 292, 293, or 297-314, wherein the VH comprises: (i) the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 71; 74 321651967.1Attorney Docket No.: V2071-3035PCT (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or (iii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of SEQ ID NO: 71. 321. The AAV particle of any one of embodiments 278-320, wherein VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 322. The AAV particle of any one of embodiments 278-321, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-76. 323. The AAV particle of any one of embodiments 278-322, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-76. 324. The AAV particle of any one of embodiments 278-300, 303-305, or 308-323, wherein VL comprises the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73. 325. The AAV particle of any one of embodiments 278-300, 303-305, or 308-324, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 73. 326. The AAV particle of any one of embodiments 278-300, 303-305, or 308-325, wherein the VL comprises an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 73. 327. The AAV particle of any one of embodiments 278-299, 299, 303, 304, 306, or 308-323, wherein the VL comprises: 75 321651967.1Attorney Docket No.: V2071-3035PCT (i) the amino acid sequence of SEQ ID NO: 72; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 72; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 72; (iii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 72. 328. The AAV particle of any one of embodiments 278-299, 299-304, or 307-323, wherein the VL comprises: (i) the amino acid sequence of SEQ ID NO: 74; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 74; (ii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 74; (iii) an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of SEQ ID NO: 74. 329. The AAV particle of any one of embodiments 278-328, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67-71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-76; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-76. 76 321651967.1Attorney Docket No.: V2071-3035PCT 330. The AAV particle of any one of embodiments 278-329, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of any one of SEQ ID NOs: 72-74; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 different amino acids relative to the amino acid sequence of any one of SEQ ID NOs: 72-74. 331. The AAV particle of any one of embodiments 278-330, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67-71, or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 67-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-76; or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 72-76. 332. The AAV particle of any one of embodiments 278-331, wherein: (a) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71, or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 67 or 69-71; and (b) the VL comprises the amino acid sequence of any one of SEQ ID NOs: 72-74; or an amino acid sequence at least 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of any one of SEQ ID NOs: 72-74. 333. The AAV particle of any one of embodiments 278-332, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ 77 321651967.1Attorney Docket No.: V2071-3035PCT ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (ii) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (iii) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (iv) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (v) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (vii) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; 78 321651967.1Attorney Docket No.: V2071-3035PCT (viii) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (ix) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (x) the VH comprises the amino acid sequence of SEQ ID NO: 68, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 68; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xi) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xii) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xiii) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xiv) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence 79 321651967.1Attorney Docket No.: V2071-3035PCT at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (xv) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xvi) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xvii) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xviii) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xix) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; (xx) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76; (xxi) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ 80 321651967.1Attorney Docket No.: V2071-3035PCT ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; (xxii) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; (xxiii) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; (xxiv) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 75, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 75; or (xv) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 76, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 76. 334. The AAV particle of any one of embodiments 278-288, 292-294, 298-300, 303-305, 308-315, 321- 326, or 329-333, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 69; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 69; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 69; and (ii) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; 81 321651967.1Attorney Docket No.: V2071-3035PCT an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 73. 335. The AAV particle of any one of embodiments 278-288, 292-294, 298-300, 303-305, 308-315, 321- 326, or 329-334, wherein the VH comprises the amino acid sequence of SEQ ID NO: 69 and the VL comprises the amino acid sequence of SEQ ID NO: 73. 336. The AAV particle of any one of embodiments 278-287, 290, 292, 293, 295, 298, 299, 301, 303, 304, 306, 308-314, 318, 321-323, 327, or 329-335, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 67; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 67; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 67; and (ii) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 72; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 72. 337. The AAV particle of any one of embodiments 278-287, 291, 292, 293, 296, 298, 299, 301, 303, 304, 306, 308-314, 319, 321-323, 327, or 329-333, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 70; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 70; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 70; and (ii) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 72; 82 321651967.1Attorney Docket No.: V2071-3035PCT an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 72; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 72. 338. The AAV particle of any one of embodiments 278-287, 291-293, 297-300, 302-314, 320-326, or 329-333, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 71; and (ii) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 73; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 73; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 73. 339. The AAV particle of any one of embodiments 278-287, 291-293, 297-299, 302-304, 307-314, 320- 232, or 329-333, wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86%, 87%, 88%, 90% 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 71; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 71; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 71; and (ii) the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91%, 93%, 95%, 96%, 97%, 98%, or 99% identical to the amino acid sequence of SEQ ID NO: 74; an amino acid sequence comprising at least one, two, three, four, or five but no more than 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to the amino acid sequence of SEQ ID NO: 74; or an amino acid sequence comprising at least one, two, three, four, or five but no more than 16 different amino acids relative to the amino acid sequence of any one of SEQ ID NO: 74. 83 321651967.1Attorney Docket No.: V2071-3035PCT 340. The AAV particle of any one of embodiments 278-339, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 156-160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 161-165; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 341. The AAV particle of any one of embodiments 278-340, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 156 or 158-160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 161-163; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 342. The AAV particle of any one of embodiments 278-288, 292-294, 298-300, 302-305, 308-315, 321- 326, 329-335, 340, or 341, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 158, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 162; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 343. The AAV particle of any one of embodiments 278-287, 289, 292, 293, 295, 298, 299, 301, 303, 304, 306, 308-314, 318, 321-323, 327, 329-333, 336, 340, or 341, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 156, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 161; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 84 321651967.1Attorney Docket No.: V2071-3035PCT 344. The AAV particle of any one of embodiments 278-287, 290, 292, 293, 296, 298, 299, 301, 303, 304, 306, 308-314, 319, 321-323, 327, 329-333, 337, 340, or 341, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 159, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 161; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 345. The AAV particle of any one of embodiments 278-287, 291-293, 297-300, 302-304, 307-314, 320- 326, 328-333, or 338-341, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 160, or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto; and / or (ii) the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NO: 162 or 163; or a nucleotide sequence at least 80% (e.g., at least 85%, 87%, 90%, 91%, 95%, 96%, 97%, 98%, or 99%) identical thereto. 346. The AAV particle of any one of embodiments 278-345, which does not comprise the amino acid sequence of SEQ ID NO: 1562 and / or the amino acid sequence of SEQ ID NO: 1573. 347. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and optionally wherein: 85 321651967.1Attorney Docket No.: V2071-3035PCT (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; S at position 14; A at position 16; K at position 19; V at position 20; R at position 38; Q at position 39; A at position 40; Q at position 43; R at position 67; V at position 68; I at position 71; R at position 72; D at position 73; T at position 74; T at position 76; T at position 84; and / or L at position 113, numbered according to SEQ ID NO: 1562; and (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 348. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and optionally wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 69, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 69; and / or (ii) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73. 349. The AAV particle of any one of embodiments 1-226, 240-252, 347, or 348, wherein the antibody molecule comprises a VH region comprising the amino acid sequence of SEQ ID NO: 69, and a VL region comprising the amino acid sequence of SEQ ID NO: 73. 86 321651967.1Attorney Docket No.: V2071-3035PCT 350. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; and optionally wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, or all of: V at position 5; E at position 6; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; M at position 48; R at position 67; V at position 68; I at position 70; A at position 76; S at position 77; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 87; T at position 91; and / or T at position 113, numbered according to SEQ ID NO: 1562; (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 351. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566 respectively; or 87 321651967.1Attorney Docket No.: V2071-3035PCT (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 67, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 67; and / or (ii) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 72. 352. The AAV particle of any one of embodiments 1-226, 240-252, 350, or 351, wherein the antibody molecule comprises a VH region comprising the amino acid sequence of SEQ ID NO: 67, and a VL region comprising the amino acid sequence of SEQ ID NO: 72. 353. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or all of: E at position 1; V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; K at position 19; V at position 20; R at position 67; V at position 68; M at position 70; I at position 76; A at position 79; Y at position 80; M at position 81; E at position 82; R at position 85; D at position 89, L at position 113; and / or S at position 115, numbered according to SEQ ID NO: 1562; and 88 321651967.1Attorney Docket No.: V2071-3035PCT (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or all of: S at position 7; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; R at position 50; S at position 68; V at position 88; Y at position 92; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 354. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 70, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 70; and / or (ii) the VL comprises the amino acid sequence of SEQ ID NO: 72, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 72. 355. The AAV particle of any one of embodiments 1-226, 240-252, 354, or 355, wherein the antibody molecule comprises a VH region comprising the amino acid sequence of SEQ ID NO: 70, and a VL region comprising the amino acid sequence of SEQ ID NO: 72. 356. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; 89 321651967.1Attorney Docket No.: V2071-3035PCT (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562; and (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or all of: I at position 2; S at position 7; S at position 12; T at position 14; P at position 15; Q at position 17; P at position 18; Q at position 50; S at position 68; V at position 88; Y at position 92; Q at position 105; and / or V at position 109, numbered according to SEQ ID NO: 1573. 357. The AAV particle of any one of embodiments 1-226 or 240-252, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 71; and / or 90 321651967.1Attorney Docket No.: V2071-3035PCT (ii) the VL comprises the amino acid sequence of SEQ ID NO: 73, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 73. 358. The AAV particle of any one of embodiments 1-226, 240-252, 356, or 357, wherein the antibody molecule comprises a VH region comprising the amino acid sequence of SEQ ID NO: 71, and a VL region comprising the amino acid sequence of SEQ ID NO: 73. 359. The AAV particle of any one of embodiments 1-226 or 240-254, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 or all of: V at position 5; S at position 7; A at position 9; V at position 11; K at position 12; A at position 16; K at position 19; V at position 20; Q at position 43; M at position 48; R at position 67; V at position 68; M at position 70; T at position 76; S at position 77; R at position 87; and / or T at position 91, numbered according to SEQ ID NO: 1562; and (ii) the VL comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or all of: I at position 2; S at position 11; T at position 14; Q at position 17; P at position 18; Q at position 42; R at position 44; P at position 48; R at position 50; S at position 68; A at position 72; N at position 81; V at position 88; and / or Q at position 105, numbered according to SEQ ID NO: 1573. 360. The AAV particle of any one of embodiments 1-226 or 240-254, wherein the antibody molecule comprises a VH region comprising an HCDR1, HCDR2, and HCDR3, and VL region comprising an LCDR1, LCDR2, and LCDR3, wherein: 91 321651967.1Attorney Docket No.: V2071-3035PCT (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 64, 1554, 1557, 1567, 1565, and 1566, respectively; (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1553, 1554, 1552, 1567, 1565, and 1566, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1555, SEQ ID NO: 1556, SEQ ID NO: 1557, SEQ ID NO: 1568, RVS, and SEQ ID NO: 1566, respectively; or (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of SEQ ID NO: 1550, 1551, 1552, 1564, 1565, and 1566, respectively; optionally wherein: (i) the VH comprises the amino acid sequence of SEQ ID NO: 71, or an amino acid sequence at least 86% (e.g., at least 90, 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 71; and / or (ii) the VL comprises the amino acid sequence of SEQ ID NO: 74, or an amino acid sequence at least 91% (e.g., at least 92, 95, 96, 97, 98, or 99%) identical to the amino acid sequence of SEQ ID NO: 74. 361. The AAV particle of any one of embodiments 1-226, 240-254, 359, or 360, wherein the antibody molecule comprises a VH region comprising the amino acid sequence of SEQ ID NO: 71, and a VL region comprising the amino acid sequence of SEQ ID NO: 74. 362. The AAV particle of any one of embodiments 1-226 or 240-361, wherein the antibody molecule is a humanized antibody molecule. 363. The AAV particle of any one of embodiments 1-226 or 240-362, which is a full length antibody molecule, a bispecific antibody molecule, an Fab, an F(ab')2, an Fv, or a single chain Fv fragment (scFv). 364. The AAV particle of any one of embodiments 1-226 or 240-363, which comprises a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4; and / or a light chain constant region of kappa or lambda. 365. The AAV particle of any one of embodiments 1-226 or 240-364, which comprises a heavy chain constant region of IgG4 and a light chain constant region of kappa. 92 321651967.1Attorney Docket No.: V2071-3035PCT 366. The AAV particle of any one of embodiments 1-226 or 240-365, wherein: (i) the antibody molecule comprises a human IgG4 constant region, comprising an amino acid other than serine at position 228 according to EU numbering; (ii) the antibody molecule comprises a human IgG4 constant region, comprising a serine to proline mutation at position 228 according to EU numbering; (iii) the antibody molecule comprises a heavy chain constant region (e.g., a human IgG4 constant region) comprising the amino acid sequence of SEQ ID NO: 2503, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2503; and / or (iv) the antibody molecule comprises a heavy chain constant region (e.g., a human IgG4 constant region), wherein the nucleotide sequence encoding the heavy chain constant region comprises the nucleotide sequence of any one of SEQ ID NOs: 2504, 2505, 2506, or 2507, or a nucleotide sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical any one of SEQ ID NOs: 2504, 2505, 2506, or 2507. 367. The AAV particle of any one of embodiments 1-226 or 240-366, wherein the antibody molecule comprises a light chain constant region (e.g., a light chain constant region of kappa), wherein: (i) the light chain constant region comprises the amino acid sequence of SEQ ID NO: 2508, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2508; and / or (ii) the nucleotide sequence encoding the light chain constant region comprises the nucleotide sequence of SEQ ID NO: 2509 or 2510, or a nucleotide sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2509 or 2510. 368. The AAV particle of any one of embodiments 1-226, 240-252, or 278-367, wherein the antibody molecule comprises a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 170- 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 170-174. 369. The AAV particle of any one of embodiments 1-226, 240-252, or 278-367, wherein the antibody molecule comprises a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 175- 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 175-179. 93 321651967.1Attorney Docket No.: V2071-3035PCT 370. The AAV particle of any one of embodiments 1-226, 240-252, or 278-369, wherein the antibody molecule comprises: (i) a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 170-174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 170-174; and (ii) a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 175-179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 175-179. 371. The AAV particle of any one of embodiments 1-226, 240-252, or 278-370, wherein the antibody molecule comprises: (i) a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 170 or 172- 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 170 or 172-174; and (ii) a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 175-177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 175-177. 372. The AAV particle of any one of embodiments 1-226, 240-252, or 278-371, which comprises: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170; and a light chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 175; (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 176; (iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 177; (iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170; and a light 94 321651967.1Attorney Docket No.: V2071-3035PCT chain comprising the amino acid sequence of SEQ ID NO: 178, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 178; (v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 170; and a light chain comprising the amino acid sequence of SEQ ID NO: 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 179; (vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 171; and a light chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 175; (vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 171; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 176; (viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 171; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 177; (ix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 171; and a light chain comprising the amino acid sequence of SEQ ID NO: 178, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 178; (x) a heavy chain comprising the amino acid sequence of SEQ ID NO: 171, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 171; and a light chain comprising the amino acid sequence of SEQ ID NO: 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 179; (xi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172; and a light chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 175; (xii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 176; 95 321651967.1Attorney Docket No.: V2071-3035PCT (xiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 177; (xiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172; and a light chain comprising the amino acid sequence of SEQ ID NO: 178, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 178; (xv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 172; and a light chain comprising the amino acid sequence of SEQ ID NO: 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 179; (xvi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173; and a light chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 175; (xvii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 176; (xviii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 177; (xix) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173; and a light chain comprising the amino acid sequence of SEQ ID NO: 178, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 178; (xx) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 173; and a light chain comprising the amino acid sequence of SEQ ID NO: 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 179; (xxi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 174; and a light 96 321651967.1Attorney Docket No.: V2071-3035PCT chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 175; (xxii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 174; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 176; (xxiii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 174; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 177; (xxiv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 174; and a light chain comprising the amino acid sequence of SEQ ID NO: 178, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 178; or (xxv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 174; and a light chain comprising the amino acid sequence of SEQ ID NO: 179, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 179. 373. The AAV particle of any one of embodiments 1-226 or 240-253, wherein the antibody molecule comprises: (a) the VH and / or VL sequences of SEQ ID NOs: 1562 and 1573, respectively; (b) the VH and / or VL sequences of SEQ ID NOs: 1512 and 1523, respectively; (c) the VH and / or VL sequences of SEQ ID NOs: 1537 and 1548, respectively; (d) the VH and / or VL sequences of SEQ ID NOs: 1583 and 1591, respectively; (e) the VH and / or VL sequences of SEQ ID NOs: 1599 and 1606, respectively; (f) the VH and / or VL sequences of SEQ ID NOs: 1619 and 1629, respectively; (g) the VH and / or VL sequences of SEQ ID NOs: 1822 and 1941, respectively; (h) the VH and / or VL sequences of SEQ ID NOs: 1849 and 1970, respectively; (i) the VH and / or VL sequences of SEQ ID NOs: 1844 and 1964, respectively; (j) the VH and / or VL sequences of SEQ ID NOs: 1803 and 1919, respectively; (k) a VH sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of any one of (a)-(j), and / or a VL sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of any one of (a)-(j); or 97 321651967.1Attorney Docket No.: V2071-3035PCT (l) a VH sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VH sequence of any one of (a)-(j), and / or a VL sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VL sequence of any one of (a)-(j). 374. The AAV particle of embodiment 373, wherein the antibody molecule comprises a VH sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VH sequence of SEQ ID NO: 1562, and / or a VL sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to the VL sequence of SEQ ID NO: 1573. 375. The AAV particle of embodiment 373, wherein the antibody molecule comprises a VH sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VH sequence of SEQ ID NO: 1562, and / or a VL sequence having at least one, two, or three modifications, but not more than 30, 20, or 10 modifications, relative to the VL sequence of SEQ ID NO: 1573. 376. The AAV particle of embodiment 373, wherein the antibody molecule comprises the VH and VL sequences of SEQ ID NOs: 1562 and 1573, respectively. 377. The AAV particle of embodiment 376, wherein the antibody molecule comprises a VH sequence encoded by a nucleotide sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any one of SEQ ID NOs: 158, 156, 157, 159, 160, 1563, 1513, 1538, 1584, 1600, or 1620 and / or a VL sequence encoded by a nucleotide sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any one of SEQ ID NOs: 1574, 1524, 1549, 1592, 1607, or 1630. 378. The AAV particle of embodiment 377, wherein the antibody molecule comprises VH and VL sequences encoded by nucleotide sequences set forth in (a) SEQ ID NOs: 1563 and 1574, respectively, (b) SEQ ID NOs: 1513 and 1524, respectively, (c) SEQ ID NOs: 1538 and 1549, respectively, (d) SEQ ID NOs: 1584 and 1592, respectively, (e) SEQ ID NOs: 1600 and 1607, respectively, (f) SEQ ID NOs: 1620 and 1630, respectively, or (g) a nucleotide sequence having at least 80% (e.g., 85, 90, 95, 96, 97, 98, or 99%) sequence identity to any one of (a)-(f). 98 321651967.1Attorney Docket No.: V2071-3035PCT 379. The AAV particle of embodiment 377 or 378, wherein the antibody molecule comprises a VH sequence encoded by the nucleotide sequence of SEQ ID NO: 1563 and a VL sequence encoded by the nucleotide sequence of SEQ ID NO: 1574. 380. The AAV particle of any one of embodiments 1-226 or 240-253, wherein the antibody molecule comprises: (a) the HCDR1, HCDR2, and / or HCDR3 sequences of SEQ ID NOs: 1777, 1778, and 1779, respectively, and / or the LCDR1, LCDR2, and / or LCDR3 sequences of SEQ ID NOs: 1889, 1890, and 1891, respectively; (b) the HCDR1, HCDR2, and / or HCDR3 sequences of SEQ ID NOs: 1790, 1792, and 1794, respectively, and / or the LCDR1, LCDR2, and / or LCDR3 sequences of SEQ ID NOs: 1908, 1910, and 1912, respectively; (c) the HCDR1, HCDR2, and / or HCDR3 sequences of SEQ ID NOs: 1761, 1762, and 1763, respectively, and / or the LCDR1, LCDR2, and / or LCDR3 sequences of SEQ ID NOs: 1880, 1881, and 1882, respectively; or (d) the HCDR1, HCDR2, and / or HCDR3 sequences, and / or LCDR1, LCDR2, and / or LCDR3 sequences of any one of (a)-(c), with at most one, two, or three substitutions (e.g., conservative amino acid substitutions) in each CDR. 381. The AAV particle of any one of embodiments 1-226 or 240-253, wherein the antibody molecule binds to all or a portion of amino acid residues of tau selected from: (a) 183-212, (b) 187-218, (c) 33-82, 159-182, 197-226, and 229-246; (d) 217-242, (e) 35-76 and 187-218, (f) 5-34, (g) 187-218, (h) 33-82, 159-188, and 191-230, (i) 35-62, 107-124, and 203-220, (j) 35-82, 159-188, and 197-224, and (k) 53-78, 329-348, or 381-408, wherein human tau is numbered according to SEQ ID NO: 9200. 382. The AAV particle of embodiment 381, wherein one or more of the serines, threonines, and / or tyrosines in the stretch of amino acids selected from (a)-(k) are phosphorylated. 383. The AAV particle of embodiment 381 or 382, wherein all of the serines, threonines, and / or tyrosines in the stretch of amino acids selected from (a)-(k) are phosphorylated. 384. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to all or a portion of amino acids 195-215 of tau, e.g., with a dissociation constant (KD) of about 1 pM to about 50 pM, or about 1-25 pM, e.g., as assessed by bio-layer interferometry. 99 321651967.1Attorney Docket No.: V2071-3035PCT 385. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to all or a portion of amino acids 191-214 of tau phosphorylated at S199, e.g., with a dissociation constant (KD) of about 0.1 nM to about 10 nM, or about 0.5-5 nM, e.g., as assessed by bio- layer interferometry. 386. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to all or a portion of amino acids 217-234 of tau phosphorylated at T217, T220, and T231, e.g., with a dissociation constant (KD) of about 0.1 nM to about 10 nM, or about 0.1-5 nM, e.g., as assessed by bio-layer interferometry. 387. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to all or a portion of amino acids 225-240 of tau phosphorylated at T231, e.g., with a dissociation constant (KD) of about 0.1 nM to about 25 nM, or about 0.1-15 nM, e.g., as assessed by bio- layer interferometry. 388. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to human tau phosphorylated at amino acid residue S404, or a peptide comprising or consisting of the amino acid sequence DHGAEIVYKSPVVSGDT(pS)PRHLSNVSSTG (SEQ ID NO: 2143), wherein p(S) corresponds to a phosphorylated serine residue, optionally wherein the antibody molecule comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2430, 2431, and 2432, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2435, LGS, and SEQ ID NO: 2437, respectively. 389. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to: (a) human tau phosphorylated at amino acid residue S199, but not at amino acid residues S202 and T205, (b) human tau phosphorylated at amino acid residue S202, but not at amino acid residues S199 and T205, (c) human tau phosphorylated at amino acid residue T205, but not at amino acid residues S199 and S202, (d) human tau phosphorylated at a combination of amino acid residues S199 and T205, but not at amino acid residue S202 (e.g., wherein binding tau phosphorylated at a combination of S199 and T205 is 100 321651967.1Attorney Docket No.: V2071-3035PCT at least 3-times stronger (e.g., at least 4-time stronger) than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), (e) human tau phosphorylated at a combination of amino acid residues S202 and T205, but not at amino acid residue S199, but not human tau phosphorylated at a combination of residues S199 and S202, but not T205, (f) human tau phosphorylated at a combination of amino acid residues (i) S202 and T205, but not S119, and (ii) S199 and T205, but not S202, e.g., at least 2 times (e.g., at least 3 times, at least 4 times, at least 5 times, 2-6 times, 2-5 times, 2-4 times, 2-3 times, 3-5 times or 4-5 times) more strongly than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control). (g) human tau phosphorylated at a combination of amino acid residues (i) S199 and S202, but not T205, (ii) S202 and T205, but not S199, (iii) S199 and T205, but not S202, and (iv) S199, S202, and T205 (e.g., wherein binding to phosphorylated tau is at least 1.6-times stronger (e.g., at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, 1.6-3 times, 1.6-2 times stronger) than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), (h) a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PGSPGTPGSRSRTPS (SEQ ID NO: 2146), (i) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPG(pS)PGTPGSRSRTPS (SEQ ID NO: 2147), (j) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPGSPG(pT)PGSRSRTPS (SEQ ID NO: 2148), or (k) a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152) (e.g., wherein binding to the peptide is at least 3 times stronger (e.g., at least 4 times stronger) than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), (l) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151), but not a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PG(pS)PGTPGSRSRTPS (SEQ ID NO: 2150), (m) peptides comprising or consisting of the amino acid sequences SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151) and SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152), wherein binding to the latter peptide is at least 2 times (e.g., at least 3 times, at least 4 times, at least 5 times, 2-6 times, 2-5 times, 2-4 times, 2-3 times, 3-5 times or 4-5 times) more stronger than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), or 101 321651967.1Attorney Docket No.: V2071-3035PCT (n) peptides comprising or consisting of the amino acid sequences SGDRSGYS(pS)PG(pS)PGTPGSRSRTPS (SEQ ID NO: 2150), SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151), SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152), and SGDRSGYS(pS)PG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2149) (e.g., wherein binding to the peptides is at least 1.6 times stronger (e.g., at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, 1.6-4 times, 1.6-3 times stronger) than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), wherein p(S) and p(T) correspond to a phosphorylated serine and phosphorylated threonine, respectively, optionally wherein binding is assessed, e.g., using ELISA, and optionally wherein human tau has the sequence set forth in SEQ ID NO: 9200, and optionally wherein the antibody molecule comprises: (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2273, 2274, and 2275, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2277, respectively; or (v) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively. 102 321651967.1Attorney Docket No.: V2071-3035PCT 390. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to: (a) human tau phosphorylated at amino acid residue S199, but not at amino acid residues S202 and T205, optionally wherein the antibody molecule comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; (b) human tau phosphorylated at amino acid residue S202, but not at amino acid residues S199 and T205, optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; or (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (c) human tau phosphorylated at amino acid residue T205, but not at amino acid residues S199 and S202, optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; or (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (d) human tau phosphorylated at a combination of amino acid residues S199 and T205, but not at amino acid residue S202 (e.g., wherein binding tau phosphorylated at a combination of S199 and T205 is at least 3-times stronger (e.g., at least 4-time stronger) than background (e.g., non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ 103 321651967.1Attorney Docket No.: V2071-3035PCT ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (e) human tau phosphorylated at a combination of amino acid residues S202 and T205, but not at amino acid residue S199, but not human tau phosphorylated at a combination of residues S199 and S202, but not T205, optionally wherein the antibody molecule comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2273, 2274, and 2275, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2277, respectively; (f) human tau phosphorylated at a combination of amino acid residues (i) S202 and T205, but not S119, and (ii) S199 and T205, but not S202, e.g., at least 2 times (e.g., at least 3 times, at least 4 times, at least 5 times, 2-6 times, 2-5 times, 2-4 times, 2-3 times, 3-5 times or 4-5 times) more strongly than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, 104 321651967.1Attorney Docket No.: V2071-3035PCT respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (g) human tau phosphorylated at a combination of amino acid residues (i) S199 and S202, but not T205, (ii) S202 and T205, but not S199, (iii) S199 and T205, but not S202, and (iv) S199, S202, and T205 (e.g., wherein binding to phosphorylated tau is at least 1.6-times stronger (e.g., at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, 1.6-3 times, 1.6-2 times stronger) than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (h) a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PGSPGTPGSRSRTPS (SEQ ID NO: 2146), optionally wherein the antibody molecule comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; (i) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPG(pS)PGTPGSRSRTPS (SEQ ID NO: 2147), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, 105 321651967.1Attorney Docket No.: V2071-3035PCT KIS, and SEQ ID NO: 2224, respectively; or (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (j) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPGSPG(pT)PGSRSRTPS (SEQ ID NO: 2148), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; or (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (k) a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152) (e.g., wherein binding to the peptide is at least 3 times stronger (e.g., at least 4 times stronger) than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; 106 321651967.1Attorney Docket No.: V2071-3035PCT (l) a peptide comprising or consisting of the amino acid sequence SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151), but not a peptide comprising or consisting of the amino acid sequence SGDRSGYS(pS)PG(pS)PGTPGSRSRTPS (SEQ ID NO: 2150), optionally wherein the antibody molecule comprises a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2273, 2274, and 2275, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2277, respectively (m) peptides comprising or consisting of the amino acid sequences SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151) and SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152), e.g., wherein binding to the latter peptide is at least 2 times (e.g., at least 3 times, at least 4 times, at least 5 times, 2-6 times, 2-5 times, 2-4 times, 2-3 times, 3-5 times or 4-5 times) more stronger than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; or (n) peptides comprising or consisting of the amino acid sequences SGDRSGYS(pS)PG(pS)PGTPGSRSRTPS (SEQ ID NO: 2150), SGDRSGYSSPG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2151), SGDRSGYS(pS)PGSPG(pT)PGSRSRTPS (SEQ ID NO: 2152), and SGDRSGYS(pS)PG(pS)PG(pT)PGSRSRTPS (SEQ ID NO: 2149) (e.g., wherein binding to the peptides is at least 1.6 times stronger (e.g., at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, 1.6-4 times, 1.6-3 times stronger) than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), optionally wherein the antibody molecule comprises (i) a heavy chain 107 321651967.1Attorney Docket No.: V2071-3035PCT variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2218, 2219, and 2220, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2248, 2219, and 2249, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2200, 2201, and 2202, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; or (iv) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2371, 2372, and 2373, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; wherein p(S) and p(T) correspond to a phosphorylated serine and phosphorylated threonine, respectively, optionally wherein binding is assessed, e.g., using ELISA, and optionally wherein human tau has the sequence set forth in SEQ ID NO: 9200. 391. The AAV particle of any one of embodiments 1-226, 240-253, or 381-383, wherein the antibody molecule binds to: (a) tau phosphorylated at T217, but not at T212 or T214, or (b) peptides comprising or consisting of the sequences GTPGSRSRTPSLP(pT)PPTRE (SEQ ID NO: 2155) and GTPGSRSRTP(pS)LP(pT)PPTRE (SEQ ID NO: 2158), but not peptides comprising or consisting of the sequences GTPGSRSR(pT)PSLPTPPTRE (SEQ ID NO: 2153), GTPGSRSRTP(pS)LPTPPTRE (SEQ ID NO: 2154), and GTPGSRSR(pT)P(pS)LPTPPTRE (SEQ ID NO: 2156), wherein p(S) and p(T) correspond to a phosphorylated serine and phosphorylated threonine, respectively, optionally wherein binding of the antibody molecule to tau or the peptide is at least 1.5 times stronger (e.g., at least 1.6 times, at least 1.7 times, at least 1.8 times, at least 1.9 times, at least 2 times, at least 3 times, at least 4 times, at least 5 times, at least 6 times, 1.5-4 times, 1.5-3, 4-6 times stronger) than background (non-specific) level of binding, e.g., binding by hIgG1 isotype control), 108 321651967.1Attorney Docket No.: V2071-3035PCT optionally wherein binding of the antibody molecule to tau or the peptide is assessed, e.g., using one point ELISA as described, e.g., in Example 11, and optionally wherein human tau has the sequence set forth in SEQ ID NO: 9200, and optionally wherein the antibody molecule comprises: (i) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2232, 2233, and 2234, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2238, DVS, and SEQ ID NO: 2240, respectively; (ii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2284, 2392, and 2393, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NOs: 2404, 2405, and 2406, respectively; or (iii) a heavy chain variable region (VH) comprising HCDR1, HCDR2, and HCDR3 sequences comprising SEQ ID NOs: 2445, 2446, and 2447, respectively, and a light chain variable region (VL) comprising LCDR1, LCDR2, and LCDR3 sequences comprising SEQ ID NO: 2452, WAS, and SEQ ID NO: 2453, respectively. 392. The AAV particle of any one of embodiments 1-226, 240-253, or 381-391, wherein the antibody molecule comprises a heavy chain variable region (VH) comprising one, two, or three of a heavy chain complementary determining region 1 (HCDR1), a heavy chain complementary determining region 2 (HCDR2), and a heavy chain complementary determining region 3 (HCDR3), and / or a light chain variable region (VL) comprising one, two, or three of a light chain complementary determining region 1 (LCDR1), a light chain complementary determining region 2 (LCDR2), and a light chain complementary determining region 3 (LCDR3), e.g., CDR sequences according to the Chothia numbering system, wherein: (i) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2200, SEQ ID NO: 2201, SEQ ID NO: 2202, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; (ii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2232, SEQ ID NO: 2233, SEQ ID NO: 2234, SEQ ID NO: 2238, DVS, and SEQ ID NO:2240, respectively; (iii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2248, SEQ ID NO: 2219, SEQ ID NO: 2249, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; 109 321651967.1Attorney Docket No.: V2071-3035PCT (iv) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2218, SEQ ID NO: 2219, SEQ ID NO: 2220, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (v) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2200, SEQ ID NO: 2257, SEQ ID NO: 2258, SEQ ID NO: 2262, KIS, and SEQ ID NO: 2264, respectively; (vi) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2415, SEQ ID NO: 2416, SEQ ID NO: 2417, SEQ ID NO: 2420, WAS, and SEQ ID NO: 2422, respectively; (vii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2273, SEQ ID NO: 2274, SEQ ID NO: 2275, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2277, respectively; (viii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2284, SEQ ID NO: 2285, SEQ ID NO: 2286, SEQ ID NO: 2289, GNS, and SEQ ID NO: 2291, respectively; (ix) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2284, SEQ ID NO: 2299, SEQ ID NO: 2300, SEQ ID NO: 2302, DAS, and SEQ ID NO: 2304, respectively; (x) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2313, SEQ ID NO: 2314, SEQ ID NO: 2315, SEQ ID NO: 2319, DDS, and SEQ ID NO: 2321, respectively; (xi) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2330, SEQ ID NO: 2331, SEQ ID NO: 2332, SEQ ID NO: 2262, KDT, and SEQ ID NO: 2337, respectively; (xii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2345, SEQ ID NO: 2346, SEQ ID NO: 2347, SEQ ID NO: 2351, KVS, and SEQ ID NO: 2353, respectively; (xiii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 2345, 2346, 2347, 2361, 2362, and 2363, respectively; (xiv) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2371, SEQ ID NO: 2372, SEQ ID NO: 2373, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; 110 321651967.1Attorney Docket No.: V2071-3035PCT (xv) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2381, SEQ ID NO: 2382, SEQ ID NO: 2383, SEQ ID NO: 2262, KDS, and SEQ ID NO: 2385, respectively; (xvi) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2284, SEQ ID NO: 2392, SEQ ID NO: 2393, SEQ ID NO: 2396, DVS, and SEQ ID NO: 2397, respectively; (xvii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2284, SEQ ID NO: 2392, SEQ ID NO: 2393, SEQ ID NO: 2404, AAS, and SEQ ID NO: 2406, respectively; (xviii) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2430, SEQ ID NO: 2431, SEQ ID NO: 2432, SEQ ID NO: 2435, LGS, and SEQ ID NO: 2437, respectively; (xix) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2445, SEQ ID NO: 2446, SEQ ID NO: 2447, SEQ ID NO: 2452, SEQ ID NO: WAS, and SEQ ID NO: 2453, respectively; (xx) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2459, SEQ ID NO: 2460, SEQ ID NO: 2461, SEQ ID NO: 2465, VGS, and SEQ ID NO: 2467, respectively; (xxi) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of any of the HCDR and LCDR sequences provided in Tables 14-16; or (xxii) a variant, e.g., functional variant, of the antibody molecules of any one of (i)-(xxi), wherein any one, two, three, four, five or all of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 comprises one, two, or at most three substitutions (e.g., conservative substitutions); or wherein any one, two, three, four, five or all of the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and / or LCDR3 comprises one, two, or at most three different amino acids relative to any of the sequences in (i)-(xxi). 393. The AAV particle of embodiment 392, wherein the antibody molecule comprises the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 sequences of any one of (i)-(xxii). 394. The AAV particle of embodiment 1-226, 240-253, or 381-393, wherein the antibody molecule comprises: (a) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2248, SEQ ID NO: 2219, SEQ ID NO: 2249, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; 111 321651967.1Attorney Docket No.: V2071-3035PCT (b) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2200, SEQ ID NO: 2201, SEQ ID NO: 2202, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2209, respectively; (c) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2232, SEQ ID NO: 2233, SEQ ID NO: 2234, SEQ ID NO: 2238, DVS, and SEQ ID NO: 2240, respectively; (d) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2218, SEQ ID NO: 2219, SEQ ID NO: 2220, SEQ ID NO: 2207, KIS, and SEQ ID NO: 2224, respectively; (e) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2415, SEQ ID NO: 2416, SEQ ID NO: 2417, SEQ ID NO: 2420, WAS, and SEQ ID NO: 2422, respectively; or (f) the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NO: 2200, SEQ ID NO: 2257, SEQ ID NO: 2258, SEQ ID NO: 2262, KDS, and SEQ ID NO: 2264, respectively. 395. The AAV particle of any one of embodiments 1-226, 240-253, or 381-394, wherein the antibody molecule comprises a heavy chain CDR1, CDR2, and CDR3, and / or a light chain CDR1, CDR2, and CDR3 of an antibody molecule comprising a heavy chain variable region (VH) and light chain variable region (VL) comprising: (i) SEQ ID NOs: 2214 and 2215, respectively; (ii) SEQ ID NOs: 2244 and 2245, respectively; (iii) SEQ ID NOs: 2253 and 2254, respectively; (iv) SEQ ID NOs: 2228 and 2229, respectively; (v) SEQ ID NOs: 2269 and 2270, respectively; (vi) SEQ ID NOs: 2426 and 2427, respectively; (vii) SEQ ID NOs: 2280 and 2281, respectively; (viii) SEQ ID NOs: 2295 and 2296, respectively; (ix) SEQ ID NOs: 2309 and 2310, respectively; (x) SEQ ID NOs: 2326 and 2327, respectively; (xi) SEQ ID NOs: 2341 and 2342, respectively; (xii) SEQ ID NOs: 2357 and 2358, respectively; (xiii) SEQ ID NOs: 2367 and 2368, respectively; (xiv) SEQ ID NOs: 2377 and 2378, respectively; (xv) SEQ ID NOs: 2388 and 2389, respectively; (xvi) SEQ ID NOs: 2400 and 2401, respectively; (xvii) SEQ ID NOs: 2411 and 2412, respectively; (xviii) SEQ ID NOs: 2441 and 2442, respectively; (xix) SEQ ID NOs: 2455 and 2456, respectively; or (xx) SEQ ID NOs: 2470 and 2471, respectively. 396. The AAV particle of embodiment 395, wherein the CDR sequences are based on the Kabat numbering system, Chothia numbering system, or IMGT numbering system. 112 321651967.1Attorney Docket No.: V2071-3035PCT 397. The AAV particle of any one of embodiments 1-226, 240-253, or 381-396, wherein the antibody molecule comprises a VH comprising: (i) the amino acid sequence of any VH provided in Table 14 or 15, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (ii) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications relative to the amino acid sequence of any VH provided in Table 14 or 15; (iii) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any VH sequences provided in Table 14 or 15; or (iv) an amino acid sequence encoded by a nucleotide sequence of any VH provided in Table 14 or 15, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. 398. The AAV particle of any one of embodiments 1-226, 240-253, or 381-397, wherein the antibody molecule comprises a VH comprising: (i) the amino acid sequence of any of SEQ ID NOs: 2253, 2214, 2244, 2228, 2426, and 2269, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (ii) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any of SEQ ID NOs: 2253, 2214, 2244, 2228, 2426, and 2269; (iii) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any of SEQ ID NOs: 2253, 2214, 2244, 2228, 2426, and 2269; or (iv) an amino acid sequence encoded by a nucleotide sequence of any of SEQ ID NOs: 2255, 2216, 2246, 2230, 2428, and 2271, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. 399. The AAV particle of any one of embodiments 1-226, 240-253, or 381-398, wherein the antibody molecule comprises a VL comprising: (i) the amino acid sequence of any VL provided in Table 14 or 15, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; 113 321651967.1Attorney Docket No.: V2071-3035PCT (ii) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications relative to the amino acid sequence of any VL provided in Table 14 or 15; (iii) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any VL sequences provided in Table 14 or 15; or (iv) an amino acid sequence encoded by a nucleotide sequence of any VL provided in Table 14 or 15, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. 400. The AAV particle of any one of embodiments 1-226, 240-253, or 381-399, wherein the antibody molecule comprises a VL comprising: (i) the amino acid sequence of any of SEQ ID NOs: 2254, 2215, 2245, 2229, 2427, and 2270, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (ii) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications of the amino acid sequence of any of SEQ ID NOs: 2254, 2215, 2245, 2229, 2427, and 2270; (iii) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any of SEQ ID NOs: 2254, 2215, 2245, 2229, 2427, and 2270; or (iv) an amino acid sequence encoded by a nucleotide sequence of any of SEQ ID NOs: 2256, 2217, 2247, 2231, 2429, and 2272, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. 401. The AAV particle of any one of embodiments 1-226, 240-253, or 381-400, wherein the antibody molecule comprises: (i) a VH comprising: (a) the amino acid sequence of any VH provided in Table 14 or 15, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (b) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications relative to the amino acid sequence of any VH provided in Table 14 or 15; 114 321651967.1Attorney Docket No.: V2071-3035PCT (c) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any VH sequences provided in Table 14 or 15; or (d) an amino acid sequence encoded by a nucleotide sequence of any VH provided in Table 14 or 15, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; and (ii) a VL comprising: (a) the amino acid sequence of any VL provided in Table 14 or 15, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; (b) an amino acid sequence comprising at least one, two or three modifications, but not more than 30, 20 or 10 modifications relative to the amino acid sequence of any VL provided in Table 14 or 15; (c) an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to any one of the amino acid sequences of any VL sequences provided in Table 14 or 15; or (d) an amino acid sequence encoded by a nucleotide sequence of any VL provided in Table 14 or 15, or a nucleotide sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto. 402. The AAV particle of any one of embodiments 1-226, 240-253, or 381-401, wherein the antibody molecule comprises the amino acid sequence of any VH of an antibody molecule provided in Table 14 or 15, and the amino acid sequence of the VL of the antibody molecule provided in Table 14 or 15. 403. The AAV particle of any one of embodiments 1-226, 240-253, or 381-402, wherein the antibody molecule comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 2253; an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2253; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2253; and (ii) a VL comprising the amino acid sequence of SEQ ID NO: 2254, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 115 321651967.1Attorney Docket No.: V2071-3035PCT different amino acids relative to SEQ ID NO: 2254; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2254. 404. The AAV particle of any one of embodiments 1-226, 240-253, or 381-403, wherein the antibody molecule comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 2214; an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2214; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2214; and (ii) a VL comprising the amino acid sequence of SEQ ID NO: 2215, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2215; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2215. 405. The AAV particle of any one of embodiments 1-226, 240-253, or 381-402, wherein the antibody molecule comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 2244; an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2244; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2244; and (ii) a VL comprising the amino acid sequence of SEQ ID NO: 2245, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2245; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2245. 116 321651967.1Attorney Docket No.: V2071-3035PCT 406. The AAV particle of any one of embodiments 1-226, 240-253, or 381-402, wherein the antibody molecule comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 2228; an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2228; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2228; and (ii) a VL comprising the amino acid sequence of SEQ ID NO: 2229, or an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% sequence identity thereto; an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 different amino acids relative to SEQ ID NO: 2229; or an amino acid sequence comprising at least one, two or three, but not more than 30, 20 or 10 modifications, e.g., substitutions (e.g., conservative substitutions) relative to SEQ ID NO: 2229. 407. The AAV particle of any one of embodiments 1-226, 240-253, or 381-402, wherein the antibody molecule comprises: (i) a VH comprising the amino acid sequence of SEQ ID NO: 2269; an amino acid sequence having at least 70%, 75%, 80%, 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 9...

Claims

Attorney Docket No.: V2071-3035PCT We claim:

1. An adeno-associated virus (AAV) particle comprising an AAV capsid variant and a nucleic acid encoding an antibody molecule which binds to human tau, wherein the AAV capsid variant comprises an amino acid sequence having the following formula: [N1]-[N2]-[N3] (SEQ ID NO: 4681), wherein [N2] comprises the amino acid sequence of DWHR (SEQ ID NO: 4682) and wherein: (i) [N1] comprises positions X1, X2, X3, and X4, wherein position X4is Q, K, E, S, P, R, N, H; and / or (ii) [N3] comprises positions X5, X6, and X7, wherein position X5is I, V, T, M, S, N, L, or F; wherein [N1]-[N2]-[N3] is present in hypervariable loop VIII; and wherein the AAV capsid variant comprises an amino acid sequence at least 95% identical to the amino acid sequence of positions 203-736 of SEQ ID NO:

138.

2. The AAV particle of claim 1, wherein [N1] comprises positions X1, X2, X3, and X4, wherein: (i) position X1is T, S, R, A, I, C, N, K, L, or Q; (ii) position X2is N, T, G, V, S, Y, K, I, H, D, or F; (iii) position X3is T, N, K, D, I, S, P, A, Y, E, V, L, M, R, H, Q, or C; and (iv) position X4is Q, K, E, S, P, R, N, or H.

3. The AAV particle of claim 1 or 2, wherein: (i) [N1] comprises TNTQ (SEQ ID NO: 4688), TNTK (SEQ ID NO: 4689), TNNQ (SEQ ID NO: 4690), SNNQ (SEQ ID NO: 4691), TNKQ (SEQ ID NO: 4692), TNNE (SEQ ID NO: 4693), SNKQ (SEQ ID NO: 4694), SNTQ (SEQ ID NO: 4695), TTNQ (SEQ ID NO: 4696), TNDQ (SEQ ID NO: 4697), TTIQ (SEQ ID NO: 4698), RNTQ (SEQ ID NO: 4699), TTKQ (SEQ ID NO: 4700), TTSQ (SEQ ID NO: 4701), TTDQ (SEQ ID NO: 4702), TNPS (SEQ ID NO: 4703), TNKE (SEQ ID NO: 4704), TTTQ (SEQ ID NO: 4705), TGKQ (SEQ ID NO: 4706), TTAQ (SEQ ID NO: 4707), TVKQ (SEQ ID NO: 4708), TNYQ (SEQ ID NO: 4709), TNTP (SEQ ID NO: 4710), STKQ (SEQ ID NO: 4711), TTEQ (SEQ ID NO: 4712), TSKQ (SEQ ID NO: 4713), TNIQ (SEQ ID NO: 4714), TYNQ (SEQ ID NO: 4715), STIQ (SEQ ID NO: 4716), TTVQ (SEQ ID NO: 4717), TGTQ (SEQ ID NO: 4718), TNTR (SEQ ID NO: 4719), TTLQ (SEQ ID NO: 4720), TTMQ (SEQ ID NO: 4721), ANNQ (SEQ ID NO: 4722), SNIQ (SEQ ID NO: 4723), TKNQ (SEQ ID NO: 4724), TYTQ (SEQ ID NO: 4725), TNKS (SEQ ID NO: 4726), SNTE (SEQ ID NO: 4727), TNTE (SEQ ID NO: 4728), TNIE (SEQ ID NO: 4729), TTRQ (SEQ ID NO: 4730), TNSQ (SEQ ID NO: 4731), TYTK (SEQ ID NO: 4732), TTTK (SEQ ID NO: 4733), TNIK (SEQ ID NO: 4734), SNTK (SEQ ID NO: 4735), TNNK (SEQ ID NO: 4736), TNSK (SEQ ID NO: 4737), TSTK (SEQ ID NO: 4738), TITK (SEQ ID 441 321651967.1Attorney Docket No.: V2071-3035PCT NO: 4739), INTK (SEQ ID NO: 4740), TNAK (SEQ ID NO: 4741), TKTK (SEQ ID NO: 4742), STNQ (SEQ ID NO: 4743), ANTK (SEQ ID NO: 4744), RNNQ (SEQ ID NO: 4745), TGNQ (SEQ ID NO: 4746), TSNQ (SEQ ID NO: 4747), THTK (SEQ ID NO: 4748), TDTK (SEQ ID NO: 4749), TNEQ (SEQ ID NO: 4750), CNTQ (SEQ ID NO: 4751), TNPK (SEQ ID NO: 4752), INNQ (SEQ ID NO: 4753), TYTE (SEQ ID NO: 4754), NNNQ (SEQ ID NO: 4755), KNNQ (SEQ ID NO: 4756), TNNR (SEQ ID NO: 4757), LNNQ (SEQ ID NO: 4758), TINQ (SEQ ID NO: 4759), TNHQ (SEQ ID NO: 4760), STTQ (SEQ ID NO: 4761), SNSQ (SEQ ID NO: 4762), STSQ (SEQ ID NO: 4763), TYIQ (SEQ ID NO: 4764), SGTQ (SEQ ID NO: 4765), THNQ (SEQ ID NO: 4766), TITQ (SEQ ID NO: 4767), TSTQ (SEQ ID NO: 4768), TNSN (SEQ ID NO: 4769), TNQQ (SEQ ID NO: 4770), RNIQ (SEQ ID NO: 4771), TNNP (SEQ ID NO: 4772), TITE (SEQ ID NO: 4773), TNTN (SEQ ID NO: 4774), TFSQ (SEQ ID NO: 4775), RNSQ (SEQ ID NO: 4776), INTQ (SEQ ID NO: 4777), RNTE (SEQ ID NO: 4778), TNNH (SEQ ID NO: 4779), TNMQ (SEQ ID NO: 4780), RTTQ (SEQ ID NO: 4781), SNIE (SEQ ID NO: 4782), TNTS (SEQ ID NO: 4783), KNTQ (SEQ ID NO: 4784), TNLQ (SEQ ID NO: 4785), TSMQ (SEQ ID NO: 4786), SYTQ (SEQ ID NO: 4787), TNCQ (SEQ ID NO: 4788), SSTQ (SEQ ID NO: 4789), TVTQ (SEQ ID NO: 4790), or QNTQ (SEQ ID NO: 4791) ; and / or (ii) [N3] comprises IAQ, IAG, IYQ, VPQ, IAN, INQ, VNQ, VYQ, VAN, ISG, ISQ, VAQ, ITQ, TAQ, MAQ, SAQ, IGQ, IEQ, IVQ, NAQ, LAQ, IAK, IAH, IPQ, IAR, IAE, IAL, IAP, FAQ, VSQ, VTM, ISM, IWQ, IFQ, IQQ, VQQ, IFM, IAM, or ISN.

4. The AAV particle of any one of claims 1-3, wherein: (i) [N1]-[N2] comprises TNTQDWHR (SEQ ID NO: 4898), TNTKDWHR (SEQ ID NO: 4899), TNNQDWHR (SEQ ID NO: 4900), SNNQDWHR (SEQ ID NO: 4901), TNKQDWHR (SEQ ID NO: 4902), TNNEDWHR (SEQ ID NO: 4903), SNKQDWHR (SEQ ID NO: 4904), SNTQDWHR (SEQ ID NO: 4905), TTNQDWHR (SEQ ID NO: 4906), TNDQDWHR (SEQ ID NO: 4907), TTIQDWHR (SEQ ID NO: 4908), RNTQDWHR (SEQ ID NO: 4909), TTKQDWHR (SEQ ID NO: 4910), TTSQDWHR (SEQ ID NO: 4911), TTDQDWHR (SEQ ID NO: 4912), TNPSDWHR (SEQ ID NO: 4913), TNKEDWHR (SEQ ID NO: 4914), TTTQDWHR (SEQ ID NO: 4915), TGKQDWHR (SEQ ID NO: 4916), TTAQDWHR (SEQ ID NO: 4917), TVKQDWHR (SEQ ID NO: 4918), TNYQDWHR (SEQ ID NO: 4919), TNTPDWHR (SEQ ID NO: 4920), STKQDWHR (SEQ ID NO: 4921), TTEQDWHR (SEQ ID NO: 4922), TSKQDWHR (SEQ ID NO: 4923), TNIQDWHR (SEQ ID NO: 4924), TYNQDWHR (SEQ ID NO: 4925), STIQDWHR (SEQ ID NO: 4926), TTVQDWHR (SEQ ID NO: 4927), TGTQDWHR (SEQ ID NO: 4928), TNTRDWHR (SEQ ID NO: 4929), TTLQDWHR (SEQ ID NO: 4930), TTMQDWHR (SEQ ID NO: 4931), ANNQDWHR (SEQ 442 321651967.1Attorney Docket No.: V2071-3035PCT ID NO: 4932), SNIQDWHR (SEQ ID NO: 4933), TKNQDWHR (SEQ ID NO: 4934), TYTQDWHR (SEQ ID NO: 4935), TNKSDWHR (SEQ ID NO: 4936), SNTEDWHR (SEQ ID NO: 4937), TNTEDWHR (SEQ ID NO: 4938), TNIEDWHR (SEQ ID NO: 4939), TTRQDWHR (SEQ ID NO: 4940), TNSQDWHR (SEQ ID NO: 4941), TYTKDWHR (SEQ ID NO: 4942), TTTKDWHR (SEQ ID NO: 4943), TNIKDWHR (SEQ ID NO: 4944), SNTKDWHR (SEQ ID NO: 4945), TNNKDWHR (SEQ ID NO: 4946), TNSKDWHR (SEQ ID NO: 4947), TSTKDWHR (SEQ ID NO: 4948), TITKDWHR (SEQ ID NO: 4949), INTKDWHR (SEQ ID NO: 4950), TNAKDWHR (SEQ ID NO: 4951), TKTKDWHR (SEQ ID NO: 4952), STNQDWHR (SEQ ID NO: 4953), ANTKDWHR (SEQ ID NO: 4954), RNNQDWHR (SEQ ID NO: 4955), TGNQDWHR (SEQ ID NO: 4956), TSNQDWHR (SEQ ID NO: 4957), THTKDWHR (SEQ ID NO: 4958), TDTKDWHR (SEQ ID NO: 4959), TNEQDWHR (SEQ ID NO: 4960), CNTQDWHR (SEQ ID NO: 4961), TNPKDWHR (SEQ ID NO: 4962), INNQDWHR (SEQ ID NO: 4963), TYTEDWHR (SEQ ID NO: 4964), NNNQDWHR (SEQ ID NO: 4965), KNNQDWHR (SEQ ID NO: 4966), TNNRDWHR (SEQ ID NO: 4967), LNNQDWHR (SEQ ID NO: 4968), TINQDWHR (SEQ ID NO: 4969), TNHQDWHR (SEQ ID NO: 4970), STTQDWHR (SEQ ID NO: 4971), SNSQDWHR (SEQ ID NO: 4972), STSQDWHR (SEQ ID NO: 4973), TYIQDWHR (SEQ ID NO: 4974), SGTQDWHR (SEQ ID NO: 4975), THNQDWHR (SEQ ID NO: 4976), TITQDWHR (SEQ ID NO: 4977), TSTQDWHR (SEQ ID NO: 4978), TNSNDWHR (SEQ ID NO: 4979), TNQQDWHR (SEQ ID NO: 4980), RNIQDWHR (SEQ ID NO: 4981), TNNPDWHR (SEQ ID NO: 4982), TITEDWHR (SEQ ID NO: 4983), TNTNDWHR (SEQ ID NO: 4984), TFSQDWHR (SEQ ID NO: 4985), RNSQDWHR (SEQ ID NO: 4986), INTQDWHR (SEQ ID NO: 4987), RNTEDWHR (SEQ ID NO: 4988), TNNHDWHR (SEQ ID NO: 4989), TNMQDWHR (SEQ ID NO: 4990), RTTQDWHR (SEQ ID NO: 4991), SNIEDWHR (SEQ ID NO: 4992), TNTSDWHR (SEQ ID NO: 4993), KNTQDWHR (SEQ ID NO: 4994), TNLQDWHR (SEQ ID NO: 4995), TSMQDWHR (SEQ ID NO: 4996), SYTQDWHR (SEQ ID NO: 4997), TNCQDWHR (SEQ ID NO: 4998), SSTQDWHR (SEQ ID NO: 4999), TVTQDWHR (SEQ ID NO: 5000), or QNTQDWHR (SEQ ID NO: 5001); (ii) [N2]-[N3] comprises DWHRIAQ (SEQ ID NO: 5027), DWHRIAG (SEQ ID NO: 5028), DWHRIYQ (SEQ ID NO: 5029), DWHRVPQ (SEQ ID NO: 5030), DWHRIAN (SEQ ID NO: 5031), DWHRINQ (SEQ ID NO: 5032), DWHRVNQ (SEQ ID NO: 5033), DWHRVYQ (SEQ ID NO: 5034), DWHRVAN (SEQ ID NO: 5035), DWHRISG (SEQ ID NO: 5036), DWHRISQ (SEQ ID NO: 5037), DWHRVAQ (SEQ ID NO: 5038), DWHRITQ (SEQ ID NO: 5039), DWHRTAQ (SEQ ID NO: 5040), DWHRMAQ (SEQ ID NO: 5041), DWHRSAQ (SEQ ID NO: 5042), DWHRIGQ (SEQ ID NO: 5043), DWHRIEQ (SEQ ID NO: 5044), DWHRIVQ (SEQ ID NO: 5045), DWHRNAQ (SEQ ID NO: 5046), DWHRLAQ (SEQ ID NO: 5047), DWHRIAK (SEQ ID NO: 443 321651967.1Attorney Docket No.: V2071-3035PCT 5048), DWHRIAH (SEQ ID NO: 5049), DWHRIPQ (SEQ ID NO: 5050), DWHRIAR (SEQ ID NO: 5051), DWHRIAE (SEQ ID NO: 5052), DWHRIAL (SEQ ID NO: 5053), DWHRIAP (SEQ ID NO: 5054), DWHRFAQ (SEQ ID NO: 5055), DWHRVSQ (SEQ ID NO: 5056), DWHRVTM (SEQ ID NO: 5057), DWHRISM (SEQ ID NO: 5058), DWHRIWQ (SEQ ID NO: 5059), DWHRIFQ (SEQ ID NO: 5060), DWHRIQQ (SEQ ID NO: 5061), DWHRVQQ (SEQ ID NO: 5062), DWHRIFM (SEQ ID NO: 5063), DWHRIAM (SEQ ID NO: 5064), or DWHRISN (SEQ ID NO: 5065); and / or (iii) [N1]-[N2]-[N3] comprises the amino acid sequence of any one of SEQ ID NOs: 343-538.

5. The AAV particle of any one of claims 1-5, which further comprises [N4], wherein [N4] comprises TGWV (SEQ ID NO: 5066), TGWA (SEQ ID NO: 5067), TNWS (SEQ ID NO: 5068), SNWV (SEQ ID NO: 5069), TNWV (SEQ ID NO: 5070), TNWI (SEQ ID NO: 5071), NNWV (SEQ ID NO: 5072), TGWS (SEQ ID NO: 5073), TGWI (SEQ ID NO: 5074), TGWC (SEQ ID NO: 5075), TGWG (SEQ ID NO: 5076), SGWV (SEQ ID NO: 5077), PGWV (SEQ ID NO: 5078), TGSV (SEQ ID NO: 5079), TDWV (SEQ ID NO: 5080), TGCV (SEQ ID NO: 5081), TGRV (SEQ ID NO: 5082), TGLV (SEQ ID NO: 5083), TGGV (SEQ ID NO: 5084), AGWV (SEQ ID NO: 5085), IGWV (SEQ ID NO: 5086), TGWD (SEQ ID NO: 5087), NGWV (SEQ ID NO: 5088), TGWF (SEQ ID NO: 5089), TRWV (SEQ ID NO: 5090), TVWV (SEQ ID NO: 5091), TGWL (SEQ ID NO: 5092), TAWV (SEQ ID NO: 5093), TSWV (SEQ ID NO: 5094), TGWT (SEQ ID NO: 5095), SVWV (SEQ ID NO: 5096), TQWV (SEQ ID NO: 5097), or PGWG (SEQ ID NO: 5098).

6. The AAV particle of claim 5, wherein [N1]-[N2]-[N3]-[N4] comprises: (i) the amino acid sequence of any one of SEQ ID NOs: 201-245, 247-250, 253-255, 257- 265, 268-274, 276-286, 288, 290-297, 299-303, 305-309, 311, 313-319, 323-328, 330-337, 339-342, 539-542, 544, 546, 547, 549-557, 559-589, 592, 593, 595, 596, 598, 599, 601-608, 610-614, 616-622, 625, 628, 630, 631, 633, 636, 638, 639-646, 649, 651-657, 667, 669, 670, 672, 673, 679-683, 685- 690, 692, 693, 695, 697, 699-701, 703-705, 708-710, 712-717, 719-723, 728-731, 733-738, 740, or 742; (ii) TNTQDWHRIAQTGWV (SEQ ID NO: 201); or (iii) TNTKDWHRIAQTGWV (SEQ ID NO: 202).

7. The AAV particle of any one of claims 1-6, wherein hypervariable loop VIII comprises positions 580-599 of SEQ ID NO:

981.

8. The AAV particle of any one of claims 5-7, wherein: 444 321651967.1Attorney Docket No.: V2071-3035PCT (i) [N1] is present at amino acids 582-585, numbered according to SEQ ID NO: 138 or 981; (ii) [N2] is present at amino acids 586-589, numbered according to SEQ ID NO: 138 or 981; (iii) [N3] is present at amino acids 590-592, numbered according to SEQ ID NO: 138 or 981; (iv) [N4] is present at amino acids 593-596, numbered according to SEQ ID NO: 138 or 981; and / or (v) [N1]-[N2]-[N3]-[N4] is present at amino acids 582-596, numbered according to the amino acid sequence of SEQ ID NO: 138 or 981.

9. An AAV particle comprising an AAV capsid variant and a nucleic acid encoding a polynucleotide encoding an antibody molecule that binds to human tau, wherein the AAV capsid variant comprises an amino acid sequence with at least 95% sequence identity to positions 203-736 of SEQ ID NO: 981, wherein the AAV capsid variant comprises the amino acid T at position 584, D at position 586, W at position 587, H at position 588, R at position 589, and I at position 590, numbered according to SEQ ID NO:

981.

10. The AAV particle of claim 9, wherein the AAV capsid variant comprises: (i) an amino acid sequence at least 98% identical to amino acids 203-736 of SEQ ID NO: 981; (ii) an amino acid sequence at least 95% or at least 98% identical to amino acids 138-736 of SEQ ID NO: 981; and / or (iii) an amino acid sequence at least 95% or at least 98% identical to the amino acid sequence of SEQ ID NO:

981.

11. The AAV particle of claim 9 or 10, wherein the AAV capsid variant comprises: (i) the amino acid sequence of amino acids 203-736 of SEQ ID NO: 981; (ii) the amino acid sequence of amino acids 138-736 of SEQ ID NO: 981; and / or (iii) the amino acid sequence of SEQ ID NO:

981.

12. The AAV particle of any one of claims 1-11, which comp rises one, two, three, four, five, six, or all of the following properties: (i) increased tropism for a CNS cell or tissue, e.g., a brain cell, brain tissue, spinal cord cell, or spinal cord tissue, relative to the tropism of a reference sequence comprising the amino acid sequence of SEQ ID NO: 138; 445 321651967.1Attorney Docket No.: V2071-3035PCT (ii) transduces a brain region, e.g., sensory cortex, motor cortex, putamen, thalamus, caudate, hippocampus, cerebellum optionally wherein the level of transduction is at least 39, 50, 100, 120, 132, 146, 150, 161, 174, 175, 200, 225, 250, 275, 283, 300, 350, 400, 450, 500, 525, 528, or 550-fold greater as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., an immunohistochemistry assay or a qPCR or ddPCR assay, e.g., as described in Example 2; (iii) is enriched at least about 10, 14, 20, 24, 50, 100, 150, 200, 250, 300, 350, 400, 425, 450, or 460-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 3; (iv) is enriched at least about 200, 300, 400, 425, 450, or 460-fold, in the brain compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1; (v) is enriched at least about 2, 3, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 190, 200, 205, or 210-fold, in the brain of at least two to three species, e.g., a non-human primate and rodent (e.g., mouse), compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 4; (vi) is enriched at least about 2, 3, 4, 5, 10, 15, 17, 20, 50, 75, 100, 103, 107, 125, 150, 200, 250, 300, 350, 400, 450, 500, 750, 1000, 1200-fold, in the brain compared to a reference sequence of SEQ ID NO: 981, e.g., when measured by an assay as described in Example 3; (vi) delivers an increased level of a payload to a brain region, optionally wherein the level of the payload is increased by at least 39, 50, 100, 120, 132, 146, 150, 161, 174, 175, 200, 225, 250, 275, 283, 300, 350, 400, 450, 500, 525, 528, or 550-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR, a ddPCR, or a qPCR assay (e.g., as described in Example 2); (v) delivers an increased level of viral genomes to a brain region, optionally wherein the level of viral genomes is increased by at least 2, 5, 7, 10, 15, 19, 20, 22, or 25-fold, as compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay, e.g., a qRT-PCR or a qPCR assay (e.g., as described in Example 2); and / or (vi) is enriched at least about 5, 10, 50, 100, 115, 120, 150, 175, 200, 207, 225, 250, or 275- fold, in the spinal cord compared to a reference sequence of SEQ ID NO: 138, e.g., when measured by an assay as described in Example 1 or 2.

13. The AAV particle of any one of claims 1-13, wherein the encoded antibody molecule: (i) binds to the N-terminal region of a human tau protein; (ii) binds to the mid-domain region of a human tau protein; 446 321651967.1Attorney Docket No.: V2071-3035PCT (iii) binds to the C-terminal region of a human tau protein, e.g., residues 409-436 numbered according to SEQ ID NO: 9200; (iv) binds a phosphorylated residue of a tau protein; (iii) binds phosphorylated serine at position 422 (e.g., pS422), numbered according to SEQ ID NO: 920; (iv) preferentially binds pathological tau (e.g., PHF-tau or ePHF), compared to wild-type tau, e.g., as measured by an assay, e.g., an ELISA assay, an SPR assay or a Biacore assay, e.g., an assay as described in Example 8 or 10; (v) reduces, e.g., inhibits, aggregation of tau; and / or (vi) binds an epitope comprising a region formed by a complex of at least two tau proteins, e.g., a tau dimer.

14. The AAV particle of any one of claims 1-13, wherein the encoded antibody molecule comprises a heavy chain variable region (VH) comprising heavy chain complementarity determining region 1 (HC CDR1), a HC CDR2, and a HC CDR3; and a light chain variable region (VL) comprising light chain complementarity determining region 1 (LC CDR1). A LC CDR2, and a LC CDR3, wherein: (i) the HC CDR1, HC CDR 2, and HC CDR 3 comprise the amino acid sequences of SEQ ID NOs: 1631, 1551, and 1552, respectively; and the LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1632, 1633, and 1566, respectively; (ii) the HC CDR 1 comprises the amino acid sequence of X1X2WMH, wherein X1is R or I and X2is Y or F; HC CDR2 comprises the amino acid sequence of SEQ ID NO: 1635; and HC CDR3 comprises the amino acid sequence of SEQ ID NO: 1552; and the LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1636, 1633, and 1566, respectively; or (iii) the HC CDR1, HC CDR 2, and HC CDR 3 comprise the amino acid sequences of SEQ ID NOs: 1637, 1638, and 1557, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 1639, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 1566, respectively.

15. The AAV particle of claim 14, wherein: (i) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1553, 1554, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1567, 1565, and 1566, respectively; 447 321651967.1Attorney Docket No.: V2071-3035PCT (ii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1550, 1551, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1564, 1565, and 1566, respectively; (iii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1555, 1556, and 1557, respectively; and the LCDR1 comprises the amino acid sequence of SEQ ID NO: 1568, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 1566; (iv) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 64, 1554, and 1557, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1567, 1565, and 1566, respectively; (v) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1576, 1577, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1585, 1565, and 1566, respectively; (vi) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1575, 1551, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1585, 1565, and 1566, respectively; (vii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1578, 1579, and 1557, respectively; and the LCDR1 comprises the amino acid sequence of SEQ ID NO: 1586, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 1566; (viii) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1594, 1595, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1601, 1602, and 1566, respectively; (ix) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1593, 1551, and 1552, respectively; and the LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of SEQ ID NOs: 1601, 1602, and 1566, respectively; or (x) the HCDR1, HCDR2, and HCDR3 comprise the amino acid sequences of SEQ ID NOs: 1596, 1556, and 1557, respectively; and the LCDR1 comprises the amino acid sequence of SEQ ID NO: 1603, the LC CDR2 comprises the amino acid sequence of RVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 1566.

16. The AAV particle of claim 14 or 15, wherein: (i) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 69, 67, 68, 70, 71, 1562, 1583, or 1599; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% 448 321651967.1Attorney Docket No.: V2071-3035PCT identical to any one of SEQ ID NOs: 69, 67, 68, 70, 71, 1562, 1583, or 1599; or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of any one of SEQ ID NOs: 69, 67, 70, 71, 1562, 1583, or 1599; and / or the VL comprises he amino acid sequence of any one of SEQ ID NOs: 73, 72, 74, 1573, 1591, or 1606; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 73, 72, 74, 1573, 1591, or 1606; or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of any one of SEQ ID NOs: 73, 72, 74, 1573, 1591, or 1606; (ii) the VH comprises the amino acid sequence of SEQ ID NO: 69; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 69, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 69; and the VL comprises the amino acid sequence of SEQ ID NO: 73; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 73, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 73; (iii) the VH comprises the amino acid sequence of SEQ ID NO: 67; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 67, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 67; and the VL comprises the amino acid sequence of SEQ ID NO: 72; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 72, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 72; (iv) the VH comprises the amino acid sequence of SEQ ID NO: 70; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 70, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 70; and the VL comprises the amino acid sequence of SEQ ID NO: 72; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 72, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 72; (v) the VH comprises the amino acid sequence of SEQ ID NO: 71; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 71, or an amino acid 449 321651967.1Attorney Docket No.: V2071-3035PCT sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 73; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 73, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 73; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 71; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 71, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 71; and the VL comprises the amino acid sequence of SEQ ID NO: 74; an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 74, or an amino acid sequence comprising at least one, two, or three modifications but no more than 30, 20 or 10 modifications relative to the amino acid sequence of SEQ ID NO: 74; (v) the VH comprises the amino acid sequence of SEQ ID NO: 1562; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1562; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1562; and the VL comprises the amino acid sequence of SEQ ID NO: 1573, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1573; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1573; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 1583; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1583; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1583; and the VL comprises the amino acid sequence of SEQ ID NO: 1591, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1591; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1591; or (vii) the VH comprises the amino acid sequence of SEQ ID NO: 1599; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1583; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1599; and the VL comprises the 450 321651967.1Attorney Docket No.: V2071-3035PCT amino acid sequence of SEQ ID NO: 1606, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1606; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1606.

17. The AAV particle of any one of claims 14-16, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 158, 156, 157, 159, 160, 1563, 7, 190, 1584, or 1600, a nucleotide sequence at least 85%,90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 158, 156, 157, 159, 160, 1563, 7, 190, 1584, or 1600; or a nucleotide sequence having at least one, two, or three, but no more than 30, 20, or 10 different nucleotides relative to any one of SEQ ID NOs: 158, 156, 157, 159, 160, 1563, 7, 190, 1584, or 1600; an / or the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 162, 161, 163, 164, 165, 1574, 22, 192, 1592, or 1607, a nucleotide sequence at least 85%,90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 162, 161, 163, 164, 165, 1574, 22, 192, 1592, or 1607; or a nucleotide sequence having at least one, two, or three, but no more than 30, 20, or 10 different nucleotides relative to any one of SEQ ID NOs: 162, 161, 163, 164, 165, 1574, 22, 192, 1592, or 1607; (ii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 158, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 162, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 159, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 161, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iv) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 156, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 161, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (v) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 160, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical 451 321651967.1Attorney Docket No.: V2071-3035PCT thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 162, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vi) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1563, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1574, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1584, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1592, or a nucleotide sequence at least 95% identical thereto; (viii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1600, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1607, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; or (ix) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 160, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 163, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto.

18. The AAV particle of any one of claims 1-13, wherein the encoded antibody molecule comprises a heavy chain variable region (VH) comprising heavy chain complementarity determining region 1 (HC CDR1), a HC CDR2, and a HC CDR3; and a light chain variable region (VL) comprising light chain complementarity determining region 1 (LC CDR1). A LC CDR2, and a LC CDR3, wherein: (i) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1503, 1504, and 1502, respectively; and the LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1514, 1515, and 1516, respectively; (ii) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1528, 1529, and 1527, respectively; and the LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1539, 1540, and 1541, respectively; 452 321651967.1Attorney Docket No.: V2071-3035PCT (iii) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1611, 1612, and 1610, respectively; and the LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of SEQ ID NOs: 1621, 1622, and 1623, respectively (iv) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2200, 2257, and 2258, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2262, the LC CDR2 comprises the amino acid sequence of KDS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2264; (v) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2371, 2372, and 2373, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2207, the LC CDR2 comprises the amino acid sequence of KIS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2224; (vi) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2200, 2201, and 2202, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2207, the LC CDR2 comprises the amino acid sequence of KIS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2209; (vii) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2232, 2233, and 2234, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2238, the LC CDR2 comprises the amino acid sequence of DVS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2240; (viii) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2248, 2219, and 2249, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2207, the LC CDR2 comprises the amino acid sequence of KIS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2224; (ix) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2415, 2416, and 2417, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2420, the LC CDR2 comprises the amino acid sequence of WAS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2422; (x) the HC CDR1, HC CDR2, and HC CDR3 comprise the amino acid sequences of SEQ ID NOs: 2218, 2219, and 2220, respectively; and the LC CDR1 comprises the amino acid sequence of SEQ ID NO: 2207, the LC CDR2 comprises the amino acid sequence of KIS, and the LC CDR3 comprises the amino acid sequence of SEQ ID NO: 2224; or (xi) the HC CDR1, HC CDR2, HC CDR3, LC CDR1, LC CDR2, and LC CDR3 comprise the amino acid sequences of any of the HC CDR and LC CDR sequences provided in any one of Tables 7-16. 453 321651967.1Attorney Docket No.: V2071-3035PCT 19. The AAV particle of claim 18, wherein: (i) the VH comprises the amino acid sequence of any one of SEQ ID NOs: 1512, 1537, 1619, 2214, 2228, 2244, 2253, 2269, 2280, 2295, 2309, 2326, 2341, 2357, 2367, 2377, 2388, 2400, 2411, 2426, 2441, 2455, or 2470, an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 1512, 1537, 1619, 2214, 2228, 2244, 2253, 2269, 2280, 2295, 2309, 2326, 2341, 2357, 2367, 2377, 2388, 2400, 2411, 2426, 2441, 2455, or 2470, or an amino acid sequence comprising at least one, two, or three but no more than 30, 20, or 10 modifications relative to any one of SEQ ID NOs: 1512, 1537, 1619, 2214, 2228, 2244, 2253, 2269, 2280, 2295, 2309, 2326, 2341, 2357, 2367, 2377, 2388, 2400, 2411, 2426, 2441, 2455, or 2470; and / or the VL comprises the amino acid sequence of any one of SEQ ID NOs: 1523, 1548, 1629, 2215, 2229, 2245, 2254, 2270, 2281, 2296, 2310, 2327, 2342, 2358, 2368, 2378, 2389, 2401, 2412, 2427, 2442, 2456, or 2471, an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 1523, 1548, 1629, 2215, 2229, 2245, 2254, 2270, 2281, 2296, 2310, 2327, 2342, 2358, 2368, 2378, 2389, 2401, 2412, 2427, 2442, 2456, or 2471, or an amino acid sequence comprising at least one, two, or three but no more than 30, 20, or 10 modifications relative to any one of SEQ ID NOs: 1523, 1548, 1629, 2215, 2229, 2245, 2254, 2270, 2281, 2296, 2310, 2327, 2342, 2358, 2368, 2378, 2389, 2401, 2412, 2427, 2442, 2456, or 2471; (ii) the VH comprises the amino acid sequence of SEQ ID NO: 1512; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1512; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1512; and the VL comprises the amino acid sequence of SEQ ID NO: 1523, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1523; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1523; (iii) the VH comprises the amino acid sequence of SEQ ID NO: 1537; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1537; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1537; and the VL comprises the amino acid sequence of SEQ ID NO: 1548, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1548; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1548; 454 321651967.1Attorney Docket No.: V2071-3035PCT (iv) the VH comprises the amino acid sequence of SEQ ID NO: 1619; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1619; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1619; and the VL comprises the amino acid sequence of SEQ ID NO: 1629, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 1629; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 1629; (v) the VH comprises the amino acid sequence of SEQ ID NO: 2269; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2269; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2269; and the VL comprises the amino acid sequence of SEQ ID NO: 2270, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2270; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2270; (vi) the VH comprises the amino acid sequence of SEQ ID NO: 2377; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2377; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2377; and the VL comprises the amino acid sequence of SEQ ID NO: 2378, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2378; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2378; (vii) the VH comprises the amino acid sequence of SEQ ID NO: 2214; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2214; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2214; and the VL comprises the amino acid sequence of SEQ ID NO: 2215, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2215; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2215; (viii) the VH comprises the amino acid sequence of SEQ ID NO: 2228; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2228; or an 455 321651967.1Attorney Docket No.: V2071-3035PCT amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2228; and the VL comprises the amino acid sequence of SEQ ID NO: 2229, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2229; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2229; (ix) the VH comprises the amino acid sequence of SEQ ID NO: 2244; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2244; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2244; and the VL comprises the amino acid sequence of SEQ ID NO: 2245, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2245; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2245; (x) the VH comprises the amino acid sequence of SEQ ID NO: 2253; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2253; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2253; and the VL comprises the amino acid sequence of SEQ ID NO: 2254, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2254; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2254; (xi) the VH comprises the amino acid sequence of SEQ ID NO: 2426; an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2426; or an amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2426; and the VL comprises the amino acid sequence of SEQ ID NO: 2427, an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2427; or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to the amino acid sequence of SEQ ID NO: 2427; or (xii) the VH comprises the amino acid sequence of any one of the VH sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of the VH sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, or amino acid sequence comprising at least one, two or three 456 321651967.1Attorney Docket No.: V2071-3035PCT modifications, but no more than 30, 20, or 10 modifications relative to any one of the VH sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14; and the VL comprises the amino acid sequence of any one of the VL sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, an amino acid sequence at least 85% 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of the VL sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, or amino acid sequence comprising at least one, two or three modifications, but no more than 30, 20, or 10 modifications relative to any one of the VL sequences provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14.

20. The AAV particle of claim 18 or 19, wherein: (i) the nucleotide sequence encoding the VH comprises the nucleotide sequence of any one of SEQ ID NOs: 1513, 1538, 1620, 2216, 2230, 2246, 2255, 2271, 2282, 2297, 2311, 2328, 2343, 2359, 2369, 2379, 2390, 2402, 2413, 2428, 2443, 2457, or 2472, a nucleotide sequence at least 85%,90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 1513, 1538, 1620, 2216, 2230, 2246, 2255, 2271, 2282, 2297, 2311, 2328, 2343, 2359, 2369, 2379, 2390, 2402, 2413, 2428, 2443, 2457, or 2472; or a nucleotide sequence having at least one, two, or three, but no more than 30, 20, or 10 different nucleotides relative to any one of SEQ ID NOs: 1513, 1538, 1620, 2216, 2230, 2246, 2255, 2271, 2282, 2297, 2311, 2328, 2343, 2359, 2369, 2379, 2390, 2402, 2413, 2428, 2443, 2457, or 2472; an / or the nucleotide sequence encoding the VL comprises the nucleotide sequence of any one of SEQ ID NOs: 1524, 1549, 1630, 2217, 2231, 2247, 2256, 2272, 2283, 2298, 2312, 2329, 2344, 2360, 2370, 2380, 2391, 2403, 2414, 2429, 2444, 2458, or 2473, a nucleotide sequence at least 85%,90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 1524, 1549, 1630, 2217, 2231, 2247, 2256, 2272, 2283, 2298, 2312, 2329, 2344, 2360, 2370, 2380, 2391, 2403, 2414, 2429, 2444, 2458, or 2473; or a nucleotide sequence having at least one, two, or three, but no more than 30, 20, or 10 different nucleotides relative to any one of SEQ ID NOs: 1524, 1549, 1630, 2217, 2231, 2247, 2256, 2272, 2283, 2298, 2312, 2329, 2344, 2360, 2370, 2380, 2391, 2403, 2414, 2429, 2444, 2458, or 2473; (ii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1513, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1524, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1538, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical 457 321651967.1Attorney Docket No.: V2071-3035PCT thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1549, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iv) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 1620, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 1630, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (v) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2271, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2272, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vi) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2379, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2380, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2216, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2217, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (viii) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2230, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2231, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (ix) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2246, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2247, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; 458 321651967.1Attorney Docket No.: V2071-3035PCT (x) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2255, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2256, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (xi) the nucleotide sequence encoding the VH comprises the nucleotide sequence of SEQ ID NO: 2248, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises the nucleotide sequence of SEQ ID NO: 2249, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; or (xii) the nucleotide sequence encoding the VH comprises any one of the nucleotide sequence encoding a VH as provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the VL comprises any one of the nucleotide sequence encoding a VL as provided in any one of Tables 7, 8, 13, 13A, 13B, 13C, or 14, or a nucleotide sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto.

21. The AAV particle of any one of claims 1-20, wherein the encoded antibody molecule is: (i) a full length antibody, a bispecific antibody, an Fab, an F(ab')2, an Fv, or a single chain Fv fragment (scFv); and / or (ii) a human antibody, a humanized antibody, or a murine antibody.

22. The AAV particle of any one of claims 1-21, wherein the encoded antibody molecule comprises: (i) a heavy chain constant region selected from IgG1, IgG2, IgG3, IgG4; and / or a light chain constant region of kappa or lambda; or (ii) a heavy chain constant region of IgG4 and a light chain constant region of kappa.

23. The AAV particle of any one of claims 1-22, wherein the encoded antibody molecule comprises: (i) a human IgG4 constant region, comprising an amino acid other than serine at position 228 according to EU numbering; (ii) a human IgG4 constant region, comprising a serine to proline substitution at position 228 according to EU numbering; 459 321651967.1Attorney Docket No.: V2071-3035PCT (iii) a heavy chain constant region (e.g., a human IgG4 constant region) comprising the amino acid sequence of SEQ ID NO: 2503, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2503; and / or (iv) a heavy chain constant region (e.g., a human IgG4 constant region), wherein the nucleotide sequence encoding the heavy chain constant region comprises the nucleotide sequence of any one of SEQ ID NOs: 2504, 2505, 2506, or 2507, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical any one of SEQ ID NOs: 2504, 2505, 2506, or 2507.

24. The AAV particle of any one of claims 1-23, wherein the encoded antibody comprises a light chain constant region (e.g., a light chain constant region of kappa), wherein: (i) the light chain constant region comprises the amino acid sequence of SEQ ID NO: 2508, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2508; and / or (ii) the nucleotide sequence encoding the light chain constant region comprises the nucleotide sequence of SEQ ID NO: 2509 or 2510, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 2509 or 2510.

25. The AAV particle of any one of claims 1-24, wherein the encoded antibody molecules comprises: (i) a heavy chain comprising the amino acid sequence of any one of SEQ ID NOs: 170-174, 8, or 65, or an amino acid sequence at least 85%, 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 170-174, 8, or 65; and / or a light chain comprising the amino acid sequence of any one of SEQ ID NOs: 175-179, 23, or 66, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 175-179, 23, or 66; (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 172, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 173, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 170, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain 460 321651967.1Attorney Docket No.: V2071-3035PCT comprising the amino acid sequence of SEQ ID NO: 175, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 176, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vi) a heavy chain comprising the amino acid sequence of SEQ ID NO: 174, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 177, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (vii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 65, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 66, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; or (viii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 8, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and a light chain comprising the amino acid sequence of SEQ ID NO: 23, or an amino acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto.

26. The AAV particle of claim 25, wherein: (i) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of any one of SEQ ID NOs: 180-184, 10, or 191, or an nucleotide acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 180-184, 10, or 191; and / or the nucleotide sequence encoding the light chain comprises the nucleotide sequence of any one of SEQ ID NOs: 185-189, 24, or 193, or an nucleotide acid sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 185-189, 24, or 193; (ii) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 182, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the light chain comprises the nucleotide sequence of SEQ ID NO: 186, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iii) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 183, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the light chain comprises the nucleotide 461 321651967.1Attorney Docket No.: V2071-3035PCT sequence of SEQ ID NO: 185, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iv) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 180, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the light chain comprises the nucleotide sequence of SEQ ID NO: 185, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; (iv) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 184, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the light chain comprises the nucleotide sequence of SEQ ID NO: 186, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; or (vi) the nucleotide sequence encoding the heavy chain comprises the nucleotide sequence of SEQ ID NO: 184, or a nucleotide sequence at least 90%, 92%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the nucleotide sequence encoding the light chain comprises the nucleotide sequence of SEQ ID NO: 187, or a nucleotide sequence at least 90%,92%, 95%, 96%, 97%, 98%, or 99% identical thereto.

27. The AAV particle of claim 25 or 26, wherein: (i) the nucleotide sequence encoding the heavy chain and the nucleotide sequence encoding the light chain are connected directly; or (ii) the nucleotide sequence encoding the heavy chain and the nucleotide sequence encoding the light chain are connected via a linker, optionally wherein the linker comprises the nucleotide sequence of any of the linker sequences provided in Table 19, or a nucleotide sequence at least 95% identical thereto.

28. The AAV particle of any one of claims 14-27, where the nucleic acid encoding the antibody molecule comprises: (i) a signal sequence present 5’ relative to the nucleotide sequence encoding the VH; and / or (ii) a signal sequence present 5’ relative to the nucleotide sequence encoding the VL; optionally wherein the signal sequence comprises the nucleotide sequence of any of the signal sequences provided in Table 20, or a nucleotide sequence at least 95% identical thereto. 462 321651967.1Attorney Docket No.: V2071-3035PCT 29. The AAV particle of any one of claims 1-28, which comprises a viral genome comprising a promoter operably linked to the nucleic acid encoding the antibody molecule which binds to human tau.

30. The AAV particle of claim 29, wherein the promoter is a ubiquitous promoter.

31. The AAV particle of claim 29, wherein the promoter is a cell-type specific promoter or a tissue- specific promoter.

32. The AAV particle of any one of claims 29-31, wherein the promoter is chosen from human elongation factor 1α-subunit (EF1α), cytomegalovirus (CMV) immediate-early enhancer and / or promoter, chicken β-actin (CBA) and its derivative CAG, β glucuronidase (GUSB), or ubiquitin C (UBC), neuron-specific enolase (NSE), platelet-derived growth factor (PDGF), platelet-derived growth factor B-chain (PDGF-β), intercellular adhesion molecule 2 (ICAM-2), synapsin (Syn), methyl-CpG binding protein 2 (MeCP2), Ca2+ / calmodulin-dependent protein kinase II (CaMKII), metabotropic glutamate receptor 2 (mGluR2), neurofilament light (NFL) or heavy (NFH), β-globin minigene nβ2, preproenkephalin (PPE), enkephalin (Enk) and excitatory amino acid transporter 2 (EAAT2), glial fibrillary acidic protein (GFAP), myelin basic protein (MBP), or a fragment, e.g., a truncation, or a functional variant thereof.

33. The AAV particle of any one of claims 29-32, wherein the viral genome further comprises: (i) an enhancer; (ii) a polyadenylation (polyA) signal region; (ii) one or two ITR sequences; (iii) at least 1, 2, or 3 intron regions; (iv) at least 1, 2, or 3 exon regions; and / or (v) a nucleotide sequence encoding a microRNA (miR) binding site, e.g., a miR binding site that modulates, e.g., reduces expression of payload encoded by the viral genome in a cell or tissue where the corresponding miRNA is expressed; optionally wherein the encoded miR binding site modulates, e.g., reduces expression of the payload encoded by the viral genome in a cell or tissue of the DRG, liver, heart, hematopoietic lineage, or a combination thereof. 463 321651967.1Attorney Docket No.: V2071-3035PCT 34. The AAV particle of claim 33, wherein the ITR sequence is positioned 5’ relative to the nucleic acid encoding the antibody molecule and / or the ITR sequence is positioned 3’ relative to the nucleic acid encoding the antibody molecule.

35. The AAV particle of any one of claims 29-34, wherein the viral genome is self-complementary or single stranded.

36. A cell comprising the AAV particle of any one of claims 1-35, optionally wherein, the cell is: (a) a mammalian cell or an insect cell; (b) a cell of a brain region or a spinal cord region (e.g., a CNS cell); (c) a cell of the brain or the spinal cord (e.g., a cell of a putamen, caudate, hippocampus, thalamus, substantia nigra, motor cortex, frontal cortex, temporal cortex, cerebral cortex, dentate nucleus, Lateral Geniculate Nucleus (LGN), cervical spinal cord, lumbar spinal cord, and / or thoracic spinal cord); or (d) a neuron or an astrocyte.

37. A method of making the AAV particle of any one of claims 1-35, comprising: (i) providing a host cell comprising a AAV viral genome; (ii) incubating the host cell under conditions suitable to enclose the viral genome in an AAV capsid protein; thereby making the AAV particle.

38. A pharmaceutical composition comprising the AAV particle of any one of claims 1-35, and a pharmaceutically acceptable excipient.

39. A method of delivering an antibody molecule that binds to human tau to a subject, comprising administering to the cell an effective amount of the pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1-25, thereby delivering the antibody molecule that binds to human tau to the subject.

40. The method of claim 39, wherein the subject has or has been diagnosed with having a genetic disorder (e.g., a monogenic disorder or a polygenic disorder); a neurological disorder (e.g., a neurodegenerative disorder); a disorder associated with tau expression, e.g., aberrant tau expression; and / or a tauopathy. 464 321651967.1Attorney Docket No.: V2071-3035PCT 41. A method of treating a subject having or diagnosed with having a genetic disorder (e.g., a monogenic disorder or a polygenic disorder); a neurological disorder (e.g., a neurodegenerative disorder); a disorder associated with tau expression, e.g., aberrant tau expression; and / or a tauopathy, the method comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1-35.

42. The method of claim 41, wherein the genetic disorder, neurological disorder (e.g., neurodegenerative disorder), disorder associated with tau expression (e.g., aberrant tau expression), and / or tauopathy is Alzheimer’s disease (AD), Frontotemporal dementia (FTD), frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17), frontotemporal lobar degeneration (FTLD), Dravet syndrome (DS), neurodegenerative disease, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), Down’s syndrome, Pick’s disease, corticobasal degeneration (CBD), corticobasal syndrome, amyotrophic lateral sclerosis (ALS), Prion diseases, CJD, Multiple system atrophy, mild cognitive impairment, Tangle-only dementia, or Progressive subcortical gliosis.

43. The method of claim 41 or 42, wherein treating comprises prevention of progression of the genetic disorder, neurological disorder (e.g., neurodegenerative disorder), disorder associated with tau expression (e.g., aberrant tau expression), and / or tauopathy in the subject in the subject.

44. The method of any one of claims 39-43, further comprising performing a blood test, an imaging test (e.g., a PET scan or a PET scan in combination with biomarker, e.g., serum biomarker staining), a CNS biopsy sample, or an aqueous cerebral spinal fluid biopsy, optionally wherein the blood test, imaging test, biopsy sample, or aqueous cerebral spinal fluid biopsy is performed prior to, during, or after treatment with the AAV particle, modulatory polynucleotide, siRNA, or pharmaceutical composition.

45. The method of any one of claims 39-44, wherein the pharmaceutical composition or AAV particle are administered to the subject: (i) intravenously, via intra-cisterna magna injection (ICM), intracerebrally, intrathecally, intracerebroventricularly, via intraparenchymal administration, or intramuscularly; (ii) via focused ultrasound (FUS), e.g., coupled with the intravenous administration of microbubbles (FUS-MB), or MRI-guided FUS coupled with intravenous administration; (iii) intravenously. 465 321651967.1Attorney Docket No.: V2071-3035PCT 46. The pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1-25, for use in a method of delivering an antibody molecule that binds to human tau to a subject.

47. The pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1-25, for use in the treatment of a genetic disorder, neurological disorder (e.g., neurodegenerative disorder), disorder associated with tau expression (e.g., aberrant tau expression), and / or tauopathy.

48. Use of the pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1- 25, in the manufacture of a medicament for delivering an antibody molecule that binds to human tau to a subject.

49. Use of the pharmaceutical composition of claim 38 or the AAV particle of any one of claims 1- 25, in the manufacture of a medicament for treating a genetic disorder, neurological disorder (e.g., neurodegenerative disorder), disorder associated with tau expression (e.g., aberrant tau expression), and / or tauopathy. 466 321651967.1

Images